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Accumulating delivered dose to the rectum to improve toxicity
prediction in prostate radiotherapy
Leila E. A. Shelley
Gastrointestinal (GI) toxicity is a clinical issue suffered by up to 22% of prostate cancer
radiotherapy patients. However, the relationship between radiation dose and toxicity is
generally poorly understood. In prostate radiotherapy, the rectum is a dose-limiting structure
to which treatment planning dose constraints are applied to minimise the risk of toxicity.
Current normal tissue complication probability (NTCP) models are based on planned dose
data and do not consider the effects of organ motion on true delivered dose.
The VoxTox research programme has developed automated solutions for segmentation
and dose calculation of the rectum for prostate cancer patients being treated with helical
TomoTherapy. Daily image guidance scans, acquired primarily for the purposes of positional
verification, are exploited by extracting quantitative information to facilitate the calculation
of daily delivered and total accumulated dose to the rectum. Prospectively collected toxicity
data at 2 years post-treatment were available for 295 patients across two separate cohorts.
In this thesis, the hypothesis being tested is that delivered dose is a better predictor of
rectal toxicity than planned dose in prostate radiotherapy. The research has successfully
demonstrated, for the first time, that delivered dose produces stronger associations with rectal
bleeding and proctitis than planned dose. Analysis was performed using dose surface maps
(DSMs) of the rectal wall, allowing spatial aspects of dose to be retained during accumulation.
A subsequent analysis on a separate cohort also found stronger links between delivered dose
and GI toxicity, stool frequency, and bowel bother, in addition to rectal bleeding and proctitis.
Biomechanical finite element (FE) modelling was introduced to provide a more anatom-
ically plausible tool for dose accumulation and allowed more accurate tracking of dose at
the voxel level. A sensitivity analysis was conducted which explored the effect of simulated
rectal motion on dose, and corresponding change in NTCP. For VoxTox patient dose-toxicity
analysis, further dose parameterisation approaches were explored in order to consider the
vi
increased resolution of information available. Voxel-based rectal subregions at risk (SRRs)
were identified using geometric and statistical approaches. In general, discriminative power
improved with FE modelling for both planned and accumulated delivered dose, and associa-
tions between accumulated dose and toxicity were strengthened by voxel-based subregion
analysis.
Multivariate NTCP models were constructed for 12 different toxicity endpoints based
on planned and accumulated dose parameters. Model performance was compared between
analysis approaches, and models were tested on a validation dataset. In general, FE-based
dose models performed best, although the optimal dose parameter selected within the model
varied with toxicity endpoint.
Overall, results suggest that there is an advantage to incorporating delivered dose into
NTCP modelling. However, the differences between planned and accumulated dose can be
subtle. Meaningful parameterisation of accumulated dose needs careful consideration, as
traditional methods for quantifying planned dose may not be directly transferable. Voxel-
based analysis techniques are recommended in order to accurately preserve and register
spatial dose information, and have been shown to improve the strength of dose-toxicity
associations. Further research into quantifying voxel level dose distributions is encouraged.
It is anticipated that the novel scientific contributions presented within this thesis will
prove valuable for future development of clinical decision-making tools for adaptive radio-
therapy, with the ultimate aim of reducing the incidence of radiation-induced toxicity for
prostate cancer radiotherapy patients.
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1.1 Radiotherapy for prostate cancer
Prostate cancer is the most common cancer amongst adult men in the UK. According to
Cancer Research UK [32], 1 in 8 men will be diagnosed with prostate cancer in their lifetime.
In 2015, there were approximately 130 new cases of prostate cancer diagnosed every day.
By 2035, the incidence rates are projected to rise by 12 % to 233 cases per 100,000, but
conversely, the rate of mortality is projected to fall by 16 % to 48 deaths per 100,000 [32, 100].
These projections suggests that increasingly more men are surviving their prostate cancer
diagnosis. Ten-year survival rates are at 84 %, a significant improvement from the 1970s
when just a quarter of patients survived beyond 10 years [32].
Radiotherapy is the primary course of treatment for approximately 30 % of prostate
cancer patients [106]. Radiotherapy is the delivery of high-energy X-ray beams, typically
6-15 megavolts (MV), via a linear accelerator (linac) mounted on a ring or rotating gantry
with the patient positioned at the central focus, or isocentre. Modern day rotational intensity-
modulated radiotherapy (IMRT) involves the use of mechanical multi-leaf collimators (MLCs)
to dynamically shape the radiation beam from multiple entry positions or continuous arcs,
building up a high dose region tightly conformed to the tumour.
Delivered for both radical and palliative intent, radiotherapy can be prescribed as a stand-
alone treatment, or to complement surgery and/or chemotherapy. The ionising properties
of the radiation beam cause damage to the DNA double helix via double and single strand
breaks resulting in chromosomal aberrations. Radiotherapy is delivered in a fractionated
regime which exploits the difference in radiobiological response between tumour and healthy
or ‘normal’ tissue by allowing time for normal tissue to repair whilst tumour damage
accumulates. The therapeutic ratio is the relative probability of tumour cell kill to that of
normal tissue complication [14].
2 Introduction
The aim of any radiotherapy treatment is to maximise the dose to the tumour, whilst
minimising dose to surrounding healthy organs. In prostate radiotherapy, the tumour volume
is considered to be the prostate gland, which sits immediately anterior to the rectum and
posterior to the bladder, as indicated by the contours in Figure 1.1a. As such, the rectum
and bladder are considered to be dose-limiting organs at risk (OARs) which limit the total
radiation dose that can be delivered to the prostate. Although tumour control improves with
increasing dose, so does the incidence and severity of normal tissue damage. Thus, a balance
is sought with sufficiently high dose for optimal probability of local control, whilst also
maintaining an acceptably low level of incidence of severe normal tissue complications.
In 2016, the standard dose prescription in the UK changed from 74 Gy delivered in 2 Gy
fractions over 37 fractions (7.5 weeks), to 60 Gy in 20 fractions of 3 Gy (4 weeks), as a result
of the Conventional or Hypo-fractionated High Dose Intensity-Modulated Radiotherapy
for Prostate Cancer ‘CHHiP’ trial [52, 108]. The 5-year outcome data demonstrated non-
inferiority of the 60 Gy hypofractionated arm with respect to the 74 Gy conventional group,
with comparable levels of late side-effects, or toxicity.
With increasing survival rates for prostate cancer patients, the consideration of post-
treatment quality of life is becoming of greater importance in the clinical decision making
process. The adverse effects of radiotherapy by can be debilitating and permanent [101],
and yet, the mechanisms of radiation toxicity are poorly understood [14]. Radiation-induced
rectal toxicity remains a clinical issue for up to a fifth of prostate cancer patients.
1.2 Radiotherapy treatment planning
In prostate radiotherapy, the prostate gland is treated as the gross tumour volume (GTV).
A margin is grown around this volume to incorporate random and systematic error into the
planning target volume (PTV), the volume to which the dose is prescribed. One example
of random error is interfraction motion; variations in the day-to-day internal positioning
due to anatomical or physiological movement. Interfraction motion affecting the position of
the PTV can introduce deviations from the intended planned dose, so daily on-line image
guidance is used prior to treatment delivery to ensure the prostate is in the intended treatment
position.
Each patient’s radiotherapy treatment is individually planned based on a computed
tomography (CT) scan of their anatomy. On this static CT image set, typically acquired a few
weeks prior to the start of treatment, the PTV and any OARs are identified and contoured.
Complex IMRT plans are generated using computational inverse-planning dose calculation
algorithms within a treatment planning system (TPS). An example of a typical prostate
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IMRT treatment plan is shown in Figure 1.1. Using the image guidance scans to register the
prostate position at the time of treatment, with the reference planning CT scan, ensures that
the radiation plan is being delivered to the PTV as intended.
Exposing normal tissue within the treatment field to some level of concomitant dose
is unavoidable due to the inherent nature of X-ray beam propagation through the patient.
The OARs abutting the PTV are at risk of receiving dose levels associated with radiation-
induced toxicity. Consequently, these OARs are dose-limiting factors when determining the
radiation levels used to target the PTV. Treatment plans are optimised so that minimum dose
coverage of the PTV is achieved, whilst also meeting OAR dose constraints. The OARs being
considered in treatment planning for prostate radiotherapy are generally the rectum, bladder,
and femoral heads. However, the bladder and rectum in particular undergo interfraction
motion which is, aside from visually verifying IGRT scans for adherence with local setup
protocols, generally unaccounted for.
Dose-volume constraints are organ-specific dose-threshold limits. For OARs, the upper
threshold indicates the maximum acceptable level of ‘Normal Tissue Complication Prob-
ability’ (NTCP), below which, the risk of radiation-induced toxicity is reduced. In the
case of the PTV, minimum thresholds are defined to ensure adequate target coverage for
maximum ‘Tumour Control Probability’ (TCP). NTCP and TCP models in various forms
have existed for several decades, historically derived from radiobiological models such as the
Lyman-Kutcher-Burman (LKB) model [91, 86, 63, 28]. Practical implementation of NTCP
dose-constraints in the clinic have been based upon published recommendations such as the
‘Quantitative Analysis of Normal Tissue Effects in the Clinic’ (QUANTEC) reports [94], as
well as clinical trials. However, these models were generally derived based on 3D conformal
radiotherapy and a thorough evidence base has not yet built up for complex radiotherapy
techniques such as IMRT.
The dose received by a structure is commonly presented graphically using a dose-volume
histogram (DVH); a plot of the cumulative dose-volume frequency distribution, as shown in
Figure 1.1b. Dose-volume constraints are generally expressed as the percentage volume of a
structure receiving less than or equal to a specified dose level. For example, the dashed black
line in Figure 1.1b indicates that the dose received by 50% of the volume of the rectum is
28 Gy or less, i.e. V50% < 28 Gy. Existing DVH-based approaches to treatment planning have
been criticised for lacking in spatial dose distribution information [3, 171]. With the standard
of care now mainly high dose-gradient rotational IMRT (VMAT and helical TomoTherapy),
geometric positioning and distribution of dose, as well as intra-organ sensitivity, become




Fig. 1.1 (a) Example of a TomoTherapy prostate radiotherapy treatment plan, prescribed 60 Gy in 20 fractions,
with (b) corresponding Dose Volume Histogram (DVH). The plan shows axial, coronal and sagittal views
centred about the prostate, with isodose colourwash from 12 Gy (20%) in blue, to 100% (60 Gy) in orange.
Shown are prostate gland PTV (PTV PG, red) with seminal vesicle PTV (PTV SV, blue), sitting anterior to the
rectum (brown), and posterior to the bladder (pink); right and left femoral heads are also contoured for dose
reporting (cyan and pale green, respectively). The DVH is a cumulative dose-volume frequency distribution
representing the absolute dose received by the percentage volume of the contoured structure.
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The steep dose-gradients associated with IMRT mean that better understanding and
tracking of interfraction motion of OARs is crucial. For organs such as the rectum in prostate
radiotherapy, small deviations from the planned position can result in large differences in the
true delivered dose. It has been shown that delivered dose to the rectum is not equal to planned
dose, despite the use of image guided radiotherapy [139, 142]. The full extent of quantitative
information available within image guidance scans has yet to be fully realised in routine
clinical practice. Online image guidance scans can provide a platform for the calculation
of delivered dose and facilitate a feedback system whereby dose can be monitored and
accumulated, with remedial modifications made to the treatment plan as necessary [144, 172].
Ultimately, if delivered dose to OARs can be quantified, this should lead to improvements
in NTCP modelling, and when considered in terms of adaptive radiotherapy, could result in
reduced toxicity rates.
1.3 The VoxTox research programme
The VoxTox research programme is an observational study linking radiation dose to toxic-
ity outcomes [46, 139]. The Cambridge-based project is a multidisciplinary collaboration
spanning engineering, mathematics, high energy physics, medical physics and radiation on-
cology [30], which aims to combine sophisticated models of delivered dose with prospectively
collected toxicity data, linking dose at the voxel level with toxicity.
Advanced imaging capabilities within the Radiotherapy Department at Addenbrooke’s
Hospital (Cambridge University Hospitals NHS Foundation Trust) provided the platform for
calculation of delivered dose throughout treatment [30]. Megavoltage image guidance scans,
acquired primarily for the purposes of tumour localisation, were used to calculate delivered
dose by accounting for daily anatomical variation and provide a more accurate representation
of the delivered radiotherapy treatment with respect to the static planning scan, as shown in
Figure 1.2. Combining these data with prospectively collected clinical toxicity data allows
us to address the hypothesis that delivered dose provides a better predictor of toxicity than
planned dose.
VoxTox received approval from the National Research Ethics Service (NRES) Committee
East of England (13/EE/0008) in February 2013 and is part of the UK Clinical Research
Network Study Portfolio (UK CRN ID 13716).
6 Introduction
Fig. 1.2 VoxTox workflow. Images on the left show the conventional radiotherapy (RT) pathway, where anatomy
is contoured on the kilovoltage computed tomography (kVCT) planning scan, allowing the intensity modulated
radiotherapy (IMRT) plan to be generated. Plan quality is assessed using the dose volume histogram (DVH)
parameters, and an optimal plan achieves adequate tumour coverage whilst minimising dose to healthy organs.
On the right hand side, the VoxTox process mirrors this workflow on megavoltage computed tomography
(MVCT) image guidance radiotherapy (IGRT) scans. Dose to the rectal wall is calculated and accumulated
using dose surface maps (DSMs) which allow spatial features to be retained. Methods of parameterising DSMs
are investigated within this thesis.
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1.4 Research aims
The focus of this PhD project is to test the hypothesis of the VoxTox research programme, that
delivered dose is a better predictor of toxicity than planed dose, specifically concentrating on
rectal toxicity in prostate radiotherapy.
Delivered dose to the rectum and toxicity data collected for VoxTox prostate cancer
patients treated between 2013-2018 have been collated and analysed. The analysis conducted
within this thesis has depended upon the prior development of autosegmentation software,
independent dose calculation algorithms, processing and tokenisation of patient data, finite
element model development, and toxicity mapping systems, and was only possible due to the
multidisciplinary nature of the VoxTox team.
Within the scope of this PhD research, delivered dose was initially represented using two-
dimensional dose-surface maps of the virtually unfolded rectal wall. Biomechanical finite
element modelling was later introduced as a more anatomically representative method for
accumulating delivered dose. Parameterisation metrics were selected using modified versions
of techniques previously applied in the literature for planned dose. These ranged from one
dimensional reductions of the dose distribution, to the identification of toxicity-specific rectal
subregions at risk. Additional information on the relationship between simulated rectal
motion and resulting change in dose and NTCP were also investigated using biomechanical
modelling. The research conducted in this thesis culminates in multivariate NTCP modelling
developed on a training set for each of 12 toxicity endpoints, and tested on a validation
set. Final models are presented based on parameters from both planned and accumulated
delivered dose. A research overview is presented in Figure 1.3. It is anticipated that the
outcomes of this PhD research will contribute towards the development of decision-making
tools in adaptive radiotherapy, ultimately to reduce toxicity incidence for prostate cancer
radiotherapy patients. A summary of the original contributions to knowledge are listed below:
• Demonstration that delivered dose to rectum can be more predictive of rectal toxicity
than planned dose;
• Use of biomechanical finite element (FE) modelling to accumulate voxel-level deliv-
ered dose to rectum and link with toxicity;
• Biomechanical FE simulation of rectal motion to quantify dose and NTCP sensitivities;
• Voxelwise analysis of delivered dose to identify subregions associated with toxicity;
• The generation of rectal NTCP models, comparing multivariate models based on
planned dose with those based on accumulated delivered dose.
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Fig. 1.3 Thesis overview; diagrammatic representation of the different analysis approaches presented in results
chapters (Ch.). In Ch.4, 2D slicewise analysis of rectal contours is used to generate 2D dose surface maps (2D-
DSMs) of the rectal wall, based on both planning CT and daily image guidance scans. 2D-DSMs of planned and
accumulated delivered dose were parameterised using equivalent uniform dose (EUD) and DSM dose-widths,
the lateral extent of an ellipse fitted to a given isodose level (white ellipse and arrow). Biomechanical finite
element modelling (FEM) improves accuracy and resolution of dose calculation. Ch.5 presents a sensitivity
study using FEM to simulate changes in rectal motion and quantify the dose impact. In Ch.6, finite element
dose surface maps (FE-DSMs) of planned and accumulated dose are parameterised using (i) EUD and DSM
dose-widths, (ii) geometric subregions (grey lines), (iii) probabilistic subregions (grey contour). In Ch.7, the
outcomes of chapters 4 and 6 are input into multivariate normal tissue complication (NTCP) models, and
validated. Discriminative ability is compared between planned and accumulated dose models with toxicity.
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1.5 Overview of chapters
Chapter 1: Introduction to radiotherapy, treatment planning, the VoxTox research pro-
gramme, and research aims;
Chapter 2: Literature review and critical analysis detailing the current scientific environment
regarding rectal toxicity in prostate cancer radiotherapy;
Chapter 3: Description of the systems providing the foundations of VoxTox, multidisci-
plinary contributions, and the data handling involved in this research;
Chapter 4: Analysis of planned and accumulated dose to rectal wall using conventional 2D
dose surface maps (DSMs) and investigating correlations with rectal toxicity;
Chapter 5: Applying biomechanical FE analysis to calculating dose to the rectal wall. Ex-
ploring the range of patient motion, and resulting sensitivity of dose and NTCP;
Chapter 6: Parameterising FE-DSMs for investigating voxel-level dose-toxicity associations;
Chapter 7: Developing multivariate NTCP models for predicting rectal toxicity, optimised
for both planned and accumulated delivered dose;




Linking dose with toxicity in prostate
radiotherapy
This chapter presents a systematic review of the relevant literature within the current research
setting of rectal dose-toxicity associations in prostate radiotherapy. This is in the form of a
summary and critical appraisal of several national and international clinical trials and studies
which have examined dose fractionation effects in prostate radiotherapy. Dose to rectum
is discussed in terms of spatial dose quantifiers beyond the dose volume histogram (DVH)
approach. Voxel-based characterisation of rectal dose is introduced, alongside applications
to different clinical sites and different methodologies. Finally, through this critical analysis,
gaps in the literature are identified and translated into the research questions addressed in
this thesis.
2.1 Clinical studies in prostate radiotherapy
Radiotherapy offers a highly effective treatment for prostate cancer. The 10 year outcome
data of the Prostate Testing for Cancer and Treatment (ProtecT) trial [72] presented evidence
from 1643 men (545 radiotherapy, 553 surgery, 545 active surveillance) showing equivalent
rates of disease-free survival between radical prostatectomy and radiotherapy, with fewer
adverse effects when treated with radiotherapy. Radiotherapy is a non-invasive treatment
option so may be preferable to surgical intervention, particularly for patients with pre-existing
contraindications to surgery. Higher rates of disease progression were observed for patients
undergoing active surveillance.
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2.1.1 Conventional treatment
Several clinical trials have investigated the effect of dose fractionation in prostate radiotherapy
in terms of biochemical disease control and gastrointestinal toxicity. Studies comparing
conventional dose fractionation schedules (dose per fraction between 1.8 - 2 Gy) have
shown that dose escalation leads to improved biochemical progression-free survival (bPFS)
[48, 55, 57, 98, 124, 130, 166]. One example conducted in the UK was the Medical Research
Council (MRC) RT01 trial. Data were accrued for 843 men with stage T1b-T3a prostate
cancer between 1998 and 2002. Patients were randomised to a standard-dose conventional
plan (64 Gy in 32 fractions) or higher-dose conformal plan (74 Gy in 37 fractions) with
radical intent [148]. The trial reported evidence that dose escalation significantly improved
bPFS [56], and subsequently dose escalation was recommended as the standard of care for
localised prostate cancer in the UK in 2008 [48].
However, a consequence of improved efficacy in disease outcome was increased incidence
of acute and late toxicities [55, 57, 149]. Additionally, despite reporting improvements in
disease-free survival, dose escalation did not translate to an increase in overall survival [99].
RT01 results indicated that although within clinically acceptable levels, a higher incidence
of bowel dysfunction was reported in the dose-escalated arm after 5 years. Rectal bleeding
was the most commonly reported side-effect, followed by proctitis and diarrhoea, which
tended to increase in severity up to 3 years [149]. Ten-year follow-up data supported the early
results, and found that dose escalation improved disease-free survival. However, emphasis
was placed on balancing this benefit against the heightened risk of prolonged toxicity effects
post-treatment.
2.1.2 IMRT and hypofractionation
A prospective study conducted by the Radiation Therapy Oncology Group (RTOG) compared
three dimensional conformal radiotherapy with intensity modulated radiotherapy (IMRT)
for prostate cancer. IMRT achieved significantly lower doses to the rectum and bladder, and
consequently reported lower rates of late rectal toxicity [99]. Findings were consistent with
the QUANTEC review [94], that large volumes of the rectum irradiated to high dose levels
were associated with toxicity.
There have been several large-scale randomised trials conducted for hypofractionation
(2.5 Gy per fraction and above) [10, 13, 56, 88, 129, 133]. The UK CHHiP trial (Conventional
or Hypofractionated High-dose Intensity Modulated Radiotherapy in Prostate Cancer) [52,
54] is a non-inferiority trial that recruited 3216 prostate cancer patients from multiple centres
between 2002 and 2011. Patients were randomised into one of three different fractionation
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schedules: 74 Gy in 37 fractions (2 Gy per fraction, the existing standard of care in the
UK at the time), 60 Gy in 20 fractions (3 Gy per fraction), or 57 Gy in 19 fractions (3 Gy
per fraction). Evidence presented at 2-year [54] and 5-year [52] follow-up indicated that
hypofractionated radiotherapy to 60 Gy was non-inferior to the 74 Gy arm. Isoeffectiveness
was achieved in terms of bPFS with equivalent levels of cumulative toxicity incidence, but no
significant difference was observed for overall survival. Non-inferiority was also observed in
the Dutch HYPRO (Hypofractionated versus conventionally fractionated radiotherapy for
patients with localised prostate cancer) study between 64.6 Gy in 19 fractions and 78 Gy
in 39 fractions [10]; PROFIT (Prostate Fractionated Irradiation Trial) between 60 Gy in
20 fractions and 78 Gy in 39 fractions [37]; RTOG 0126 between 70.2 Gy in 39 fractions
and 79.2 Gy in 44 fractions; and recent outcomes of the Scandinavian-led HYPO-RT-HC
(hypofractionated radiotherapy of intermediate risk localised prostate cancer) trial have
now shown non-inferiority of ultra-hypofractionated radiotherapy (42.7 Gy in 7 fractions
compared with 78 Gy in 39 fractions) [167]. In 2016, as a consequence of the CHHiP
recommendations and the evidence base for non-inferiority of hypofractionation, the standard
of care for external-beam radiotherapy of localised prostate cancer was changed to 60 Gy in
20 fractions [108].
2.2 Quantifying dose to rectum
2.2.1 Dose volume histograms
Dose volume histograms represent the cumulative frequency dose distribution to an organ
(Figure 2.1a). DVHs are a powerful tool used in radiotherapy treatment planning to deter-
mine a clinically optimal treatment plan. The plan is iteratively optimised until a balance is
achieved between coverage of the planning target volume (PTV) and organ at risk (OAR)
sparing. This is evaluated by assessing whether DVH dose constraints have been met and
compromising where necessary. However, existing DVH approaches have been criticised
for lacking in information on spatial dose distribution [3, 171], and with high dose-gradient
treatments such as IMRT, the geometric location of the high dose region becomes an in-
creasingly important concern. Despite this limitation, they are widely used even though
dose-volume constraints from 30 - 70 Gy have been found to be significantly associated with
rectal toxicity [70], and high-doses in particular have been linked with rectal bleeding [87].
An additional clinical consideration not currently accounted for within the clinical trials
discussed above is intra-organ radiosensitivity; all organs are assumed to be uniformly
sensitive. For a serial organ such as the rectum, different regions may be more sensitive, and
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some more tolerant, to the effects of radiation [4]. It has been demonstrated that discrete
rectal toxicity endpoints have different underlying pathophysiologies, which may be attributed
to different areas of the rectum. Data from the CHHiP trial have recently been interrogated
to derive dose constraints optimised for each of four rectal toxicity endpoints [168]. The
constraints were tighter than those applied in the CHHiP trial, which may result in reduced




Fig. 2.1 (a) Example Dose Volume Histogram (DVH); (b) Example Dose Surface Map (DSM)
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2.2.2 Dose surface maps
Using data from the RT01 trial, approaches beyond the traditional DVH were investigated in
order to characterise the shape and location of the dose distribution, and link with toxicity.
Buettner et al. proposed the dose-surface map (DSM) as a representation of planned dose to
the rectal wall [27]. By considering the rectal wall as a tubular surface that can be virtually cut
and unwrapped, the dose could be visualised on a 2D plane. Generation of the DSM involved
cutting the rectal contour at the posterior-most location and normalising longitudinally and
circumferentially to a 21×21 matrix where each pixel represents the interpolated dose level.
Visually, this creates a map with the high dose region positioned centrally, representing the
anterior portion of the rectum closest to the prostate, with dose fall-off towards the edges of
the DSM, as shown in Figure 2.1b.
Presenting dose to the rectal wall using DSMs allows characterisation of the shape
and location of the dose distribution. Geometric features in the DSMs were extracted by
computationally generating binary images corresponding to isodose clusters of discrete dose
levels, and fitting an ellipse to the largest cluster. From the ellipse, measures of lateral extent,
longitudinal extent, and eccentricity were recorded. Cumulative dose surface histograms
(DSHs) were also generated for each DSM. Parameters were investigated for associations
with rectal toxicity.
Results demonstrated several significant correlations between the proposed shape-based
dose distribution features and various toxicity endpoints; in particular the lateral extent
of medium to high isodose levels were significantly associated with rectal bleeding. The
concluding recommendation of this study was that spatial dose patterns should be considered
at the treatment planning stage
A follow-up study used sigmoidal functions fitted to histograms of dose-lateral-extent,
dose-longitudinal-extent and dose-eccentricity, and used these as input for a machine learn-
ing algorithm [26]. A support vector machine was trained to predict toxicity based on the
sigmoidal functions with the strongest predictive power for each clinical endpoint, i.e. rectal
bleeding based on lateral extent, and so on. This allowed calculation of individual compli-
cation probabilities rather than binary outcomes, and patients could be ranked according to
complication probability. Patterns were identified that correlated to low risk of complication,
which improved upon DVH based models alone. Results verified the previous findings, that
the lateral dose extent was found to be a significant predictor of toxicity.
The DSM approach to representing dose to the rectal wall has been applied in several
studies interrogating the links between dose and toxicity [115, 139, 171]. Buettner’s findings
have subsequently been supported by independent studies that found rectal bleeding to be
associated with the lateral extent of the mid to high isodoses [103, 115]. Moulton et al. [103]
16 Linking dose with toxicity in prostate radiotherapy
also reported an association between the high doses and diarrhoea, stool frequency, and
urgency, as well as further toxicity associations with spatial features of DSMs. Casares-Magaz
et al. [34] found defecation urgency and faecal leakage to be associated with intermediate to
high dose in the central to upper rectal wall. Wortel et al. [171] found links between several
spatial DSM patterns with acute rectal toxicity.
By comparing the DSMs of patients with and without toxicity, it is possible to observe
patterns and test for significance. Onjukka et al. [115] found that dose to the caudal extent
of the treated volume and anal canal were associated with faecal incontinence. The authors
recommended the inclusion of the anal canal as an OAR in treatment planning. Moulton et
al. [103] suggest that reducing dose to the superior and inferior rectum may be important
considerations for rectal pain and faecal urgency, respectively.
DSMs of the rectal wall have also been used to combine external beam radiotherapy
doses with brachytherapy in the treatment of cervical cancer [42]. The DSM approach has
also been applied to provide spatial dose information for the duodenum [169], and to the
bladder to investigate spatial effects associated with bladder toxicity [121, 122].
Some considerations and limitations must be identified for the use of DSMs, Due to
the relatively new adoption of the technique, few large scale studies have been conducted.
There are no consensus guidelines on determining splitting point and normalisation for DSM
generation; users have developed their own in-house systems. To date, DSM feature analysis
has primarily focused on properties of ellipses fitted to isodose levels. However, alternative
methods to characterising DSM dose distributions may be more beneficial for determining
dose-toxicity associations. Further complexities arise when considering DSMs as a tool for
accumulating dose, as rows from planned DSMs correspond to axial slices, and the tracking
the same anatomical region for the same patient throughout the course of treatment may
require methods for tracking extraplanar motion.
2.2.3 Dose line histograms
An alternative method has been used to parameterise rectal dose, the Dose Line Histogram
(DLH). At each slice, a histogram of the dose to the rectal circumference is produced.
Longitudinally, the histogram corresponds to the maximum length of each isodose level [73].
Using this approach on planning CT data only, strong DLH correlations were established. The
authors acknowledge that improvements could be made to increase reliability of correlation
models by accounting for interfraction motion.
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2.3 Voxel-based analysis
For effective registration and modelling of intra and inter patient dose distributions, greater
spatial accuracy is required than previously achievable using DVH or DSM approaches.
Voxel-based analysis is a research focus that has been gaining momentum with the paradigm
shift towards spatial dose analysis. Some advantages of voxel-based approaches are that they
are not limited by imaging slice width, and do not require normalisation around the rectal
circumference. Furthermore, voxelwise analysis offers a solution for extraplanar expansion
and tracking which is closer to anatomical behaviour, allowing increased resolution of data,
which in turn may reveal information on intra-organ inhomogeneous radiosensitivity.
2.3.1 Image-intensity based voxel mapping
A dose-image-based approach to inter-patient mapping was presented by Acosta et al [3, 116].
For 105 patients, the 3D dose distribution was mapped to a common template using a non-
rigid hybrid organ/intensity registration method [41, 151]. A subregion was identified in a
region of the anterior rectal wall, located within 15 mm of the prostate, where the absolute
dose difference between patients with and without rectal bleeding was measured to be 6 Gy.
The most significant mean-DVH differences were observed at the 40-65 Gy intermediate
dose levels, corresponding with Buettner’s [27] DSM findings.
A subsequent publication by the same group [61] exploits the voxel-level resolution of
the model by dividing the rectum into rectal subregions at risk (SRR). Planned dose data
at the voxel level were registered to a common template for 118 test patients. The rectal
wall was divided into ‘geometric’, ‘personalised’, and ‘generic’ SRRs to explore spatial
dose-toxicity associations. Subregions and toxicity correlations were investigated using a
training set of 118 patients, and tested on a validation cohort of 53 patients. Validated results
show that the dose to the inferior-anterior hemi-anorectum was highly predictive of rectal
bleeding.
The voxel-based framework described above was used to develop toxicity prediction
models for rectal bleeding using independent component analysis [64]. The model was
generated using planned DVH parameters from training data, and has been successfully
validated in a test cohort.
Similar voxel-based approaches have been used to determine spatial dose patterns associ-
ated with radiation-induced pneumonitis and fibrosis in lung cancer radiotherapy [118–120],
and with urinary toxicity in prostate cancer radiotherapy [105]. The latter found dose to the
urethra, and posterior and superior regions of the bladder, to be significantly associated with
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different toxicity endpoints. The results for both urinary toxicity and rectal toxicity support
the recommendation that spatial dose pattern should be considered at treatment planning.
2.3.2 Finite element modelling
Finite element modelling (FEM) can be used to predict anatomical organ motion and de-
formation by simulating biomechanical properties and tissue interactions. Organs can
be deformably registered between two different image sets either on an individual organ
basis according to material properties, or by surface interactions for multi-organ align-
ment [20]. These computational biomechanical models can account for the inhomogeneities
and anisotropy associated with soft tissues undergoing large deformations [21], which cannot
be accounted for by the approaches previously described.
The internal anatomy is discretised into individual deformable bodies with boundary
conditions defined from the geometries of the clinical contours. Organs are assigned specific
material properties, geometries, surface interactions, and the computer simulation is used
to characterise the motion. FEM accuracy is more dependent upon the applied loading and
boundary conditions than material properties [33], which is an important feature because
material properties can be difficult to physically measure directly [21]. Additionally, unlike
the solution presented by Acosta et al [3, 116] described in Section 2.3.1, FEM does not
depend on image-intensity information which is known to be problematic in the case of the
rectum due to the varying internal contents [143].
FEM can successfully model the intricacies of organ motion in 3D. By tracking of voxels
according to biomechanical properties, we make the assumption that voxels are surrogates
for groups of cells, and that the same cells remain in a particular voxel throughout the period
of monitoring the organ deformation. However, the FE model cannot account for biological
effects at the cellular level, e.g. cell cycle repair, repopulation, regeneration, or cell death.
Furthermore, inter-voxel cell migration may be plausible, possibly in a similar phenomenon
to the radiation ‘bystander effect’ whereby radiation-induced damage can be detected in
unirradiated healthy cells away from primary the target site. Tracking of biological changes
within deformable organs is difficult to measure, but could perhaps be better quantified and
included into models in the future.
Biomechanical FEM provides a robust and anatomically-representative solution for 3D
modelling and tracking of intra-organ variations [21]. Several studies have acknowledged
the potential for significant improvements in radiotherapy treatment delivery by integrating
biomechanical modelling into dosimetry tracking systems for adaptive radiotherapy.
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Fig. 2.2 Example of a biomechanical finite element model of the rectum based on the kVCT planning contour
and dose per fraction.
2.3.2.1 Biomechanical FEM of the pelvis
Biomechanical FE modelling of the pelvic region has previously focused on studies of the
prostate. Physically, the prostate is located immediately posterior to the bladder and anterior
to the rectum, therefore its absolute position is not fixed within the body and can vary
depending upon distension/filling/voiding of these adjacent organs [93]. In terms of prostate
radiotherapy, not only does this motion pose a problem for image registration between scans
acquired on different days and/or using different imaging modalities, but interfraction motion
between fractions of radiotherapy treatment can introduce significant deviations between
planned and delivered dose to the prostate and OARs. Image guided radiotherapy is used to
ensure that the tumour is being accurately targeted at each fraction, and a key hypothesis of
the VoxTox research programme is that these image guidance scans can be registered using
FEM to accumulate delivered dose to the rectum.
Brock et al. [24] investigated the accuracy, sensitivity, and efficiency of contour variation
and model parameters for FEM registration of the prostate. The accuracy was quantified
by comparing residual error in the centre of mass of the implanted fiducial markers in the
prostate, and the alignment of surface points, before and after deformation. Accuracy was
found to be less than 1.5 mm in three-dimensions; this was less than the dimensions of the
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image voxels, and therefore within acceptable limits for detectable accuracy. Sensitivity
was determined by examining the change in accuracy for different scenarios of forward and
backwards deformation, and was found not to be significant for different model resolutions
or intraobserver variation in the anterior-posterior or right-left directions, with marginal
differences detected in the superior-inferior direction (likely due to the effect of slice thickness
in this direction). An increase in model size (number of elements used for surface mesh) by
a factor of 24 was found to significantly increase calculation times from under a minute to
over 30 minutes, without a significant improvement in model accuracy. This indicates that
the level of accuracy associated with a higher resolution model, can in practice be achieved
using a more efficient model that can be run in real-time using a reduced number of elements
in the FEM calculation. The study was designed to provide evidence that FEM can be used
to integrate multimodality imaging into radiotherapy treatment planning for accurate tumour
definition. The conclusions are also applicable to registration of OARs such as the rectum.
An example of FEM being used to address the issue of organ mobility in the pelvic region
was presented by Alterovitz et al. [9]. FEM was used to deformably register the prostate
between two magnetic resonance imaging (MRI) scans acquired at different times; one
acquired with an endorectal probe in-situ for diagnostic purposes, and the other without the
probe for the purposes of radiotherapy treatment planning. This allows the specific disease
site, as confirmed on a diagnostic quality scan, to be translated onto the scan of the patient in
the actual treatment position, so that the area can be appropriately targeted. This may also be
useful when considering the effect on prostate positioning when implanting rectal spacers
or gels [62, 112, 128, 147, 159], which is a procedure that has recently been introduced
clinically in the UK [109].
Boubaker et al. [18, 19] presented a predictive model for pelvic organ motion where the
deformation of the prostate is dependent upon displacements of the neighbouring bladder
and rectum, and is limited by fixed bony anatomy such as the sacrum and pubic symphysis.
Extensive detail is provided for material properties, element types, thickness parameters,
boundary conditions, and mesh generations. Urodynamic data were generated from exper-
imental measurements from human cadavers [83], as well as porcine substrate [19]. As
with the 2D-DSM approach in Section 2.2.2, a hollow-cylinder approach is adopted for the
rectum. The rectal FE model is constructed of 3D shell elements of thickness 3 mm, whereas
the prostate is modelled using tetrahedral solid-volume elements. Frictionless contact was
assumed between rectum and prostate to simulate possible sliding between the organs. Rectal
motion was up to 3 mm in the craniocaudal direction, and 5 - 20 mm in the anterior-posterior
direction, as measured by Marchal et al. [93], and was fixed in place at the superior and
inferior ends. A first order Ogden hyperelastic strain-energy model was used for the rectum,
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assuming tissue homogeneity and isotropy. The mean intra-rectal inflation pressure was
1 kPa, applied uniformly to the innerpart of the rectal wall. Global error in rectal volume
calculated at 12 displacement positions was 6 %. In the context of radiotherapy, this magni-
tude of change could make a large difference in the dose calculation, and hence estimation of
toxicity risk. The author acknowledges that experimental discrepancies may exist between
urodynamic properties in a living human, compared with ex-vivo measurements on a cadaver.
However, the response of pig rectum tissue fell within the expected range of inter-subject
variability [19]. Further experimental validation measurements to build a database for robust
identification of constitutive laws were recommended. These would help to improve the
predictive numerical FE platform so that the system could be considered a useful tool for
adaptive radiotherapy.
Biomechanical properties of the rectum have been investigated using MRI imaging [36].
Internal rectal pressure was monitored using a pressure transducer with a balloon inflated
in 50 ml increments. MRI images were acquired in order to quantify rectal wall thickness
and elasticity. The maximum tolerable volume was 150 - 200 ml, corresponding to rectal
pressure of 1.3 - 4.0 kPa. The rectal wall thickness was shown to vary across the rectum
(1.8 - 4.0 mm); with increasing thickness from upper to lower rectum, and from anterior to
posterior rectum. Strain also varied across the rectal wall, from 1.5 - 7.0 kPa from different
areas. Biomechanical rectal properties varied on an intra- and inter-patient basis, which
could perhaps reflect underlying radiation-induced toxicity issues. The author suggests that
the results provide motivation for the inclusion of spatial properties into predictive response
modelling for GI toxicity. This has been supported by other studies in the literature but
further analysis may be required on larger patient cohorts due to relatively low incidence
rates. Furthermore, the author proposes the inclusion of biomechanical properties into
spatial evaluations of dose surface maps may better explain associations between particular
subregions of the rectal wall and toxicity due to improved tracking capabilities offering
heightened accuracy.
These studies into the biomechanical and material properties of the rectum have pro-
vided useful guidance for implementing FEM into the VoxTox workflow. Intra-rectal pres-
sure has been shown to be difficult to measure and validate experimentally, which is why
displacement-loading is used for many FEM anatomical simulations. It has been identified
that biomechanical FEM can be used to identify regions of the rectum associated with rectal
toxicity, with greater accuracy and resolution than existing approaches currently applied in
clinical practice.
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2.3.2.2 The Morfeus system
One of the most prolific systems for biomechanical finite element anatomical modelling
in the current literature is an independent biomechanical-model based deformable image
registration algorithm for multi-modality imaging, tissue tracking and dose calculation,
known as Morfeus [20]. The Morfeus system has gone through many iterations and feasibility
studies to improve accuracy and efficiency since its development in 2005 based on organ
surface deformation in the Abaqus Computer Aided Engineering (CAE) Finite Element
Analysis (FEA) environment (Dassault Systèmes) [20, 22]. The system has now been
incorporated into commercial software [165] for abdomen, thorax, and pelvis.
Developed within the context of radiotherapy, for a solid structure example such as the
liver, the initial anatomical contour is defined on the planning CT and used to generate an
initial volumetric mesh to which material properties are applied. From a given daily kV
cone-beam CT image guidance scan, a surface mesh is generated based on the liver contour
of the day. Boundary conditions are then updated based on the new contour information, and
the FE analysis is performed to determine a deformation map solution where the original
volume is deformed to the new 3D volume. Through FEM, organ motion and interactions
can be predicted, and the magnitude of the deformation can be used to quantify registration
parameters between a reference and test image.
Deformation of the prostate has been successfully predicted in Morfeus using surface
representations of the bladder and rectum to an accuracy of 2 mm, with the positioning
of fiducial markers agreeing to less than the voxel resolution [76]. Sensitivity to mesh
size was investigated for the prostate in order to minimise calculation time; where the
calculations could be reduced to less than 1 minute, without significant impact on accuracy
[24]. It was possible to reduce calculation time further, but at the expense of registration
accuracy. Although sufficiently quick for on-treatment application in radiotherapy, in practice
the system required anatomical contours as an input, and therefore the implementation of
an autosegmentation system for image guidance scans was a vital development prior to
implementation in order to be feasible within a clinical workflow [24].
Developing a model for the thoracic region involved many iterative cycles of complex anal-
ysis: methodical evaluation of element type, material properties and geometrical analysis [6];
friction and compressibility investigations [7, 5]; incorporating an image intensity-based
hybrid system [135]; increasing the spatial resolution of the lung by applying boundary
conditions to bronchioles [38]; and even reconstruction of 3D models from 2D planar im-
ages [110, 111]. The author suggests that the latter could be used to calculate historical
treatments retrospectively to investigate late toxicity effects.
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Morfeus has been applied for deformable image registration and FEM to retrospectively
accumulate delivered dose for liver stereotactic body radiotherapy. A study explored the
difference between planned and accumulated dose accounting for positioning, breathing and
deformation effects which were found to range from -15 % to 5 % for tumours, and -42 % to
8 % for normal tissues [163]. This result prompted further investigation into the possibility
of dose escalation to the tumour [164]. Margins surrounding the tumour were assessed using
FEM and consequently, a smaller ‘dose-probability-based PTV’ was defined enabling dose
escalation of 4 Gy to the tumour. Breathing motion was significantly different to predicted
breathing for over 50 % of patients, and for the majority of patients, accumulated dose
deviations were greater than 5% with respect to planned dose. These results were important
because lower doses to the tumour in liver SBRT are associated with poorer survival and
disease control. The authors suggest that accumulated delivered dose can be an important tool
for adaptive radiotherapy, and may facilitate dose escalation to improve clinical outcomes in
the future.
Dose accumulation as modelled using Morfeus has been verified experimentally using CT-
based matching of a novel 3D deformable gel dosimeter [114]. Early models were based on
MRI-contoured images, offering superior image quality over the CT and MVCT or CBCT im-
age guidance scans [20]. However, validation results were within sub-millimetre agreement.
The algorithm utilised external boundaries to perform the deformation registration, which
was then confirmed by comparing planned and delivered dose distributions [162]. Though
the experimental results seem promising, clinical validation was reportedly challenging due
to difficulty in feature identification in low-contrast images.
The Morfeus system was translated from a development research platform into the routine
online image guidance workflow at the developing centres. The system has recently been
integrated into the Raysearch treatment planning system [165]. The system allows quanti-
tative assessments of interfraction variability across many anatomical sites, demonstrating
the versatility of FEM application in medical imaging. Accumulated dose calculations have
been reported, however, the focus has been mainly on localisation and adaptive management.
As yet, there have been no publications in the literature using FEM to link delivered dose to
the rectum with toxicity in prostate radiotherapy.
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2.4 Overcoming current limitations by accounting for in-
terfraction motion of the rectum
A limitation of each of the studies and clinical trials discussed in this chapter so far is that the
quoted dose to rectum is based upon the position at a single snapshot in time, the planning
CT scan. This image of the internal anatomy is usually acquired several weeks prior to
the beginning of the radiotherapy treatment, and although daily treatment setup images
are qualitatively compared against the planning CT as a baseline, no accounting has been
made for interfraction movement. However, rectal motion has been shown to be significant
throughout the course of radiotherapy [117], and has the largest influence on the shape
and motion of the prostate [19]. Further studies [79, 176] have attempted to approximate
delivered dose from planned dose by applying a Gaussian filter to effectively blur the static
dose to account for intrafraction and interfraction motion, cell migration, and the bystander
effect. However, it is acknowledged that variations in daily rectal filling are random and
could significantly impact the actual delivered dose, which cannot be accounted for by the
blurring filter. Even with the use of image guidance in prostate radiotherapy, the position of
the rectum has been shown to vary more than expected [136], which indicates that the dose
received by the rectum in prostate radiotherapy is different to that planned.
Studies are beginning to emerge where the effect of interfraction motion is accounted for
by calculating delivered dose. Thor et al. [155] calculated ‘motion-inclusive’ delivered dose
for 38 patients who had 9 repeat CT scans acquired during treatment. Repeat CT scans were
manually contoured by radiation oncologists and rigidly registered to the planning CT scan
so that a new dose calculation could be performed. QUANTEC dose-volume constraints
were investigated and compared [97] between planned and motion-inclusive dose, and
toxicity associations were assessed using logistic regression. Rectal volumes were found
to be smaller amongst patients with higher toxicity and the rectal volume receiving more
than 67 Gy was significantly associated with GI morbidity using the motion-inclusive dose.
The author acknowledges the potential benefit to quantifying delivered dose using spatial
dose metrics such as the dose-surface map in order to be able to identify specific areas of the
rectum associated with toxicity effects. Further studies into dose-toxicity associations using
motion-inclusive delivered dose were recommended.
Scaife et al. [139] demonstrated using dose-surface histograms generated from DSMs
that planned dose was different to delivered dose for all patients. Casares-Magaz et al. [35]
performed estimates of motion-inclusive dose to rectum by using the average dose calculated
using the cone-beam CT images from approximately 30% of fractions in a case-control study
of 28 patients. Several studies acknowledge that the effects of interfraction motion of the
2.5 Predicting toxicity using accumulated dose 25
rectum have not been accounted for, and recommend research into this area as a worthwhile
endeavour [25, 75, 96, 156, 173].
2.5 Predicting toxicity using accumulated dose
In 2010, the QUANTEC vision paper recommended the development of techniques for dose
accumulation in order to improve the understanding of radiation-induced toxicity effects [94].
This landmark publication recognised that planned dose is not equal to delivered dose, and
that with the increasingly high dose gradient techniques available, small deviations from the
planned position can lead to larger differences in the dose actually received. Additionally,
with the increasing use of higher dose-per-fraction delivery techniques such as stereotactic
ablative body radiotherapy, daily anatomical deviations have a greater impact on the total
delivered dose. Whereas previously the effects of interfraction motion would be averaged
across 20 or 37 fractions, now a single fraction can represent a fifth of the total treatment
delivery.
Research has been undertaken to improve NTCP modelling since the publication of this
article, whereby spatial aspects or specific dose-volume constraints have been investigated in
terms of principal component analysis [64] and machine learning neural networks [25, 177].
However, models based on delivered dose have yet to be developed. By relating delivered
dose to toxicity, it may become possible to maximise the therapeutic ratio, advance adaptive
radiotherapy, and improve treatment outcomes.
2.6 Identifying research questions
To summarise the scientific literature reviewed in this chapter, there have been extensive
international studies exploring the effects of rectal toxicity in prostate radiotherapy. Toxicity
remains a clinical issue in radiotherapy and the underlying mechanisms are fairly poorly
understood. Existing toxicity prediction models seem insufficient for the modern high-dose
gradient complex treatments currently being delivered, as the historic data used to derive
constraints for dose-limiting organs were based on 3D conformal techniques. Nevertheless,
these DVH constraints are commonly applied in radiotherapy treatment planning to achieve
a compromise between tumour coverage and healthy organ sparing. As acknowledged by
many authors, DVH parameters are limited by their lack of any spatial dose dimension. The
search for more appropriate dose descriptors for the rectal wall seems to be focused on
parameterisation of dose surface maps. An overarching limitation and recommendation of
studies examining dose-toxicity associations in prostate radiotherapy, has been that motion-
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inclusive dosimetric data is required for a more complete understanding. Radiation treatments
to the pelvis region are particularly susceptible to interfraction motion which can lead to large
deviations between planned dose and that actually delivered. This introduces an inherent
uncertainty in dose-toxicity modelling based on planned dose.
Parallel advances have seen the application of the finite element approach to anatomical
modelling, which facilitates 3D tracking of organ motion. Rather than image intensity-based
deformable registration tools that can be limited to planar expansions or struggle at large
deformations, FEM applies constitutive biomechanical laws to anatomical simulations. This
provides the capability to track voxel-level extraplanar deformations, which can improve the
accuracy and resolution within a system for the calculation of delivered dose. FE models
have previously been applied for accumulating daily dose to the liver, but not yet to the
rectum in prostate radiotherapy.
Here, we seek to combine gaps in the literature to explore dose-toxicity associations with
delivered dose to rectum, explore the application of FEM to the rectum in terms of sensitivity,
interrogate the voxel levels resolution of FE rectal simulations for patterns of spatial dose
asscociated with toxicity, and finally, culminate this data with patient factors into multivariate
normal tissue complication probability models.
This PhD research has been conducted as part of the VoxTox research programme, linking
dose at the voxel level with toxicity. The hypothesis of the study is that delivered dose is a
better predictor of toxicity than planned dose. The focus of the research conducted within
this thesis is on delivered dose to the rectum as a predictor of rectal toxicity in prostate
radiotherapy. The mechanisms for calculating delivered dose to a 2D-DSM were already
in place prior to the commencement of this research. The areas of research that have
been identified as missing from the literature, and are being addressed as original scientific
contributions within this thesis, are:
• The use of spatial aspects of delivered dose to rectum, represented using 2D-DSMs, to
investigate associations with toxicity
• Optimisation of a biomechanical FE model for the purposes of accumulating delivered
dose to the rectum
• Application of FE modelling to a sensitivity study to improve knowledge of the
relationship between rectal motion and dose
• Exploiting the voxelwise nature of FEM dose accumulation to interrogate dose-toxicity
associations at a higher resolution using subregion analysis
• Development of NTCP models based on spatial aspects of delivered dose to rectum
Chapter 3
Data management in VoxTox
In this chapter, the intricacies of the VoxTox data and workflow are described. The fol-
lowing processes were developed by others prior to commencement of this PhD project:
autosegmentation of the rectum on megavoltage (MV) image guided radiotherapy (IGRT)
scans, independent dose calculation of image guidance scans, calculation of two-dimensional
dose surface maps of the rectal wall, anonymisation of patient data, automated processing
system, collection of baseline and toxicity data, and coding for a 3D finite element rectal
simulation from experimental data. These systems provided the foundations for the work
conducted within this thesis. Appropriate accreditation for the work undertaken in developing
these systems is acknowledged within this chapter, and further summarised in Appendix A,
Statement of originality.
Within this PhD project, further modification of several processing systems and manipu-
lation of data were required to address the research question, ‘Is delivered dose to the rectum
a better predictor of toxicity than planned dose in prostate radiotherapy?’. These included:
improvements and updates to the autosegmentation algorithm, parameterisation of 2D-DSMs
for calculation of equivalent uniform dose and dose-widths, combining fractionation sched-
ules to equivalent dose in 37 fractions, interpretation and processing of toxicity data, and
translation of the experimental 3D finite element model to a model appropriate for handling
patient DICOM data. Each of these stages involved collaborative working and have been
accredited as such in the relevant sections.
3.1 VoxTox infrastructure
Radiotherapy is an advanced technology for cancer treatment involving large quantities of
complex data; from imaging systems and planning algorithms, to treatment delivery and
verification. The VoxTox dataset is unique in that it incorporates full treatment planning data
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(CT images, structures, plan, dose) alongside daily treatment data (image guidance scans,
structures, dose) and toxicity data (baseline, acute, late), all prospectively collected for 874
patients (Table 3.1). The VoxTox project was launched in 2013, and it took several years to
develop systems capable of handling and processing such large volumes of patient imaging,
structure, dose, and outcome data.
Table 3.1 VoxTox patient numbers for ‘discovery’ and ‘consolidation’ cohorts across 3 clinical sites (prostate,
head and neck, and central nervous system, CNS), treated between 2013 and 2018, as recorded May 2018.
Prostate Head & Neck CNS
Discovery 268 95 -
Consolidation 267 220 24
Total (n = 874) 535 315 24
The VoxTox dataset consists of two discrete patient cohorts, ‘discovery’ and ‘consolida-
tion’. The discovery cohort patients were patients who had previously been treated and were
recruited retrospectively. Full imaging and dosimetric information were available. Toxicity
data were collected prospectively, but baseline data were sparse and, where available, were
extracted manually from clinical notes. Furthermore, these patients were treated prior to the
implementation of formalised VoxTox contouring and imaging protocols. The consolidation
cohort patients were recruited prospectively, at diagnosis. Detailed toxicity data, including
baseline, acute, and late symptoms, were recorded using electronic case reporting forms.
Standardised protocols were followed for contouring and imaging.
VoxTox patients were treated using TomoTherapy, a dedicated image-guidance intensity-
modulated radiotherapy system. The Hi-ART TomoTherapy linear accelerator is a 6 MV
linear accelerator on a rotating CT-type ring-gantry. The patient is positioned on one of
two TomoTherapy Hi-ART units, on the treatment couch, and megavoltage image guidance
scans are acquired to ensure accurate targeting of the tumour. Any required positional
corrections are made based on the daily images. The radiation treatment plan is then
delivered. Mechanical multi-leaf collimators shape the fan beam to deliver helical intensity
modulated radiotherapy (IMRT).
3.1.1 Megavoltage image guidance scans
A Xenon-filled CT detector is mounted on the ring-gantry, directly opposing the linear
accelerator, providing megavoltage computed tomography (MVCT) imaging capabilities.
The beam energy is reduced to 3.5 MV to enhance soft-tissue contrast and reduce imaging
dose to the patient to less than 3 cGy [174]. The MVCT field of view is shorter than the kVCT
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planning scan field of view which limits the imaging dose, yet is sufficient for positional
verification using soft tissue matching. The ‘coarse’ image setting is used, providing imaging
slices every 6 mm. Compared to kVCT imaging, the MVCT image quality is poorer due to
lower contrast at soft tissue boundaries and reduced signal to noise ratio.
For each treatment fraction, an MVCT image is acquired immediately prior to treatment
delivery for the purposes of online target localisation. Patient positioning and anatomy is
compared with the reference planning kVCT image to visually verify target accuracy. Small
rigid translations of the treatment couch (anterior-posterior, superior-inferior, left-right)
or gantry angle (roll) may be applied to register the MVCT with the kVCT and align the
anatomy. Motion during treatment, or intrafraction motion, was not possible to monitor and
is outwith the scope of this investigation. For prostate radiotherapy, image registration is
prioritised for the planning target volume (PTV). IGRT scans are inspected for rectal dilation
and if deemed excessive, remedial action is taken prior to treatment delivery. However, other
than qualitative visual inspection of rectum and bladder volumes, variations in size, shape, or
position of organs at risk (OARs) are generally not taken into consideration.
The VoxTox project identified that the full potential and value of information available
within IGRT images was being unrealised. Important information on daily positioning of,
and hence true dose being received by, OARs at time of treatment is generally disregarded
in routine clinical practice. Within VoxTox, systems have been developed for automatic
detection of OARs on MVCT scans, and independent calculation of dose based on the
Hounsfield Units (HU) of the MVCT scan. This enables quantitative information to be
extracted from MV IGRT scans, which facilitates the calculation of delivered dose to the
OARs.
3.1.2 Calculating delivered dose
An independent dose calculation software, CheckTomo, was internally developed at Cam-
bridge University Hospitals by Dr Simon Thomas [152, 154]. CheckTomo is a ray-tracing
dose calculation algorithm, utilising the HU values directly from the MVCT images. The
MVCT HU values have been shown to be sufficiently stable for accurate dose calculation, and
imaging systems are calibrated weekly. Initially developed for the purposes of treatment plan
verification, the system is capable of calculating full 3D volumetric dose distributions [154].
In the first iteration of dose-toxicity analysis, accumulated dose calculated using Check-
Tomo was compared with planned dose from the TomoTherapy treatment planning system.
Further advances were made so that a comparison could be made between planned and
accumulated dose, both calculated using CheckTomo. Comparative measurements were
acquired at each stage to test the effect of updating the algorithms.
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3.1.3 Autosegmentation of the rectum
The development of robust and automated approaches to segmentation has been identified as
a key aspect in the pursuit of delivered dose calculation for adaptive radiotherapy [82], as
manual contouring of daily image guidance scans is unfeasible for large volumes of patients.
Autosegmentation was an essential tool for the VoxTox study; with over 500 prostate patients,
each with 20 or 37 IGRT scans each, and an average of 12 slices per scan, it would have been
unfeasible to manually contour over 14,000 image sets, totalling over 170,000 image slices.
Fig. 3.1 Rectal contours (red); (a) manually contoured on the kVCT scan, (b) autosegmented on a daily MVCT
image guidance scan, showing a larger contour with air cavities, (c) autosegmented contour on another daily
MVCT image guidance scan, showing another change in contour with respect to baseline due to increased
rectal contents.
A common approach in the literature for identifying contours from IGRT is through
deformable image registration (DIR). The anatomy can be morphed from the image of the
day to the template planning CT scan via deformation vectors. Registering anatomy to the
planning scan can allow dose calculation to the organs using the treatment planning system.
However, a problem when considering the application of DIR to the rectum is that it undergoes
large and unpredictable spatial deformations caused by rectal contents and intestinal gas [97,
114, 136, 161]. Common DIR algorithms struggle due to intensity variations and the lack of
one-to-one correspondence between a full, gassy, or empty rectum [40, 114, 175]. Previous
studies investigating the dosimetric effects of interfraction rectal motion have been dependent
upon manual delineation of the rectum on IG scans [11, 43, 44, 75, 85, 96, 123, 125,
145], consequently being limited in sample size. One approach attempting to address this
limitation was to apply a blurring filter and implement statistical simulations to estimate
motion-inclusive delivered dose [155]. A common recommendation of these studies was the
development of robust systems for autosegmentation of the rectum, as a crucial component
towards achieving automated adaptive radiotherapy for prostate patients.
The algorithm developed for autosegmentation of the rectum on MVCT scans within the
VoxTox study was developed by Prof Michael Sutcliffe, Cambridge University Department
of Engineering. The algorithm is a primary segmentation system based on a modified Chan-
Vese algorithm [39]. Pre-processing steps involve HU/intensity scaling, identifying search
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regions, dealing with air pockets, and handling the prostate. Optimal values were derived
for smoothing, weighting, and bias parameters. For each slice, the starting point and search
region are defined by the planning contour from the original kVCT. HU values in the soft
tissue range corresponding to rectal material (-10 - 100 HU), as well as regions identified
as air pockets (< -130 HU), are rescaled and assigned a greyscale intensity value between
0 - 1. The algorithm then identifies the rectal contour in 2D. Post-processing in 3D is used to
detect erroneous contours (often in regions of low contrast-to-noise such as the lower-third),
and improves these either via interpolation or direct replacement with the original kVCT
planning contour as a best estimate.
Within this PhD, work was done to identify areas of improvement in the autosegmentation
algorithm. A small study was undertaken to identify erroneous contours, which occurred
particularly around regions of air pockets and at large diameters. The results of this study
were reported back to Prof Sutcliffe and improvements were implemented within the code.
With each iteration, dosimetric evaluations were conducted to assess the effect, and fed
back to VoxTox colleagues. The final version used for reporting all patient results for the
consolidation cohort was version 1.6. The details of version 1.6 of the autosegmentation
algorithm were published jointly by Shelley & Sutcliffe [143] in the journal of Biomedical
Physics & Engineering Express.
3.1.4 Automated processing
Plan, imaging, contour, and dose data were stored as Digital Imaging and Communications in
Medicine (DICOM) files and tokenised to VoxTox identifiable labels [132]. Down-sampled
kVCT images were extracted from the TomoTherapy archive. Once removed of patient
identifiable information, the data were transferred from the hospital to the University of
Cambridge Department of Physics. Batch processing was performed using the computational
task-management system GANGA (Gaudi and Grid Alliance) [102, 154]. Automated pro-
cessing was an essential element of the VoxTox workflow, allowing large-scale calculation of
patient data, independent of clinical systems. Total data volume for 870 patients amounted to
approximately 250 GB and was stored on the Large Hadron Collider (LHC) Tier 2 Centre at
the University of Cambridge Cavendish Laboratory.
3.1.5 Recording toxicity
With ever improving disease control [53, 50] and survival rates [32], post-treatment quality of
life becomes an increasingly significant consideration during treatment planning, alongside
target coverage. Despite technological advances allowing improved tumour targeting and
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avoidance of organs at risk due to the tight dose conformity achieved through intensity
and volumetric modulated, rectal toxicity in prostate radiotherapy remains a clinical issue,
with rates reported in the literature of up to 22 % for late rectal bleeding greater than
grade 2 [71, 87].
Interpretation of toxicity studies in the literature can be difficult due to the plethora
of different reporting systems available [77]. For example, rectal toxicity outcomes have
been reported using scoring systems such as Common Terminology Criteria for Adverse
Events (CTCAE) [158], Late Effects of Normal Tissues/Subjective, Objective, Management,
Analytic (LENT-SOMA) [1], University of California, Los Angeles, Prostate Cancer Index
(UCLA-PCI) [89], Radiation Therapy Oncology Group (RTOG) [127], as well as outcome
measures developed locally from reporting institutes. Furthermore, definitions of symptoms
and grading intervals can differ between reporting systems. Toxicity is considered to be noisy
data, as conditions and severity can be subjective to the patient and/or reporting clinical staff.
A toxicity questionnaire was purpose-designed for the VoxTox study by Dr Jessica Scaife
and Amy Bates, Lead Research Radiographer, which encompassed all observational toxicity
endpoints reported in prostate radiotherapy trials in UK within the previous 15 years [137].
Electronic case reporting forms (eCRF) and patient reported outcome measures (PROMs)
were used for prospective data collection of baseline (prior to start of treatment), acute (during
treatment and up to 90 days post-treatment), and late (beyond 90 days post-treatment) toxicity
incidence. Toxicity was assessed via radiographer interview and patients were followed for 5
years following treatment.
For analysis of the consolidation cohort, 7 clinical endpoints were investigated, as
shown in Table 3.2. The range of toxicity endpoints investigated were selected based on
the most commonly reported toxicity outcomes presented in the literature [70, 77]. For
each endpoint, increasing grades of severity were included where the incidence rate was
greater than approximately 10%. In general, grade 1 toxicity refers to asymptomatic or mild
symptoms with no intervention required, grade 2 indicates moderate symptoms requiring
clinical intervention, and grade 3 denotes severe symptoms. Within the VoxTox dataset, no
patients reported grade 4 toxicity or above.
3.1 VoxTox infrastructure 33
Table 3.2 Definitions of toxicity endpoints investigated in the VoxTox consolidation cohort dataset. The grading
system refers to increasing severity. CTCAE = Common Terminology Criteria for Adverse Events v4.03 [158],
RTOG = Radiation Therapy Oncology Group [127], RMH = Royal Marsden Hospital [70], UCLA-PCI =
University of California, Los Angeles, Prostate Cancer Index [89]. A semicolon indicates ‘or’, and a dash
indicates that a grade is not available. ADL = activities of daily living. Grade 0 would indicate no reportable
toxicity.
Toxicity endpoint
(Scoring system) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhoea
(CTCAE)
Increase of <4 stools
per day; mild increase
in ostomy output
Increase of 4 - 6 stools
per day; moderate increase
in ostomy output
Increase of ≥ 7 stools
per day; incontinence;
hospitalisation; severe
increase in ostomy output;
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3.2 Interpreting rectal toxicity
The processing of patient reported toxicity data was not fully automated, and required manual
intervention in order to be output in a useful format. Data from PROMs recorded within
the eCRFs, were exported in a raw format. Translating PROMs into formalised clinical
endpoints requires deep clinical understanding and interpretation. The mapping rules from
raw questionnaire answers to populating standardised reporting systems were externally
verified by Dr Agnieszka Lemanska, University of Surrey. The process of extracting raw
toxicity data and translating into standardised reporting formats ready for analysis involved
several stages and depended upon the input of Amy Bates, Lead Research Radiographer,
Cambridge University Hospitals, Karl Harrison, Research Associate, Cavendish Laboratory,
and Dr David Noble, Clinical Research Fellow, Cambridge University Hospitals. The final
interpretation of the data and combining with dosimetric and baseline data was performed
within the scope of this PhD.
The VoxTox research programme ceased patient recruitment in May 2018. The data
analysed in this thesis for the consolidation cohort are from the patient spreadsheet frozen in
January 2018. This included 186 patients with full dose information, baseline toxicity, and a
minimum of 2 year follow up, with complete data entries at 6 months, 1 year, and 2 years.
Of these, 110 patients were prescribed 74 Gy, and 76 patients prescribed 60 Gy.
The clinical endpoints reported for rectal toxicity within this thesis covered the most
commonly reported toxicity endpoint in the literature and included: CTCAE Diarrhoea [158],
CTCAE faecal incontinence [158], CTCAE proctitis [158], CTCAE rectal bleeding [158],
UCLA-PCI bowel bother [89], LENT-SOMA stool frequency [1], and RTOG gastrointestinal
(GI) toxicity [127]. For bowel bother, UCLA reporting system has been translated to the
Royal Marsden Hospital (RMH) scale [70] so that increasing severity is reflected in an
increase in numerical scale (from 0 to 5), similar to other toxicity endpoints being reported.
Incidence rates are presented for all consolidation cohort patients in Figure 3.2. The toxicity
rates recorded within the VoxTox trial were generally on the high side of the ranges reported
in the literature. This could be due to the study commencing prior to CHHiP [57] dose
constraints being applied in treatment planning, or to the heightened sensitivity of reporting
facilitated by the design of the patient questionnaires. However, the rate of bowel toxicity
≥Grade 2 (CTCAE), 5 year cumulative incidence, amongst VoxTox prostate patients was
17%, which falls within the RTOG bowel toxicity ≥ Grade 2 (RTOG) range of 13.7–24.9%
for IMRT over the same timeframe, reported by Dearnaley et al. [52] and Wortel et al. [171],
respectively. These rates of incidence indicate that toxicity remains an important clinical
issue.
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Fig. 3.2 Cumulative incidence of rectal toxicity at 2 years for consolidation cohort patients (March 2018).
Grade 0 indicates no toxicity.
3.3 Combining fractionation schedules
The standard dose prescription for men with localised prostate cancer receiving radical
radiotherapy in the UK was updated in 2016 as a result of evidence published by the CHHiP
trial [52, 108]. The 5-year follow-up analysis demonstrated that 60 Gy delivered in 20
fractions of 3 Gy was non-inferior in terms of biochemical control, with non-significant
differences in toxicity incidence, than the previous recommendation of 74 Gy delivered in 37
fractions of 2 Gy. Of 497 VoxTox prostate patients (as of 5th April 2017), 34% (n = 171)
were prescribed 60 Gy in 20 fractions, and 66% (n = 326) were prescribed 74 Gy in 37
fractions (60/192 of 252 discovery and 111/134 of 245 consolidation patients, prescribed
60/74 Gy, respectively). Because the CHHiP trial found the two prescription regimes to be
equieffective, VoxTox data were combined into a single dataset for toxicity analysis.
In the clinic, radiobiological equations are used to compare or combine different fraction-
ation schedules. The biologically effective dose (BED), Equation 3.1, is a common measure
which accounts for dose per fraction (d), number of fractions (n), and total dose (D), as well
as the tissue-specific biological response, characterised by the α/β ratio. The constants α
and β determine the shape of the cell survival curve in the linear-quadratic model, where
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surviving fraction SF = exp(αD+βD2). Typically, the α /β ratio is around 3 Gy for normal








The metric commonly quoted in clinical practice for combining different fractionation






However, for combining the VoxTox data it was not desirable to obtain the EQD2Gy, but
instead convert the 60 Gy fractionation to Equivalent Dose in 37 fractions, EQD37#. This is
because although 60 Gy in 20 fractions is now the recommended dose prescription in the
UK, within this thesis fractionations have been converted to 37 fraction equivalence in order
to retain validity and applicability within the wider international context, where generally
doses of up to 84 Gy are delivered over a longer treatment course duration. Furthermore, the
prescription dose to the tumour is distinct from the inhomogeneous doses received by the
rectum, whereas the fractionation schedule has a direct impact on the dose response. This
approach was also followed by Holyoake et al. for modelling duodenum toxicity [78], and is
more appropriate when combining and analysing equivalent effects.














The α /β ratio for late response of the rectum often reported in the literature is 3 Gy [97].
This value assumes a uniform dose distribution received by the whole organ which is not
the case for modern IMRT so may not be appropriate for combining VoxTox dose data.
Studies in the literature have quoted derived α/β ranges from 1.5 to 4.8 [58, 31, 95]. For
VoxTox patient analysis, a study-specific α /β ratio was derived by fitting the data to CHHiP
dose constraints and assuming equieffectivness between the two fractionation schedules [52].
The Equivalent Uniform Dose (EUD) for all dose bins up to 74 Gy was calculated to be
64.4 Gy, using Equation 3.4. The α/β ratio was iteratively refined until the EUD of the
60 Gy prescription converted to EQD37# was also equal to 64.4 Gy. The optimal α/β ratio
was found to be 2.149. This was close to the optimised α/β ratio of 2.3 Gy determined by
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Table 3.3 Sensitivity of dose-toxicity association to change in α/β ratio. Comparison of EUD discriminative
ability for CTCAE grade 2 rectal bleeding, quantified using area under the receiver operator curve (AUC) with
corresponding 95% confidence intervals (CI). Presented α /β ratios representative sample within range reported
in the literature.
α/β AUC 95% CI
1.5 0.665 [0.550, 0.780]
2.149 0.638 [0.527, 0.749]
2.5 0.622 [0.509, 0.735]
3 0.613 [0.496, 0.729]
4 0.565 [0.440, 0.689]
4.8 0.547 [0.415, 0.680]
Marzi et al. [95]. Using an α/β ratio of 2.149, the EQD37# of 60 Gy in 20 fractions was
calculated as 74.31 Gy, and the final BED calculations for 60 Gy in 20 fractions and 74 Gy
in 37 fractions were 143.76 Gy and 142.87 Gy, respectively, agreeing to within 1 Gy (<1%).
By comparison, using the standard α/β ratio of 3 produced a difference of 1.5 Gy in EUD
calculation between the two fractionation regimes, and a difference of 3.3 Gy (2.3%) between
BEDs .
To examine the sensitivity of dose-toxicity association to a change in α /β , a representative
sample of values within the range reported in the literature was used to calculate EQD37#.
The effect on the magnitude of dose-toxicity association between EUD and CTCAE grade 2
rectal bleeding was compared using the area under the receiver operator characteristic curve
(AUC). Results are shown in in Table 3.3. The extremes of the range of α/β ratios reported
in the literature (1.5 v 4.8) can lead to a 12% discrepancy in reported AUC, where one
could be considered predictive of rectal bleeding, and the other considered insignificant.
However, the VoxTox derived value of 2.149 and the commonly accepted value of 3 yielded
a difference in AUC of only 2.5%, where overlapping confidence intervals suggest that the
difference between these results could be non-significant. Due to the consideration of the
inhomogeneous dose distribution received by the rectal wall in determining the VoxTox-
derived α /β ratio, the value of 2.149 is used for analysis of the combined cohort throughout
this thesis. Once these values and equations had been determined the DSMs for patients
prescribed 60 Gy in 20 fractions were corrected to EQD37#. Combining the datasets this way
allowed a larger patient population to be analysed.
To generate EQD37#, EUD was equalised between 60 and 74 Gy fractionation regimes.
EUD represents the uniform dose which would lead to equivalent probability of normal tissue
injury as the corresponding inhomogeneous dose distribution [66]. As shown in Equation 3.4,
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EUD is a form of weighted mean, calculated over N unit increments, dependent upon model









For gastrointestinal toxicity, n has been commonly accepted as 0.09, but ranges from 0.03
to 0.5 have been applied in the literature [87]. To investigate an optimal value for n based on
VoxTox data, the sensitivity of dose-toxicity correlation to parameter n was investigated for
0.02≤ n ≤1, corresponding to a ∈ {50,1}. Toxicity associations were assessed between EUD
and CTCAE grade 2 rectal bleeding, as well as CTCAE grade 2 proctitis, and corresponding
AUC values are presented in Figure 3.3. AUC results were found to plateau for both rectal
bleeding and proctitis at approximately a = 11, corresponding to n = 0.09, before a slow AUC
decrease at a > 25. Above a = 5, AUC varied by less than approximately ± 1 %. Therefore,
in accordance with previous findings in the literature, the value a = 11.11(n = 0.09) was
retained for all EUD calculations throughout this thesis.
Fig. 3.3 Dose-toxicity sensitivity to EUD parameter a (where a = 1/n), shown for CTCAE grade 2 rectal
bleeding and CTCAE grade 2 proctitis. Discriminative ability is compared using the area under the receiver
operator characteristic curve (AUC).
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Table 3.4 Toxicity rates for consolidation (consol.) cohort, training and validation sets, subdivided by prescrip-
tion level. Faecal incont. = faecal incontinence, Proct. = proctitis, RB = rectal bleeding, GI tox = gastrointestinal





















186 (100.0) 110 (59.1) 76 (40.9) 139 (75) 82 (59.0) 57 (41.0) 47 (25) 28 (59.6) 19 (40.4)
Diarrhoea 48 (25.8) 30 (16.1) 18 (9.7) 36 (25.9) 22 (15.8) 14 (10.1) 12 (25.5) 8 (17.0) 4 (8.5)
Faecal incont. 32 (17.2) 21 (11.3) 11 (5.9) 24 (17.3) 16 (11.5) 8 (5.8) 8 (17.0) 5 (10.6) 3 (6.4)
Proct. ≥ G1 35 (18.8) 18 (9.7) 17 (9.1) 26 (18.7) 13 (9.4) 13 (9.4) 9 (19.1) 5 (10.6) 4 (8.5)
Proct. ≥ G2 27 (14.5) 13 (7.0) 14 (7.5) 20 (14.4) 9 (6.5) 11 (7.9) 7 (14.9) 4 (8.5) 3 (6.4)
RB ≥ G1 62 (33.3) 32 (17.2) 30 (16.1) 46 (33.1) 24 (17.3) 22 (15.8) 16 (34.0) 8 (17.0) 8 (17.0)
RB ≥ G2 21 (11.3) 10 (5.4) 11 (5.9) 16 (11.5) 8 (5.8) 8 (5.8) 5 (10.6) 2 (4.3) 3 (6.4)
GI tox. ≥ G1 98 (52.7) 58 (31.2) 41 (22.0) 73 (52.5) 43 (30.9) 30 (21.6) 25 (53.2) 15 (31.9) 10 (21.3)
GI tox. ≥ G2 30 (16.1) 15 (8.1) 15 (8.1) 22 (15.8) 11 (7.9) 11 (7.9) 8 (17.0) 4 (8.5) 4 (8.5)
Bowel freq. 45 (24.2) 28 (15.1) 17 (9.1) 34 (24.5) 21 (15.1) 13 (9.4) 11 (23.4) 7 (14.9) 4 (8.5)
Bother ≥ G1 73 (39.2) 43 (23.1) 30 (16.1) 55 (39.6) 32 (23.0) 23 (16.5) 18 (38.3) 11 (23.4) 7 (14.9)
Bother ≥ G2 43 (23.1) 24 (12.9) 19 (10.2) 32 (23.0) 18 (12.9) 14 (10.1) 11 (23.4) 6 (12.8) 5 (10.6)
Bother ≥ G3 17 (9.1) 12 (6.5) 5 (2.7) 13 (9.4) 9 (6.5) 4 (2.9) 4 (8.5) 3 (6.4) 1 (2.1)
3.4 Training and validation data sets
The 186 consolidation cohort patients were split into training (75%, n = 139), and validation
(25%, n = 47). The reason for splitting the cohort was to validate final toxicity prediction
models using data that were not used in the construction of the model. A model generated
using training set data only will have greater variance than models generated using the entire
cohort. However, this approach is preferable for strengthening the power of a predictive model
according to the Transparent reporting of a multivariable prediction model for individual
prognosis or diagnosis (TRIPOD) statement [45], and recommendations from experienced
lecturers on the ESTRO course on Dose Modelling and Verification for External Beam
Radiotherapy held in MAASTRO, 2018. The data were non-randomly split by stratifying
patients first by fractionation schedule, then by toxicity incidence. This is considered a
Type 2b analysis type in the TRIPOD statement. In order to retain the proportions of toxicity
between training and validation sets, patients were randomised for each individual toxicity
endpoint. Final toxicity incidence rates for consolidation cohort patients are displayed
in Table 3.4 for the entire cohort, as well as training and validation sets, and are further
subdivided by prescription level.
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3.5 Dose surface maps of the rectal wall
In the early dose-toxicity analysis of the discovery cohort conducted within this thesis, dose
to the rectal wall was represented using dose surface maps (DSMs). This was identified as
an appropriate analysis technique because the rectum is a hollow tubular-like organ where
dose to the rectal wall is the parameter of interest. Furthermore, for the purposes of dose
accumulation, DSMs retain spatial information which would be lost if adopting the more
conventional dose-volume histogram approach.
The process of constructing the DSMs from the VoxTox dose and structure data was
initially developed by Dr Simon Thomas, Head of Medical Physics & Clinical Engineering,
Cambridge University Hospitals. Following the methods first described by Buettner et al. [27],
a two-dimensional representation of dose to the rectal wall was generated by virtually ‘cutting’
along the posterior rectal wall and ‘unfolding’ to produce the dose surface map. Rather than
identifying the posterior cutting point as the most posterior point of the rectal contour on a
given slice, in VoxTox this point is identified as the point directly posterior to the centroid
of the rectal contour. Each slice was normalised to a set number of pixels, defined as the
number of slices along the full length of the rectum from the planning CT scan.
3.6 Integrating finite element analysis into VoxTox
For analysis of the consolidation cohort, physical-based biomechanical models were devel-
oped for accumulation of dose at the voxel level. Using biomechanical modelling to simulate
inter-fraction motion of the rectum provides a more anatomically representative basis for
dose accumulation than the 2D DSM approach described previously, which is limited to
normalised planar expansion only. Three-dimensional finite element analysis allows high
resolution accumulation of dose-histories at the voxel level. Similar to the Morfeus system
described previously, the biomechanical model was developed using Abaqus, a Computer
Aided Engineering (CAE) Finite Element Analysis (FEA) environment (Dassault Systèmes).
The simulated rectal model was initially developed by Prof Michael Sutcliffe, Cambridge
University Engineering Department and was adapted for experimental feasibility studies by
BSc and MEng students. Within the scope of this PhD project, the code was modified in
order to read and process patient DICOM files, model parameters were optimised for the
rectal wall, and the system was integrated into the VoxTox workflow.
Patient data were stored in DICOM proprietary format which requires careful handling
and consideration before it can be meaningfully processed. In order to streamline biomechan-
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ical modelling of large-scale patient data, an automated workflow was implemented. Total
processing time for a patient with 37 fractions was approximately 25 minutes.
An overview of the four data processing stages is shown in Figure 3.4, with detailed
explanation below:
3.6.1 Input
The kVCT contours, manually defined for the purposes of treatment planning, and the daily
autosegmented MVCT contours were stored as DICOM (RS) structure files which were read
into MatLab. The contours were assigned geometric coordinates from the corresponding
image set (RI). At the time of treatment, the patient is set up on the couch by aligning small
tattoos on the skin with in-room lasers. Image guidance scans (MVCT) were used to confirm
that the positioning of the internal anatomy matches that of the treatment planning scan
(kVCT). Minor positional corrections can be applied in the right-left, superior-inferior, and
anterior-posterior directions via ‘couch shifts’ to ensure the target is adequately covered (roll
can also be corrected for using small gantry rotational offsets). These small daily couch
shifts were recorded by the TomoTherapy unit and added to private tags in the DICOM image
header during the data extraction process. In order to register all MVCT images, structures,
and doses to a common coordinate system, i.e. that of the original kVCT scan, these shifts
were appropriately applied.
3.6.2 Pre-processing
Once all patient information was registered, the input file for Abaqus was generated. For
each patient, a common starting structure was defined, based upon the centreline of the rectal
contour from the kVCT scan. A central mandrel ‘innerpart’ was generated by expanding from
the centreline to a cylindrical tube of fixed radius, with an ‘outerpart’ consisting of 8-node
brick elements. This allows identification and tracking of individual material elements,
surrogates for voxels, undergoing simulated deformation throughout the entire course of
treatment.
The registration-corrected contours direct the final innerpart positioning using displace-
ment loading, simultaneously expanding the outerpart through surface contact interaction.
Deformation of individual elements was dependent upon the biomechanical properties and
boundary conditions applied.
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3.6.3 Finite element simulation
Biomechanical modelling was run autonomously using input files. Starting from the internal
mandrel, the deformation of individual elements depends on the biomechanical properties
and boundary conditions applied. Final surface data are extracted from the deformed model
using a Python script.
3.6.4 Post-processing
The coordinates of the deformed rectal contour were imported into MatLab. The correspond-
ing DICOM dose (RD) matrix was read and registered to the corrected coordinate system.
The delivered dose to each element was then calculated via interpolation. Final delivered dose
accounts for the effect of interfraction motion, improving upon previous solutions through
the application of biomechanical modelling to predict voxel-level deformations.
Fig. 3.4 Diagram demonstrating the interaction between patient data (DICOM RS structure, RI image, and RD
dose files), finite element modelling (FEM), and final dose output when integrating biomechanical modelling
into the VoxTox process
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3.7 Summary
The components described in this chapter provide the foundations for the work conducted
within this PhD thesis and will be referred to throughout. Automation was a primary focus
when developing these systems due to the large scale processing of patient data required. The
systems have been collaboratively developed by members of the multidisciplinary VoxTox
team with the ultimate aim of addressing the hypothesis that delivered dose to the rectum is
a better predictor of toxicity than planned dose in prostate radiotherapy. During this PhD
project scientific contributions were made in several areas; identifying where improvements
could be made in the autosegmentation software (which led to system updates), comparative
measurements were conducted for updates in both the dose calculation and autosegmentation
algorithms, dose-toxicity analysis was performed using parameters extracted from DSMs,
the biomechanical modelling system was adapted for handling VoxTox patient data, high
volumes of toxicity data were processed and analysed, and novel methods were developed
for analysing and parameterising accumulated delivered dose to rectum from finite element
models, and finally, all data were combined in order to translate and communicate these




Dose-toxicity analysis using rectal dose
surface maps
In this chapter, two-dimensional dose surface maps (DSMs) of the rectal wall are parame-
terised for both planned and accumulated dose in order to explore dose-toxicity associations.
Methods previously developed for quantifying planned DSMs are applied to accumulated
DSMs that have been calculated by summation of daily delivered DSMs. Two cohorts from
the VoxTox study were investigated: the discovery cohort, collected prior to formalised
imaging protocols or collection of baseline data; and the consolidation cohort, with full
baseline data and standardised imaging.
4.1 Introduction
In prostate radiotherapy, the correlation between dose to rectum and toxicity has been the
focus of many research studies. The rectum is one of the dose-limiting organs when planning
intensity-modulated radiotherapy (IMRT) to the prostate due to the risk of radiation-induced
adverse effects. Modern systems for inverse IMRT treatment planning iteratively seek to
achieve an optimal plan, delivering maximal dose to the tumour volume and minimal dose
to healthy organs. Current normal tissue complication probability (NTCP) models and
conventional treatment planning constraints are based upon dose–volume histogram (DVH)
data to minimise the risk of toxicity. With ever improving disease control [51, 53] and
survival rates [32], there is an increasing emphasis on post-treatment quality of life and many
research institutes are now focusing on improving the understanding of adverse effects of
radiation to healthy organs in order to reduce toxicity incidence.
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The DVH-based approach to radiotherapy treatment planning has been criticised for
lacking in spatial dose consideration [3]. Consequently, accumulation of DVHs is not dosi-
metrically representative and results in false overestimations of dose. A review by Landoni
et al. [87] emphasises the need to assess associations between spatial dose patterns and late
toxicity [47], particularly as results may reveal inhomogeneous intra-organ radiosensitivities.
Several research groups have explored alternative approaches for parameterisation of dose
distributions in order to establish links with toxicity. Methods have included dose-surface
histograms [26, 27, 74, 121], dose-surface maps [26, 27, 104], dose-line histograms [74],
principal component-based pattern analysis [150], and voxel-based approaches for identifying
rectal subregions [3, 60]. These studies have been limited in their analysis by the availability
of planned dose data only, based on a single anatomical snapshot in time.
A common recommendation in the literature has been the need to establish dose-toxicity
models based on delivered dose [82]. However, this has proven technically challenging
to date due to hardware and software limitations. These challenges have been addressed
within the VoxTox Research Programme [30, 46] where contours generated from on-treatment
megavoltage computed tomography (MVCT) image guidance scans are used to calculate daily
delivered dose. This approach has made it possible to account for the effect of interfractional
anatomical variation. Total delivered dose can be estimated by accumulating daily delivered
dose throughout the course of radiotherapy. Studies by the VoxTox group have demonstrated
that the rectum moves more than previously predicted based on estimates from prostate
motion [136], and that planned dose is not equal to delivered dose [139].
The dose–surface map (DSM) approach has been implemented within this study as a
solution enabling meaningful accumulation and conservation of geometric information, an
advantage over the DVH methodology. The concept of accumulating DSMs to estimate
total delivered dose has been applied previously for the bladder [121]. By extracting spatial
parameters from DSMs of delivered dose, and linking with the archive of patient follow-
up data available within VoxTox, it was hypothesised that stronger correlations could be
established with late toxicity than previously achievable using planned dose alone. Ultimately,
improved dose-toxicity modelling based on delivered dose could facilitate real-time in silico
prediction of NTCP within the clinical pathway.
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4.2 Discovery cohort analysis
4.2.1 Material and methods
4.2.1.1 VoxTox study design & patient information
One hundred and nine prostate cancer patients were selected from the discovery cohort of
the VoxTox research programme [30, 46]. This cohort comprised patients treated prior to
the formal collection of baseline data, but for whom prospective follow-up data of at least
2 years were available (median 4 years). Early VoxTox patients were selected based on
expected benefit from IMRT rather than conventional 3D conformal radiotherapy. Patients
in this study were included on the basis of availability of pre-existing toxicity status from
clinical notes, or no reported toxicity, and were limited to those prescribed IMRT to a dose of
74 Gy in 37 fractions, the standard of care in the UK at the time [107]. VoxTox patients were
treated with TomoTherapy® (Accuray, Sunnyvale, CA). Manual contouring of the anatomy
on the kilovoltage computed tomography (kVCT) planning scan was performed according
to local procedures [139], adapted from clinical trials. Daily MVCT image guidance scans
were acquired immediately prior to treatment delivery for the purposes of online target
localisation [29]. Following departmental imaging protocols, scans were inspected for rectal
dilation and if deemed excessive, remedial action was taken prior to delivery of radiation
therapy [153].
4.2.1.2 Dose–surface map construction & dose accumulation
Fig. 4.1 A cutting point di-
rectly posterior to the cen-
tre of mass of the rectal con-
tour (red cross) at each slice
was found to be more sta-
ble for DSM dose accumu-
lation than the most poste-
rior point (blue cross).
Within the VoxTox research programme, MVCT scans are multi-
functional; primarily for the purpose of routine image guidance,
they also provide a platform for calculation of delivered dose. The
rectum was identified on each MVCT image series using an in-house
autocontouring system based on a customised Chan-Vese segmenta-
tion algorithm [143]. Delivered dose was independently calculated
using a locally implemented ray-tracing algorithm [152, 154] and
the rectal contour-of-the-day, accounting for inter-fraction motion.
Automation and integration of dose calculation and contouring sys-
tems were essential for large-scale processing of the 4142 scans in
this study.
Planned and daily DSMs were generated based on algorithms
described by Buettner et al. [27] and Murray et al. [104]. The rectal
wall was considered the structure of interest, and was treated as a
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tubular surface rather than a volume. Contours were virtually ‘cut’ along the superior–inferior
axis and ‘unfolded’ to a two-dimensional plane. The ‘cutting point’ was identified as the
point on the contour surface directly posterior to the centre of mass of the rectal outline, on
each CT slice [139], rather than the most posterior point as used by Buettner et al. [27] in
their analysis of planned DSMs, as shown in Figure 4.1. For the purposes of accumulating
multiple DSMs per patient, the position of the most posterior point was found to be sensitive
to daily contour changes and large variations were observed. The cutting point selected here,
posterior to the rectal contour centre of mass, was found to be a more stable landmark.
The length of the planned-DSM was defined by the number of slices of the manually
contoured rectum on the kV planning scan (slice thickness 3 mm). The circumference of the
rectal contour on each slice was normalised such that the unfolded width of the planned-DSM
was equal to the length. Daily delivered DSMs calculated from the image-guidance MVCT
scans (slice thickness 6 mm) were normalised to the same width as the planned-DSM but
were restricted in length by the field of view (FOV), resulting in a shorter DSM, as shown in
Figure 4.2.
Rectal DSMs were calculated for each treatment fraction, and corrected for daily couch
shifts. For the purposes of dose accumulation, any ‘missing’ dose data cropped by the re-
stricted FOV superiorly or inferiorly (as indicated in grey in Figure 4.2) were substituted from
the planned-DSM [139] in order to maintain common dimensions between final accumulated-
DSM and planned-DSM . The final accumulated-DSM was resampled to match the 3mm
resolution of the planned-DSM, producing an easily comparable and interpretable spatial
Fig. 4.2 Generation of planned, daily delivered, and total accumulated dose surface maps (DSMs). Four of
37 daily DSMs are displayed. Daily DSMs are limited in length by the imaging field-of-view, and ‘missing’
(greyed) data were substituted using planned dose for the purposes of total dose accumulation.
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representation of total delivered dose to the rectal wall throughout the course of prostate
radiotherapy [154].
The use of planned-DSM data as a surrogate beyond the boundaries of the MVCT
FOV is assumed to be an acceptable estimate because the relative anatomical motion of
the rectum becomes more confined by surrounding musculature as the distance from the
prostate increases in the inferior direction [139]. However, this could reduce detection
sensitivity of potential differences and is a limitation when using DSMs to compare planned
and accumulated dose.
4.2.1.3 Dose parameters & clinical endpoints
Dose was parameterised from DSMs using two methods implemented in MATLAB ®(Math-
Works, Natick, MA):
1. Calculation of Equivalent Uniform Dose (EUD)
2. Fitting of DSM ‘dose-widths’ to discrete isodose clusters
Equivalent Uniform Dose (EUD) reduces the dose information extracted from the DSMs
to a single generalised value which allows comparison between inhomogeneous dose dis-
tributions [113]. An ‘a’ value of 11.11 was used to calculate EUD [94], as discussed in
Section 3.3. Spatial dose information was generated by reproducing Buettner’s ellipse-fitting
method [27], reporting the most significant dose quantifier, the lateral extent, termed here the
‘DSM dose-width’. An example case demonstrating how DSM dose-widths were extracted is
shown in Figure 4.3.
For a given isodose level, a binary image was created from the DSM by assigning a
pixel value of 1 to doses greater than or equal to the nominated isodose, with lower doses
assigned a value of 0. An ellipse was then fitted to the largest central cluster. The maximum
lateral extent of the ellipse was projected onto the DSM axis, accounting for any rotation
with respect to the DSM coordinate system. The resulting DSM dose-width, expressed as a
the percentage of total normalised DSM width, allowed parameterisation of the geometrical
dose distribution which would have been masked using a DVH approach.
For each patient, EUD and DSM dose-widths for isodose levels of 30, 40, 50, 60, 65,
and 70 Gy were calculated from planned-DSM and accumulated-DSM. Doses less than
30 Gy were not included as DSM dose-width measurements became dominated by values
greater than 100 %, indicating that the entire rectal circumference was receiving more than or
equal to the selected isodose level. By comparison to the binary image shown in Figure 4.3,
this would appear as a white band spanning the width of the DSM, at the plane where the
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Fig. 4.3 Calculation of DSM dose-widths. Binary images were generated in MATLAB at each discrete dose
level. The area in white indicates the largest cluster of pixels receiving a dose greater than or equal to the
specified dose level. MATLAB’s regionprops tool was used to fit an ellipse to the isodose cluster (red) and
extract the width of that ellipse (blue dashed arrow) as the DSM dose-width. This example shows the isodose
cluster and ellipse fitted to a dose level of 30 Gy for a patient prescribed 60 Gy in 20 fractions. The measured
DSM-dose width was 53 %.
DSM dose-width was being measured. Hence, DSM dose-widths at low dose levels were
being extrapolated beyond the dimensions of the DSM, and were therefore excluded from
the analysis. This was identified as a limitation of the ellipse fitting method when seeking
to analyse low dose toxicity correlations. At the other end of the dose scale, doses greater
than 70 Gy were also excluded from toxicity analyses due to the increasing frequency of
0 % DSM dose-widths, indicating that doses greater than or equal to the selected isodose
level were not received by the rectal wall. By comparison to Figure 4.3, the binary image
would be entirely black at the highest dose levels. From accumulated dose at 74 Gy, 55 %
of patients recorded a 0 % dose-width, increasing to 91 % at 75 Gy (compared with 3 %
and 41 % for planned dose, respectively). It was identified that a 0 % DSM dose-width
result could conceal information leading to misinterpretation of data when performing AUC
calculations so results at these dose levels were not reported. Despite these restriction, the
dose levels included within this study incorporate the 39–61 Gy range at which Buettner [27]
determined significant correlations between lateral extent and toxicity.
Study specific clinical reporting forms were developed by clinical colleagues when
setting up VoxTox to ensure robust collection of toxicity data, and raw data were used to
populate recognised systems, including: Common Terminology Criteria for Adverse Events
(CTCAE) v4.03 [158], Late Effects of Normal Tissues/Subjective, Objective, Management,
Analytic (LENT SOMA) scores [1]; Radiation Therapy Oncology Group (RTOG) grading
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Table 4.1 Clinical endpoints, scoring systems and incidence rates of the 6 most frequently reported toxicities
within the patient sample. † LENT SOMA [1] rectal bleeding ≥ grade 2 was equivalent to CTCAE [158] rectal
bleeding ≥ grade 1. ∗ Data were missing for 4 patients so sample size was reduced to 105.
Clinical Endpoint Scoring System Incidence% (n)
Objective rectal bleeding ≥ grade 2† LENT SOMA [1] 25.7 (28/109)
Proctitis ≥ Grade 2 Gulliford [70]/ RTOG [127] 16.5 (18/109)
Sphincter control ≥ grade 1 LENT SOMA [1] 10.1 (11/109)
Subjective rectal pain ≥ grade 1 LENT SOMA [1]/ CTCAE [158] 15.6 (17/109)
Bowel problems ≥ grade 1 Gulliford [70] 30.7 (32/105∗)
Bowel problems ≥ grade 2 Gulliford [70] 11.5 (12/105∗)
system [127]; University of California, Los Angeles, Prostate Cancer Index (UCLA-PCI)
questionnaire [89]. Receiver Operator Characteristic (ROC) curves were generated using
SPSS®(IBM®23.0.0.2) to evaluate the link between dosimetric parameters extracted from
planned and accumulated DSMs, and the six most prevalent clinical endpoints, listed in
Table 4.1.
The mean area under the curve (AUC), with associated upper and lower 95% confidence
intervals (CIs), was calculated for each ROC curve as a measure of the level of association
between dosimetric parameter and toxicity. An ideal correlation would have an AUC of 1.
Results were reported for dosimetric parameters with AUC≥0.6 and lower 95% CI≥0.5,
considered statistically significant by Gulliford et al. [71]. Generally, an AUC greater than
0.6 indicates acceptable discrimination, with AUCs below this level considered poor or
non-discriminative.
4.2.2 Results
4.2.2.1 Difference between planned and accumulated dose
Accumulated delivered dose was found to be systematically lower than planned dose. For all
patients, EUD of accumulated-DSM was lower than that of planned-DSM (mean difference
-2.2 Gy, standard error 0.3 Gy, range [-7.1, -0.3] Gy). Table 4.2 shows EUD breakdown for all
patients, as well as comparing patients with and without toxicity. DSMs provide insight into
the spatial distributions of regions of high dose difference. Difference maps between planned
and accumulated DSMs (Figure 4.4a) indicate concentrated regions of lower accumulated
dose up to -4 Gy corresponding to right and left lateral sides of the middle-third of the rectal
wall. Lower magnitudes of dose difference were observed in the mid-anterior rectal wall
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(a)
(b)
Fig. 4.4 (a) Difference between mean planned dose surface maps (DSM) and mean accumulated DSM for 109
patients from the discovery cohort, (b) Mean accumulated dose surface maps for patients with (n = 28) and
without (n = 81) rectal bleeding (RB). S = superior, I = inferior, P = posterior, R = right, L = left, A = anterior.
where the highest dose levels are recorded, closest to the prostate. This suggests that dose to
the right and left lateral sides are most affected by interfraction motion of the rectum. This
information is lost if considering EUD as a single spatial metric alone.
Splitting 109 patients from the discovery cohort into groups with and without rectal
bleeding, and calculating the mean DSM per group reveals further information (Figure 4.4b).
Results show that those experiencing RB received a greater dose than those who did not, and
the spatial DSMs in Figure 4.4b indicate that on average, these patients received a higher
dose of over 4 Gy across a lateral band spanning the circumference of the mid to upper rectal
wall.
4.2.2.2 Linking dosimetric parameters with rectal toxicity
Rectal bleeding
Twenty-eight patients reported rectal bleeding CTCAE ≥ Grade 1, which was equivalent
to LENT SOMA ≥ Grade 2. The AUC was greater for all accumulated DSM dose-widths
than planned DSM dose-widths up to 70 Gy (Table 4.3). Accumulated dose was found to be
discriminative of rectal bleeding at three DSM dose-widths where planned dose was not; 60
Gy, 30 Gy, and 40 Gy, ordered greatest to least significance (see Table 4.3). As shown in
Figure 4.5 (a), the lower 95% CI for the corresponding planned DSM dose widths extended
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Table 4.2 Breakdown of equivalent uniform dose (EUD) calculation for mean planned and accumulated dose
surface maps (DSMs), split by patients experiencing CTCAE rectal bleeding (RB) for 109 patients from the




Accumulated DSM Difference (Gy)
All patients 60.06 57.99 -2.07
No RB (n=81) 59.82 57.70 -2.12
RB ≥ G1 (n=28) 60.84 (+1.02) 58.92 (+1.22) -1.92
G1 RB (n=18) 60.34 (+0.52) 58.09 (+0.39) -2.24
G2 RB (n=9) 62.00 (+2.18) 60.77 (+3.07) -1.23
below 0.5 indicating that planned dose can not be considered a significant predictor of rectal
bleeding at these DSM dose-width levels.
A similar level of statistical correlation was observed for both accumulated and planned
dose with rectal bleeding at three DSM dose-widths; 50, 65, and 70 Gy. The strongest spatial
predictor of rectal bleeding was the accumulated 65 Gy DSM dose-width (AUC 0.664), and
the largest difference between planned and accumulated DSM dose widths was at 60 Gy
(AUC difference 0.035). The relatively low variability between different AUCs at different
dose levels may be due to the collinear nature of radiotherapy dose delivery, where a greater
high-dose proportion subsequently leads to a greater low-dose contribution depending on the
gradient of dose fall-off.
Overall, EUD exhibited the strongest correlation with rectal bleeding for both accumu-
lated and planned dose, AUC 0.682 and 0.673 respectively.
Table 4.3 Mean Area Under the Curve (AUC) for planned and accumulated DSM dose-widths and EUD
corresponding to rectal bleeding ≥ Grade 2 (LENT SOMA) and ≥ Grade 1 (CTCAE), n = 28/109. The greater
AUC of each parameter has been presented in bold.
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(a)
(b)
Fig. 4.5 Mean area under the receiver operator characteristic curve (AUC) for dosimetric predictors of (a) rectal
bleeding and (b) proctitis. Error bars indicate 95 % confidence intervals (CI).
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Proctitis
Eighteen patients reported RTOG proctitis ≥ Grade 2. Accumulated-EUD was found to
be the sole significant result correlating with RTOG/Gulliford proctitis ≥ Grade 1 (AUC
0.673) (Figure 4.5(b)). Planned EUD was not considered to be a significant indicator as
the lower 95% CI ≤ 0.5. Accumulated DSM dose-widths had greater AUC than planned
DSM dose-widths at 50, 60, 65 and 70 Gy, and were equivalent at 40 Gy. At 30 Gy, the
AUC of planned DSM dose-width was slightly higher than the accumulated AUC (0.004
difference). Differences between planned and accumulated dose were greater than observed
for rectal bleeding, and the variability in mean AUC was greater between dose levels, perhaps
supporting the suggestion that different endpoints have different pathophysiologies, which in
turn may have different radiosensitivities.
4.2.3 Discussion
Radiation dose received by the rectal wall during prostate radiotherapy was calculated and
accumulated using DSMs. Geometric aspects of dose distribution - information not distin-
guishable from DVHs - were parameterised using DSM dose-widths. EUD was calculated
to compare planned and accumulated DSMs using a single metric. Extracted dosimetric
parameters were evaluated against six clinical endpoints reported by patients within the
VoxTox research programme. Previous dose-toxicity investigations in the literature have been
limited to planned dose only. This study has demonstrated, for the first time, that delivered
dose can be a stronger predictor of toxicity in the case of rectal bleeding and proctitis in
prostate radiotherapy.
Toxicity rates reported in the literature have been variable. The rate of bowel toxicity
≥ Grade 2 (CTCAE), 5 year cumulative incidence, amongst VoxTox prostate patients was
17%. This falls within the bowel toxicity ≥ Grade 2 (RTOG) range of 13.7% - 24.9% for
IMRT over the same timeframe, reported by Dearnaley et. al [52] and Wortel et. al [170],
respectively. The rates of incidence indicate that toxicity remains an important clinical issue.
Many associations were found between DSM dose-widths with rectal bleeding. Accu-
mulated DSMs generated greater AUCs than planned DSMs for 5 DSM dose-width levels
up to 70 Gy. The strongest correlation between rectal bleeding and any spatial parameter
was the 65 Gy DSM dose-width from accumulated dose (AUC 0.664). At 30, 40 and 60 Gy,
accumulated DSM dose-widths produced AUC≥ 0.6 and lower 95% CI≥ 0.5, where corre-
sponding planned DSM dose-widths did not. These thresholds were considered indicative of
significance following the methods of Gulliford et al [71]. The greatest difference between
planned and accumulated AUCs was observed at the 60 Gy DSM dose-width. Overall,
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the results compared well with the findings of Buettner et al [27] who reported the most
significant correlation with rectal bleeding to be the 61 Gy lateral extent (AUC 0.66), derived
from planned dose data.
Accumulated EUD was found to have the strongest correlation overall with rectal bleeding
(AUC 0.682), and was the only predictor of proctitis (AUC 0.673).
For all patients, accumulated-EUD was systematically lower than planned-EUD. A con-
tributory factor was possibly the inherent blurring of high dose regions during accumulation.
Upon visual inspection of daily DSMs, the differences in size, shape and position of the high
dose region due to anatomical variation was clearly visible (for example, shown in deep red
in Figure 4.2). During accumulation, high doses were superimposed in overlap regions, but
reduced where isodose edges differed, due to averaging over the full course of radiotherapy.
This affected the maximum dose of the final accumulated-DSM, on which EUD calculation
was heavily weighted.
The dose-blurring effect could also have been responsible for the increased frequency
of 0% DSM dose-width results at high dose levels from accumulated-DSMs with respect
to planned-DSMs. At 70 Gy, 4/109 patients recorded a 0% accumulated DSM dose-width
(including 1 patient experiencing toxicity), whereas all corresponding planned DSM dose-
widths had non-zero results. Furthermore, dose levels could not be considered independent
variables, as a low 70 Gy DSM dose-width was likely to be associated with a low 65 Gy
DSM dose-width, and a cooler plan overall. These issues were not accounted for within the
scope of this study.
The generally lower reported values for EUD and DSM dose-widths from accumulated
dose compared with planned dose should not be interpreted as delivered treatment erring on
the ‘safe side’ in terms of dose to rectum. Where current NTCP models are based on planned
dose, the presented results suggest that the same magnitude of risk would be associated with
a systematically lower delivered dose.
The findings for 109 patients from the discovery cohort show that the difference in dose
between patients with and without rectal toxicity is greater from delivered dose than planned
dose. This indicates that dosimetric parameters from accumulated-DSMs could provide new
information to improve understanding of the relationship between dose and toxicity. The
single parameter EUD was a superior predictor of rectal bleeding and proctitis than spatial
dose quantifiers. However, DSM-dose widths produced several strong correlations with
rectal bleeding, and for 5/6 dose levels, accumulated dose generated AUC values greater than
planned dose.
Parameterisation of delivered dose to the rectal wall during prostate radiotherapy has
revealed stronger correlations with rectal bleeding and proctitis than achievable from planned
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dose. New information from accumulated delivered dose could lead to improved dose-toxicity
modelling in the future, with the aim of reducing post-treatment toxicity.
4.3 Consolidation cohort analysis
4.3.1 Methods and materials
The consolidation cohort includes patients who were prospectively identified to be enrolled
into the VoxTox study once the programme had been granted ethics approval in 2013.
Formalised contouring guidelines, imaging protocols, baseline data collection, and regular
follow-up questionnaires were formally implemented for this cohort [30, 137].
Recruitment to the VoxTox study closed in March 2018, so follow-up data continue to
be collected and mature for a large number of patients. The patient database was frozen in
January 2018, allowing interim analysis of the consolidation cohort for the purposes of this
research project. A summary of the frozen cohort is presented in Table 4.4.
Table 4.4 VoxTox prostate patient figures, January 2018. * One patient was removed from the analysis due to
incomplete data, leaving n = 186.
60 Gy 74 Gy Total
Total number of patients 161 326 508
Number of consolidation patients 111 134 245
Consol. patients with 2 year follow-up 77 110 187*
The consolidation cohort (n = 186) were split into training (75 %, n = 139) and validation
(25 %, n = 47) sets. For each endpoint (Table 4.5), the incidence rates of patient toxicity
were conserved, as well as the relative proportions of patients prescribed 60 Gy and 74 Gy.
After dividing patients into groups to ensure toxicity and prescription parity was maintained,
patients were randomised to either the training or validation set. This resulted in a different
training set composition for each of the 12 endpoints, as shown in Table 4.5.
This investigation was limited to the training set only. During subsequent analysis, one
patient was removed from the training set due to a failing finite element model, and was
retrospectively removed from the analysis conducted in this chapter. This has been reflected
in the patient numbers and analysis presented here.
The toxicity endpoints investigated were: CTCAE diarrhoea ≥ G1 [158], CTCAE faecal
incontinence ≥ G1 [158], CTCAE proctitis ≥ G1 and ≥ G2 [158], CTCAE rectal bleeding
≥ G1 and ≥ G2 [158], RTOG gastrointestinal (GI) toxicity ≥ G1 and ≥ G2 [127], stool
frequency ≥ G1 [1], and UCLA PCI bowel bother ≥ G1, ≥ G2, and ≥ G3 [89]. Incidence
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Table 4.5 Consolidation cohort training set split by toxicity endpoint and prescription group
Toxicity rates in
training set (n = 139)
Toxicity rates in
74 Gy group (n = 82)
Toxicity rates in
60 Gy group (n = 57)
Toxicity endpoint n (tox) (%) n (tox) (%) n (tox) (%)
Diarrhoea 36 25.9 22 26.8 14 24.6
Faecal incontinence 24 17.3 16 19.5 8 14.0
Proctitis ≥ G1 26 18.7 13 15.9 13 22.8
Proctitis ≥ G2 20 14.4 9 11.0 11 19.3
Rectal bleeding ≥ G1 46 3.1 24 29.3 22 38.6
Rectal bleeding ≥ G2 16 11.5 8 9.8 8 14.0
RTOG GI toxicity ≥ G1 73 52.5 43 52.4 31 54.4
RTOG GI toxicity ≥ G2 22 15.8 11 13.4 11 19.3
Bowel frequency 34 24.5 21 25.6 13 22.8
Bowel bother ≥ G1 54 38.8 32 39.0 22 38.6
Bowel bother ≥ G2 31 22.3 18 22.0 13 22.8
Bowel bother ≥ G3 13 9.4 9 11.0 4 7.0
rates are shown in Table 4.5.Endpoints were included on the basis of previous endpoints
reported in the literature [70, 77]. When splitting into training and validation cohorts, the
rates of toxicity incidence were maintained as closely as possible for each prescription group
within each cohort. As a result, discrete training sets were randomised per endpoint. Further
details have been discussed in Chapter 3, Section 3.4. To combine patient prescription groups,
the DSMs of the 60 Gy group were converted to the equivalent dose in 37 fractions (EQD37)
using an α/β ratio of 2.149 (as derived in Chapter 3, Section 3.3). The EQD37 correction
was applied to each pixel of the planned and final accumulated delivered dose surface maps
(DSMs) per applicable patient. A breakdown of the training cohort by toxicity endpoint and
prescription group is included in Table 4.5.
As in Section 4.2, dose surface maps (DSMs) of the rectal wall were generated by virtually
cutting the rectum at the point directly posterior to the centroid of the rectal contour, at each
slice. The width of the rectal DSM was set to be equal to the length of the rectum as defined
on the manually delineated kVCT planning scan. For each slice, the rectal circumference was
isotropically normalised to the DSM width, where the width remains constant per patient.
For the daily MVCT IGRT images where the field of view is restricted, the width remains
fixed, but where the field of view is shorter than the full length of the rectum in the superior
and/or inferior regions, the ‘missing’ data are substituted with kVCT planned data as a best
estimate (as shown in Figure 4.2).
For all patients, the dosimetric parameters extracted from the planned and accumulated
DSMs were equivalent uniform dose (EUD) and dose-widths from 30 - 70 Gy in 5 Gy
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increments. Where a 0 % dose-width was recorded, the measurement was removed from
the analysis for the dose-width under investigation, alongside the corresponding planned or
accumulated dose measurement for the particular patient. This was because a 0 % dose-width
could conceal information leading to a misrepresentation of the data [142]. As a consequence,
across all endpoints, 1 - 2 measurements were removed from the 65 Gy dose-width, and
6 - 10 measurements were removed from the 70 Gy dose-width. This was not expected to
significantly affect discrimination AUCs with respect to lower dose levels, but may have led
to wider confidence intervals.
Dosimetric parameters were evaluated for their discriminative ability of predicting each
endpoint using the area under the curve (AUC) calculated from the receiver operator charac-
teristic (ROC) curve. Differences between planned and delivered DSMs were analysed using
the rectal bleeding validation cohort as a representative sample.
4.3.2 Results
4.3.2.1 Planned versus accumulated dose
Planned EUD was greater than accumulated EUD for 125 of 139 patients, as shown in
Figure 4.6. The mean difference in EUD was -1.5 Gy, SE 0.1 Gy, range [-7.2, 1.4] Gy. For 89
patients (63 %), the difference was greater than ±1 Gy. The mean absolute difference between
planned and accumulated dose-widths increased with increasing dose level (Figure 4.7).
Mean planned dose-widths were greater than mean accumulated dose-widths at dose levels
above 30 Gy, with a maximum difference of -5.2 % at the 70 Gy dose-width.
Each planned dose parameter was very strongly positively correlated with the correspond-
ing accumulated dose parameter (r> 0.8, p< 0.001), indicating that an increase in planned
dose results in an increase in delivered dose. The results of a paired samples t-test showed
that average differences between planned and accumulated dose were significant for EUD
(p< 0.001), and dose-widths 40 Gy (p= 0.002), and 45 - 70 Gy (p< 0.001).
4.3.2.2 Dose-toxicity associations
Results of dose-toxicity analysis for all endpoints are discussed below. The highest perform-
ing dose metrics are listed in Table 4.6. The area under the receiver operator characteristic
curve (AUC) and 95 % confidence intervals (95%CI) for rectal bleeding ≥ G1 and proctitis
≥ G2 are shown in Figure 4.8 for comparison with the previous discovery cohort analysis
shown in Figure 4.5. AUC indicates the ability of the dosimetric parameter to correctly
discriminate between patients with and without toxicity. An ideal correlation would have an
AUC of 1. Results were considered significant if AUC ≥ 0.6 and lower 95%CI ≥ 0.5 [71].
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(a)
(b)
Fig. 4.6 (a) Comparison between EUD calculated from planned and accumulated dose surface maps (EUDp and
EUDa, respectivly). Grey line indicates y = x reference. Dashed line indicates line of best fit, where equation
assumes intercept at the origin, and R2 is an indicator of the goodness-of-fit. (b) Histogram of differences
between planned and accumulated EUD.
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Fig. 4.7 Difference between planned (plan) and accumulated (acc) DSM dose-widths. Dose difference was
found to increase with dose level. Dotted line shows line of best fit. Error bars indicate standard error of the
difference.
Diarrhoea (n = 36, 25.9%)
The strongest predictor of diarrhoea was the planned 35 Gy dose-width, with AUC = 0.689
[95%CI: 0.587, 0.792]. Planned dose-widths of 30-50 Gy were also predictive. At these
dose-widths, planned AUCs were greater than corresponding accumulated AUCs, which
were also significant. Additionally, the accumulated 55 and 60 Gy dose-widths and EUD
were predictive of diarrhoea, where corresponding planned dose parameters were not.
Faecal incontinence (n = 24, 17.3%)
Planned and accumulated dose-widths at 40 - 60 Gy achieved AUCs greater than 0.6. How-
ever, all lower bounds of the 95%CI were less than 0.5, so no single dosimetric parameter
could be considered significantly predictive of faecal incontinence.
Proctitis ≥ G1 (n = 26, 18.7%)
Planned dose-widths at 45 - 65 Gy and EUD were predictive of G1 proctitis, with the 65 Gy
dose-width producing the greatest AUC (0.656 [0.554, 0.757]). The accumulated 60 Gy
dose-width and EUD were also significant predictors, but less so than the corresponding
planned dose metrics.
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Table 4.6 Dosimetric parameters most discriminative of toxicity from planned and accumulated dose surface
maps. Dose-width levels or equivalent uniform dose (EUD) resulting in the greatest area under the receiver
operator characteristic curve (AUC) are listed. Results for faecal incontinence have been omitted as no parameter
produced an AUC with minimum 95% confidence interval greater than 0.5, so was not considered significant.
Dashed entry indicates no significant parameter was determined.






Diarrhoea 35 0.689 35 0.642
Proctitis ≥ G1 65 0.656 EUD 0.626
Proctitis ≥ G2 60 0.635 60 0.648
Rectal bleeding ≥ G1 EUD 0.631 EUD 0.651
Rectal bleeding ≥ G2 65 0.796 60 0.788
RTOG GI toxicity ≥ G1 - - EUD 0.604
RTOG GI toxicity ≥ G2 45 0.722 50 0.743
Stool frequency 35 0.646 45 0.648
Bowel bother ≥ G1 40 0.607 60 0.638
Bowel bother ≥ G2 - - EUD 0.648
Bowel bother ≥ G3 - - EUD 0.686
Proctitis ≥ G2 (n = 20, 14.4%)
The strongest predictor of proctitis G2 was the accumulated 60 Gy dose-width (AUC 0.648
[0.524, 0.772]), as shown in Figure 4.8b. This differs from the discovery cohort result, which
found the only association with G2 proctitis to be accumulated EUD. However, accumulated
EUD was also predictive of G2 proctitis for the consolidation cohort analysed here, along
with planned dose-widths at 55-65 Gy and EUD. The AUCs from all accumulated dose
parameters increased with respect to those reported for G1 proctitis. Of the significant
planned dose parameters, the AUCs reduced with respect to those reported for G1 proctitis,
with the exception of the 55 Gy dose-width (increase in AUC by 0.001, but wider 95%CI).
Rectal bleeding ≥ G1 (n = 46, 33.1%)
Accumulated EUD was the strongest predictor of G1 rectal bleeding (AUC 0.651 [0.556,
0.747]), as shown in Figure 4.8a, supporting the findings of the discovery cohort analysis
in Section 4.2. Accumulated 45-65 Gy dose-widths were also associated with G1 rectal
bleeding, and 60 and 65 Gy dose-widths were greater than corresponding planned metrics.
Dosimetric parameters from planned dose predictive of rectal bleeding G1 were EUD and
45 - 60 Gy dose-widths.
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(a)
(b)
Fig. 4.8 Consolidation cohort dose-toxicity analysis. Area under the receiver operator characteristic curve
(AUC) is shown for dose-widths and equivalent uniform dose (EUD), calculated from planned and accumulated
dose surface maps (DSMs) of the rectal wall for (a) Rectal Bleeding ≥ grade 1, and (b) Proctitis ≥ grade 2.
Results were considered significant where mean AUC > 0.6 and lower 95% CI > 0.5.
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Rectal bleeding ≥ G2 (n = 16, 11.5%)
The strongest predictor of G2 rectal bleeding was the planned 65 Gy dose-width, with AUC
0.796 [0.705, 0.887]. This was the highest AUC recorded across all toxicity endpoints. All
dosimetric parameters were associated with G2 rectal bleeding, with the exception of the
planned 70 Gy dose-width. Accumulated AUCs were greater than corresponding planned
AUCs for EUD, 30, 35, 55, and 70 Gy dose-widths. Planned AUCs were greater than
accumulated for 40, 45, 60, and 65 Gy dose-widths.
RTOG GI toxicity ≥ G1 (n = 73, 52.5%)
The only dosimetric parameter associated with G1 GI toxicity was accumulated EUD (AUC
0.604 [0.510, 0.698]). No other parameter produced an AUC ≥ 0.6 or lower 95%CI ≥ 0.5.
RTOG GI toxicity ≥ G2 (n = 22, 15.8%)
The accumulated 50 Gy dose-width was the strongest predictor of G2 GI toxicity (AUC
0.743 [0.621, 0.865]). All AUCs were greater for G2 GI toxicity than G1. Dose-widths of
30-65 Gy were associated with G2 GI toxicity for both planned and accumulated DSMs.
Accumulated dose-widths had greater AUCs than planned dose-widths at 30-60 Gy, and the
planned 65 Gy dose-width produced a greater AUC than the accumulated 65 Gy dose-width.
Accumulated EUD was also predictive of G2 GI toxicity, where planned EUD was not.
Stool frequency (n = 34, 24.5%)
The accumulated 45 Gy dose-width was most strongly associated with increased stool
frequency, with AUC = 0.648 [0.536, 0.759]. Planned dose-widths from 30 to 50 Gy were
predictive of stool frequency, as were accumulated dose-widths from 30-60 Gy. Planned
dose-widths from 30 - 40 Gy produced greater AUCs than corresponding accumulated dose-
widths. For all other dosimetric parameters, accumulated AUCs were greater than planned
AUCs.
Bowel bother ≥ G1 (n = 55, 39.6%)
The strongest predictor of bowel bother G1 was the accumulated 60 Gy dose-width (AUC
0.638 [0.543, 0.733]). Also predictive were planned dose-widths 40-50 Gy, accumulated
dose-widths 50-65 Gy, and accumulated EUD. This is in contrast to discovery cohort analysis,
which found no associations with bowel bother ≥ G1.
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Bowel bother ≥ G2 (n = 32, 23.0%)
The only predictor of bowel bother G2 was the accumulated EUD (AUC 0.648 [0.539,
0.757]). This was also in contrast to discovery cohort analysis, which found no associations
with bowel bother ≥ G2.
Bowel bother ≥ G3 (n = 13, 9.4%)
The only predictor of bowel bother G3 was the accumulated EUD (AUC 0.686 [0.533,
0.839]), which was greater than the accumulated EUD AUC from both G1 and G2 bowel
bother. As severity of bowel bother increased, AUC also increased. However, width of
95% CIs also increased.
4.4 Discussion
DSMs of the rectal wall, calculated for planned and accumulated delivered dose, were
parameterised using EUD and dose-widths for 139 patients in the consolidation cohort
of the VoxTox research study. Previous results for 109 patients from the discovery cohort
demonstrated for the first time that accumulated dose can be a better predictor of rectal toxicity
than planned dose in patients receiving radiotherapy for prostate cancer. Toxicity endpoints
reported in the analysis of the discovery cohort were selected based upon availability of
baseline information. For patients in the consolidation cohort, formalised reporting systems
were introduced into the VoxTox study, so prospective baseline data were available for all
patients. Additionally, imaging and contouring were more standardised and robust due to the
implementation and dissemination of study protocols and guidelines. A further difference
between the analysis presented for the consolidation cohort here, and the discovery cohort in
Section 4.2 was that the software for autosegmenation of the rectum on MVCT images was
upgraded from version 1.4 to 1.6. Improvements were made in identifying the rectal contour
in regions where air pockets were detected on the MVCT scan. Details of version 1.6 of the
autosegmentation software have been presented in the literature [143].
Twelve endpoints were explored in the analysis of the consolidation cohort. Endpoints
were selected based on the most commonly reported toxicities in the literature, as well as
prevalence within the dataset. Increasing grades of severity (i.e. ≥ grade 1, ≥ grade 2) were
included if the level of toxicity was experienced by greater than 5 % of patients.
Significant dose-toxicity associations were observed for 11 of 12 endpoints. The dose
parameter most discriminative of toxicity was from accumulated dose, rather than planned
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dose, for 8 of 11 endpoints. Spatial dose-widths (at various dose levels) were more predictive
of toxicity for 7 endpoints, and EUD was found to be the strongest predictor for 4 endpoints.
Accumulated dose was lower than planned dose, when comparing EUD, for 90 % of
patients. The previous discovery cohort analysis found all patients to have lower accumulated
dose than planned dose. This result supports the suggestion that interfraction motion leads
to a dose-blurring effects at higher dose levels when accumulating daily delivered dose.
As with the discovery cohort, some 0 % dose-width results were recorded at higher dose
levels. For planned dose, 2/139 patients recorded null values at the 70 Gy dose-width, and
for accumulated dose, 2/139 and 7/139 patients recorded null values at 65 Gy and 70 Gy
dose-widths, respectively.
Overall, the analysis suggests that stronger dose-toxicity associations are determined
using accumulated dose, rather than planned dose. In general, spatial dose-widths produced
stronger associations than EUD.
Where significant associations were observed from the discovery cohort analysis, either
the same result was found (accumulated EUD was most associated with CTCAE ≥ Grade 1
rectal bleeding for both discovery and consolidation cohorts), or results were complementary
(for grade 2 proctitis, the discovery cohort analysis found accumulated EUD to be the sole
predictor, whereas the consolidation cohort analysis considered a different scoring system
and found accumulated 60 Gy dose-width to produce the greatest AUC, but accumulated
EUD was also significant).
Analysis from two separate cohorts of the VoxTox study, discovery and consolidation,
support the hypothesis that accumulated delivered dose is more predictive of rectal toxicity in
prostate radiotherapy than planned dose. However, the benefit of incorporating spatial dose
information (dose-widths) over a one-dimensional dose descriptor (EUD) is not distinctly ev-
ident. Further investigation of dose parameterisation approaches more suited to interpretation
of accumulated dose are recommended. By improving the understanding of accumulated
dose distribution to the rectal wall, we aim to develop better models for predicting rectal
toxicity.
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4.5 Concluding discussion
Dose-toxicity analysis was performed for two separate cohorts of the VoxTox research pro-
gramme. Dose surface maps of the rectal wall have shown that accumulated dose can be a
better predictor of rectal toxicity in prostate radiotherapy than planned dose. The ability to
preserve and accumulate spatial dose information throughout treatment is a novel process
requiring careful consideration of data interpretation and parameterisation. Future work
may involve exploring alternative methods for geometrical quantification of spatial dose
distributions in order to determine stronger correlations with toxicity. Further analysis of de-
livered dose to the rectal wall could facilitate the identification of inhomogeneous intra-organ
radiosensitivities, allowing shape-based dose constraints to be derived. Additionally, spatial
considerations could complement current DVH-based approaches to treatment planning.
Through novel characterisation of delivered dose, beyond the limitations of the static
planned DVH, the aim was to determine those parameters strongly associated with rectal
toxicity which could be incorporated into multivariate NTCP models. Emerging dose
quantifiers could be integrated into planning constraints, as well as being prospectively
monitored throughout treatment. Delivered dose can be accumulated in ‘real-time’ and
analysed with each fraction, allowing on-treatment toxicity risk assessment. Towards the
end of the course of treatment, if toxicity prediction was found to be lower than planned,
the decision could be made to increase the total delivered dose to the target. The potential
scope for further individualisation and adaptation of treatment could ultimately reduce rates
of toxicity incidence and improve clinical outcomes.

Chapter 5
Voxel-level dose analysis for interfraction
motion of the rectum
In this chapter, biomechanical finite element (FE) analysis is introduced as a method for
improving the accuracy of calculation and accumulation of dose to the rectum for prostate
radiotherapy patients in the VoxTox study. In the previous chapter, dose surface maps
(DSMs) were generated where analysis of rectal motion was limited to isotropic deformation
in the plane of the 2D imaging slice. These will henceforth be referred to as 2D-DSMs, to
distinguish from DSMs generated from biomechanical FE modelling, which will be referred
to as FE-DSMs. Biomechanical FE modelling provides a more anatomically plausible
solution for rectal motion by allowing anisotropic deformation in 3D. The material elements
used to construct the model facilitate increased resolution of dose-history tracking, enabling
voxelwise analysis of dose. This chapter is divided into three sections:
• Biomechanical modelling for voxelwise dose analysis, where details of generating the
model based on VoxTox patient data are presented.
• Quantifying interfraction motion of the rectum, where the range of interfraction rectal
deformation is evaluated across the full course of treatment. Geometric correlations
and dosimetric associations are investigated.
• Sensitivity of dose response with simulated rectal motion, where discrete intervals of
rectal expansion and contraction, as well as extremes of rectal deformation as measured
from patient data, are simulated. The dose response is determined for two different
clinical scenarios. Resulting implications for normal tissue complication probability
(NTCP) are also presented.
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The research questions being addressed in this chapter, through the use of biomechanical
FE modelling, are: how does rectal positioning change during the course of radiotherapy,
and how does rectal motion correlate with delivered dose, and hence NTCP?
The original biomechanical FE model and corresponding MATLAB code was developed
by Professor Michael Sutcliffe, Cambridge University Engineering Department, and was
previously adapted by former Masters students for experimental purposes. Within the scope
of this PhD project, the code has been adapted to read and process patient DICOM files,
model parameters have been optimised for the rectal wall, and the system has been integrated
into the VoxTox workflow. Interfraction motion has been analysed based on the outcome
of the autosegmentation system developed by Prof Sutcliffe (as described previously in
Section 3.1.3). Systems for extracting and processing properties of contour data, and the
design and analysis of the sensitivity study, now possible through the application of FEM,
have all been developed as part of of this PhD thesis.
5.1 Biomechanical modelling for voxelwise dose analysis
Biomechanical models are physical-based simulations that incorporate material properties
of anatomy in addition to geometry and boundary conditions [21]. Biomechanical finite
element (FE) analysis enables tracking of soft tissues undergoing large deformations, and
has previously been applied to rectal simulation in the context of investigating motion of the
prostate [18]. An advantage of biomechanical FE modelling is that accuracy remains constant
in low contrast imaging (such as MVCT), provided that the boundary conditions can be
defined [21, 23, 162]. The FE models described here were based upon manually segmented
rectal contours from the kVCT planning scan, and autosegmented rectal contours from the
MVCT image guidance scans. Autosegmentation of image guidance scans was essential to
this work, and has been identified as a crucial component for bringing FE modelling into the
clinical workflow [21]. Model performance is limited by the accuracy of the segmentation of
the anatomy that defines the boundary conditions applied to the model (see Section 3.1.3).
The rectal model consists of material elements, acting as surrogates for 3D volumetric pixels,
or voxels, and hence clusters of cells. By tracking the interfraction movement of each
voxel, the accuracy and resolution of dose accumulation is improved with respect to the
methods previously adopted in Chapter 4 due to the capability of calculating individual
dose histories. The previous method of dose accumulation using two-dimensional dose
surface maps (2D-DSMs) allowed only for isotropic in-plane expansion, where the rectal
circumference was uniformly normalised. Biomechanical FE modelling provides a more
anatomically plausible solution for tracking rectal deformation, and hence a more accurate
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(a) (b) (c)
Fig. 5.1 Comparison of 2D and FE based approaches for generating DSMs. The rectal contour is shown in
brown, black dotted lines correspond to rows in the resulting DSMs, and blue boxes correspond to voxels.
(a) shows an example of the rectum from the reference kVCT treatment planning scan. For the 2D-DSM, voxels
are normalised around the circumference of the rectum, in the plane of the image slice; (b) shows the deformed
rectum at the time of treatment, and to generate the 2D-DSM, voxels are sampled in the same imaging plane,
and uniformly normalised around the new rectal circumference in that plane; (c) demonstrates how FE-DSMs
are generated, through out-of-plane expansion, and non-uniformly distributed voxels that deform according to
material properties and applied boundary conditions. This presents a more anatomically representative model.
platform for delivered dose calculation [8]. This is illustrated in Figure 5.1. FE models of the
rectum were generated in the Abaqus Computer Aided Engineering (CAE) Finite Element
Analysis (FEA) environment (Dassault Systèmes). The process of generating and running
the model for the VoxTox patient dataset is described within the following section.
5.1.1 Reading patient DICOM data
Rectal contours, whether manually contoured on kVCT images or autosegmented from
MVCT scans, were stored as DICOM structure files. DICOM structure files must be read
alongside the corresponding image set to be assigned a coordinate system. For each patient,
the DICOM structure files of manually contoured and autosegmented rectal contours were
imported into MATLAB alongside the respective kVCT and MVCT DICOM image sets
for 20 or 37 fractions. Raw pixel coordinates were translated into millimetres by scaling
by the image resolution (typically 272×272 pixels per slice, pixel size 1.953 mm for the
downsampled kVCT; 512×512 pixels per slice, pixel size 0.754 mm for MVCT) and slice
thickness (3 mm for kVCT and 6 mm for MVCT). When importing the MVCT rectal contours,
an additional step was required in order to register the coordinate systems of the daily MVCT
image set with the kVCT. The translational shifts applied during patient positioning at the
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time of treatment were extracted and stored as private tags within the DICOM header; these
made it possible to rigidly register the image sets. Any rotational offsets applied at time
of treatment by small adjustments to gantry rotation were accounted for within the dose
calculation step.
5.1.2 Model geometry
The simulated rectal model was constructed of ‘innerpart’ and ‘outerpart‘ structures, as
indicated in Figure 5.2. The outerpart represents the rectal wall, and the innerpart is the
structure to which a displacement loading is applied. The innerpart and outerpart were
constructed of material elements (voxels) and nodes (element vertices). The innerpart used
surface membrane elements with 4 vertex nodes, negligible thickness, and reduced integration
(element type SFM3D4R), with 30 nodes around the circumference of the rectum, and 120
nodes along the length (the patient’s cranio-caudal z-direction). The outerpart, or rectal wall,
was constructed of stress/displacement elements (type C3D8); fully integrated 8-node linear
brick of initial thickness 3 mm and material density 0.05 g/cm3 [18, 36]. The outerpart was
assigned 80 nodes along the rectal length, and 30 nodes around the circumference. A previous
study demonstrated no advantage to increased model resolution; increasing the number of
elements by a factor of 36 not only increased computational time from 1 to 34 minutes,
but had no significant effect on model accuracy [24]. Here, the resolution of the outerpart
was assigned to approximate the number of voxels around the circumference as used in the
2D-DSM study (Chapter 4), but with increased resolution along the length of the rectum in
order to accurately track out-of-plane motion along the rectal length (or z-direction). This
was previously not possible to account for using the 2D-DSM approach.
The starting geometry of the innerpart was based on a ‘central mandrel’ - a cylindrical
structure of radius 10 mm. This was common to all patients, and provided the basis for intra
and inter-registration between fractions and patient contours allowing tracking of individual
voxels. The coordinates of the patient’s kVCT rectal contour were used to assign coordinates
in space to the central mandrel. The centre of mass of each contour was calculated and
then smoothed; the resulting coordinates formed a ‘centreline’. The cylindrical contour of
the central mandrel was then centred about this centreline. The centreline-adjusted central
mandrel formed the starting geometry for each patient’s FE rectal model and was used as a
starting point for the kVCT based model, as well as each subsequent daily MVCT model
generated for that particular patient, as shown in Figure 5.2.
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Fig. 5.2 Finite element (FE) model generation for the kVCT-based planning contour and a MVCT-based daily
contour for an example patient. The patient’s centreline-adjusted central mandrel shows the original 10 mm
radius cylindrical central mandrel offset by the centreline of the kVCT planning contour, which provides the
starting geometry for all models generated for this patient. The deformed rectal wall shows the final output of
the biomechanical FE model. The corresponding resultant vector fields illustrate the out-of-plane displacement,
which could not be modelled by the previous 2D-DSM approach in Chapter 4. FE-calculated dose shows the
planned and daily delivered dose based on the anatomical changes of the rectum. The effect of rectal motion
on dose is addressed in this chapter. Differences between planned and accumulated delivered FE-DSMs are
investigated in Chapter 6.
5.1.3 Hyperelastic modelling
Hooke’s Law can be used to solve simple linear elastic problems with material constants
such as Poisson’s ratio (ratio of lateral strain to longitudinal strain) and Young’s modulus
(elasticity). However, for anatomical modelling, soft tissues demonstrate a non-linear elastic
stress-strain relationship [65] which can be better represented using hyperelastic constitutive
laws. These depend on a strain-energy function (U) describing the energy stored in the
material caused by deformation [21]. Here, the rectal wall was assumed to be an incom-
pressible rubber-like material and was modelled using an isotropic hyperelastic model. The
neo-Hookean model was applied, with initial model parameters normalised such that the
shear modulus µ0 (measure of rigidity) and bulk modulus, K0 (measure of compressibility)
corresponded to a Poisson’s ratio of 0.49 [18]. The shape of the stress-strain curve, rather
than the absolute values of the applied material properties, determines the mechanical be-
haviour of the rectal wall as it deforms. Many hyperelastic models have been adopted for
modelling of rubberlike materials in FE simulations in the literature [68]. Of the physical-
based models, the popular choices for anatomical modelling have been: the Mooney-Rivlin
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model, reported to be of high accuracy and efficiency; and the Ogden model, an efficient and
well-established model but dependent on 6 experimentally-derived material parameters [68].
The neo-Hookean model mimics the Mooney-Rivlin model with a single material parameter,
and was selected here for its simplicity and applicability over a strain range appropriate for
rectal expansion.
5.1.4 Loading and boundary conditions
For the VoxTox rectal simulation, the focus was on strains and deformations rather than
stresses. Therefore, displacement loading was applied which expands the model based on
geometrical information from the rectal contour data, rather than by applying a force. This
approach is recommended due to the difficulties in measuring applied forces [21]. The
accuracy of the defined boundary conditions has a greater impact on model performance than
the applied elastic modulus [21, 134]. Final FEA solutions are computed per node based on
the material properties and boundary conditions.
Boundary conditions are defined from the coordinates of the manual or autosegmented
rectal contours. Nodal coordinates were determined by converting DICOM rectal contour
coordinates to a polar system and using spline interpolation. Polar coordinates were translated
back to the Cartesian system. The displacement loading was the difference between the
final contour position and the corresponding nodal coordinate of the centreline-adjusted
central mandrel, and was applied as a uniformly increasing load (Figure 5.2). The contact
interaction between innerpart and outerpart was defined as a frictionless sliding surface.
Further boundary conditions were applied at the most superior and inferior extremes of the
rectal contour, which allowed the model to move in the patient’s cranio-caudal z-direction by
±3 mm, accounting for the uncertainty in defining these edges of the rectum inherent to the
MVCT slice thickness. This also corresponded to the rectal displacement measured in the
cranio-caudal direction by Boubaker et al. [19].
5.1.5 Running the model in Abaqus
Model parameters were processed and combined in MATLAB to generate an input file for
FE modelling in Abaqus. The input file used the above information to define:
• Geometry (node numbers and coordinates, element type, surface density, for each part)
• Assembly (initiating parts and instances)
• Material (apply hyperelastic model properties, density)
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• Boundary conditions (defining range of motion restrictions)
• Interaction properties (i.e. define sliding surface behaviour, set displacements and
loading amplitude)
• Steps (i.e. non-linear, dynamic, explicit)
The final simulated rectal model was deformed according to these properties. Batch pro-
cessing was performed using DOS commands. The coordinates of the final deformed outer
surface of the rectal wall were automatically extracted using a Python script.
5.1.6 Post-processing and dose calculation
The patient’s DICOM radiation dose file corresponding to the day of imaging was imported
into MATLAB. For daily dose, the treatment couch shifts were applied to register to the
kVCT coordinate system (as with the MVCT images and structures during pre-processing of
model geometry). Any corrections for roll during treatment (implemented by gantry rotation),
were also incorporated into the dose matrix. Dose was interpolated in 3D at each of the
2400 final node positions on the surface of the outerpart and displayed on the 3D contour
(as shown in Figure 5.3). Similar to the 2D-DSM approach, where data at the superior and
inferior extremes of the rectum were cropped due to the limited MVCT field of view, missing
data were substituted with planned dose during daily dose accumulation. By starting from a
common starting structure, each element was tracked through its daily deformation, allowing
a greater level of accuracy and resolution in the calculation and accumulation of delivered
dose than previously achievable.
Fig. 5.3 Biomechanical FE model showing rectal motion; (a) Planned dose based on kVCT contours, (b) Daily
delivered dose calculated on MVCT contour, (c) Standard deviation across 37 fractions shown on kVCT
planning contour, (d) QR code link to rectal motion example. QR code can be read using the camera application
on a tablet or smartphone. Focus camera on code. QR reader may need to be installed.
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5.2 Quantifying interfraction motion of the rectum
5.2.1 Introduction
The hypothesis of the VoxTox research programme is that delivered dose to the rectum is more
predictive of rectal toxicity in prostate radiotherapy than planned dose. Part of the motivation
for this comes from studies reporting significant rectal motion in patients undergoing prostate
radiotherapy [43, 117]. When the rectal position at time of treatment differs to that identified
on the pre-treatment planning scan, this introduces deviations between the intended planned
dose to the rectum as accepted at the time of treatment planning, and the dose actually
received by the rectum.
Daily interfraction motion of the rectum can be visualised on daily image guidance scans,
but to date has been difficult to quantify due to the quality of the images. In particular,
segmentation of anatomy within the pelvic region can be challenging due to soft tissue
boundaries which lack distinction and worsen in low contrast imaging [67, 90]. Methods used
for segmentation of the prostate, such as deformable image registration (DIR), are generally
not applicable for the rectum due to the large and unpredictable spatial deformations caused
by rectal contents and intestinal gas [97, 114, 136, 161]. Common DIR algorithms struggle
due to intensity variations and the lack of one-to-one correspondence between a full, gassy,
or empty rectum [40, 114, 175]. Previous studies investigating the dosimetric effects of
interfraction rectal motion have been dependent upon manual delineation of the rectum on
image guidance scans [11, 43, 75, 85, 96, 125, 145], and are consequently limited in sample
size.
Within the VoxTox research programme, the autosegmentation software was developed by
Professor Michael Sutcliffe, Cambridge University Engineering Department. An automated
solution for identifying the rectum on daily image guidance scans was vital for the contouring
of over 56000 slices. A full description of the autosegmentation algorithm was published by
Shelley & Sutcliffe in Biomedical Physics & Engineering Express [143].
The following section presents results of quantitative analysis of the magnitudes of
rectal motion throughout the course of 37 fractions of prostate radiotherapy as defined using
the VoxTox autosegmentation system. The geometric measures of rectal deformation are
explored for associations with delivered dose as calculated and accumulated using finite
element dose surface maps.
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5.2.2 Material and methods
Seventy-six patients treated with 37 fractions were selected from the VoxTox consolidation
cohort. Patients were prescribed 74 Gy to the prostate, with daily image guided radiotherapy
(IGRT) delivered using TomoTherapy®. Baseline rectal measurements were extracted
from the kilovoltage computed tomography (kVCT) planning scans, which were manually
contoured by experienced clinical oncologists according to the VoxTox protocol. Imaging
specifications for the downsampled kVCT were: 272×272 pixels per slice, pixel size 1.953
mm, slice thickness 3 mm. Scan length included the full extent of the rectum. Rectal length
was defined from the rectosigmoid junction, at the last slice where the bowel turns anteriorly
and to the left, to the most inferior slice containing both ischial tuberosities [136]. Images
were inspected in both the axial and sagittal planes. Measured rectal length was taken as the
number of kVCT slices containing rectal contours multiplied by the slice thickness. Daily
rectal contours were determined from the megavoltage computed tomography (MVCT) image
guidance scans using in-house autosegmentation software [143] based on the Chan-Vese
algorithm. MVCT specifications were: 512 × 512 pixels per slice, pixel size 0.754 mm, slice
thickness 6 mm. The field of view for MVCT imaging was limited to typically 8–12 slices
according to local protocols to minimise additional dose and time for prostate IGRT [15], so
only a proportion of the rectum was imaged.
For each kVCT or MVCT slice containing a rectal contour, the equivalent diameter of
the contour was extracted using MATLAB’s regionprops function. The equivalent diameter




Due to the use of daily image guidance, the prostate was assumed to be a fixed landmark.
A reference plane containing the most anterior point of the prostate contour as identified on
the planning scan, was used to define a surrogate z-origin. This approach was recommended
by Dr Rajesh Jena, consultant clinical oncologist within the VoxTox research programme, as
opposed to using mid-prostate, for example, which depends upon the accuracy of identifying
the superior and inferior boundaries of the prostate. Defining the origin in this way presented
a solution for registering contour data from daily MVCT images with the planning kVCT
scan, and across multiple patient datasets.
Daily MVCT image guidance scans were corrected for couch positional adjustments
applied at the time of treatment. This information was stored in private DICOM tags and used
to apply rigid transformations in x, y, and z-directions [132]. Once registered to the frame of
reference of the planning scan, the MVCT slice closest to the reference plane, was defined
as the z-origin. Due to differences in slice thickness (kVCT 3mm v MVCT 6mm), it was
possible that the MVCT z-origin may differ by up to 3mm with respect to the kVCT z-origin,
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and for a discrepancy of up to 6 mm to exist between the z-origins defined on MVCT images
acquired on different days.
Due to differences in daily MVCT scan lengths and positioning, less data were available
as slice position from the z-origin increases. Contour measurements were acquired at each
slice location, provided that there were data from more than 15 patients (approximately
20 %), and mean measurements per patient were calculated from a minimum of 5 fractions.
This restricted analysis to ±7 slices about the z-origin. A positive slice number indicates
the cranial direction. Where applicable, mean values, standard deviations, and ranges of
motion were recorded for each patient across the 37 fractions. The standard deviation across
all fractions was taken as a measure of rectal motion for each patient.
Associations between continuous variables were assessed using the Pearson correlation
coefficient, r, where 0 indicated no relationship, and +/-1 indicates a perfect positive/negative
linear relationship. Correlation coefficients between 0.2-0.39 were considered weakly corre-
lated, and between 0.4-0.59 were considered moderately correlated. The significance of the
correlation was indicated by the accompanying p-value test statistic.
5.2.3 Results
5.2.3.1 Geometric correlations
The mean rectal length measured from the kVCT planning scan was 98.9 mm (SD 16.3,
range [66, 165] mm). This did not incorporate the systematic error of +/- 1.5 mm at superior
and inferior boundaries, or the effect of multi-observer contouring (discussed by Scaife et al.
in [138]). Results were similar to Marcello et al. [92], who found the median rectal length
for 709 patients to be 95 mm. Rectal length was plotted against height for all patients as
shown in Figure 5.4. No significant correlation was observed between height and rectal
length (Pearson correlation coefficient r = -0.009, p = 0.939).
Overall, rectal length was not found to be correlated with equivalent diameter from kVCT,
or MVCT mean or maximum equivalent diameter, suggesting that longer rectums are not
prone to larger lateral expansion. However, from MVCT slices -1 to +7, weak to moderate
negative correlations were observed between rectal length and minimum MVCT equivalent
diameter, suggesting that longer rectums tend to narrow towards the superior portion of
the rectum. Rectal length was moderately correlated with rectal motion (quantified by the
standard deviation of the MVCT equivalent diameter throughout treatment) from slices -1 to
-4, i.e. in the middle to inferior section of the rectum, suggesting that longer rectums tend to
move more in the lower aspect.
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Fig. 5.4 Plot of patient height versus rectal length as defined on the manually segmented kVCTs scan for 76
patients. Dotted line indicates line of best fit, m = 0.026.
Differences between equivalent diameters calculated from kVCT contours and mean, min-
imum, and maximum MVCT contours averaged across all fractions are shown in Figure 5.5.
Quoted differences between kVCT and MVCT contours are quantified using differences
in equivalent diameter. The kVCT contours were significantly different to the correspond-
ing mean MVCT contours at central slices from slices -2 to +4, and at the most superior
and most inferior slices, +7 and -7 respectively (paired samples t-test, p<0.05). Minimum
MVCT contours were significantly different from corresponding kVCT contours for slices -5
to +7. Maximum MVCT contours were significantly different from corresponding kVCT
contours across all slices. Additionally, both minimum and maximum MVCT contours were
significantly different to the mean MVCT contour across all slices. This suggests that the
change in contour size due to interfraction motion throughout the course of treatment can be
considered a significant effect. No correlation was found between the equivalent diameter
of the planning kVCT contour and rectal motion (standard deviation of MVCT contour
equivalent diameters), at any slice. This suggests that the rectal contour used for treatment
planning is not indicative of the subsequent change in rectal contour due to interfraction
motion throughout the course of treatment, despite the use of image guidance (i.e. a narrower
rectum at treatment planning will undergo the same amount of interfraction motion as a
larger rectum throughout the course of treatment).
The rectum is often described as being divided into thirds; superior (sup), middle (mid),
and inferior (inf) [136]. Anatomically, the superior third connects to the sigmoid, the middle
third is generally at the level of the prostate, and the inferior third connects to the anal canal.
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Fig. 5.5 Change in rectal equivalent diameter throughout the course of treatment. kVCT data are based on
manual segmentation, MVCT data are based on autosegmentation. Equivalent diameter is calculated at each
slice where sufficient data were available. The 0 slice is defined as the registration origin; positive slice number
indicates cranial direction, negative slice number indicates caudal direction. Slice thickness is 6 mm. MVCT
mean, max, and min equivalent diameters are averaged across all patients and error bars represent the standard
deviation in the overall average. Slices +6, 0, -6 were used as surrogates for the superior, middle, and inferior
rectal thirds, respectively.
To investigate whether the rectal thirds behave differently, rectal geometries of sup and inf
thirds were compared with the mid-third. For a mean rectal length of approximately 10 cm,
contours from the MVCT +6 slice (+36 mm) were used as surrogates for the sup-third, the
zero slice for the mid-third, and the -6 slice (-36 mm) for the inf-third, shown in Figure 5.5.
For kVCT contours, equivalent diameter was significantly narrower at the inferior third
(-2.6 mm [SD 4.6], p<0.001), and wider at the superior third (4.5 mm [SD 5.8], p<0.001),
with respect to the zero slice mid-third. However, from MVCT contours, the mean equivalent
diameter measured across all patients and all fractions, were narrower at the inf and sup thirds
than the mid-third. Mean difference at the inf-third with respect to the mid-third was -5.5 mm
(SD 7.2, p<0.001), but the difference between sup and mid-third was not significant. For
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minimum equivalent diameter, the difference between inf and mid third was not significant,
but the sup third was significantly narrower than the mid third by 2.6 mm (SD 5.4, p = 0.001).
The maximum equivalent diameter was significantly narrower at the inf third than mid third
(-15.5 mm [SD 11.2], p≤0.001), but differences were not significant between sup and mid
thirds.
Rectal motion was significantly less at the inf third than mid third. The standard deviation
of the measured equivalent diameters across all fractions and patients was 4.0 mm lower at the
inf-third than mid-third (p≤0.001). In contrast, rectal motion at the sup-third was greater than
at the mid-third, with a difference in standard deviation of 1.5 mm (p≤0.001). The standard
deviation of equivalent diameters measured across all fractions and patients increased towards
the superior/cranial direction. Results suggest that the sup-third demonstrates greater rectal
contour deformation due to interfraction motion than the mid-third, and that the inf-third
undergoes less interfraction motion than the mid-third which may be due to the stiffness of
surrounding musculature. Therefore, substituting planned dose in areas where daily delivered
dose information is missing due to field of view limitations may be more appropriate at the
inferior end of the rectum than at the superior end. However, this conclusion is extrapolated
beyond the data presented here.
5.2.3.2 Dosimetric associations
Rectal length was weakly negatively correlated with both planned EUD (r = -0.278, p = 0.02)
and accumulated EUD (r = -0.308, p = 0.01), suggesting that longer rectums receive a
greater proportion of low dose contribution leading to a lower overall EUD. Correlations
with rectal length may be weak due to the low variance in measured rectal length. Equivalent
diameters from kVCT planning contours were not found to be associated with planned EUD.
kVCT equivalent diameter at the 0 and -1 slice were weakly negatively correlated with the
50 Gy dose-width (r = -0.236, p = 0.042 and r = -0.240, p = 0.038, respectively). Overall,
min/mean/max equivalent diameters from MVCT contours, and rectal motion over the course
of treatment, were not correlated with accumulated EUD. Mean MVCT equivalent diameter
at the -5 and -6 slice were weakly negatively correlated with the 50 Gy dose-width (r = -0.307,
p = 0.041 and r = -0.397, p = 0.030, respectively), indicating that an intermediate dose level
of 50 Gy may be affected by rectal expansion.
Rectal motion in the mid to sup portions of the rectum (slices +2 to +6) were weakly
and negatively correlated with accumulated 60 Gy and 65 Gy dose-widths, supporting the
suggestion that increased rectal motion leads to a blurring effect at higher dose levels.
The difference between kVCT and mean MVCT equivalent diameters at slices -2 to +5
were weakly to moderately correlated with the difference between planned and accumulated
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EUD (range r = 0.447, p < 0.0001 at slice 0, to r = 0.234, p = 0.047 at slice +4). This indicates
that in the mid to sup region of the rectum, an increase in rectal diameter is proportional to
an increase in EUD, and therefore it may be possible to predict the change in dose based on
the change in diameter.
5.2.4 Discussion
Using the automated segmentation system developed within the VoxTox programme, it was
possible to extract geometric properties of the rectum from daily MVCT image guidance
scans and present information on rectal motion that has not previously been extractable
from daily image guidance scans. This enabled tracking of inter-fraction rectal motion
through expansion and contraction, throughout the course of radiotherapy. This has been
a challenging task in the past due to the poorer image quality of MVCT scans, and the
sheer quantity of contours required (over 30,000 contours analysed within this sub-study).
Significant differences were found between the geometry of the rectal contour accepted at
the treatment planning stage, and the mean rectal position at the time of treatment delivery.
The amount of rectal motion was evaluated within discrete thirds - sup, mid, inf - and it was
found that the mid to sup thirds suffer more rectal motion than the most inferior third which
was found to be narrower and more fixed by the surrounding musculature.
A change in rectal contour results in a change in the dose received by the rectum with
respect to planned dose. Contour geometries were analysed for correlations with dose.
Although the equivalent diameters of kVCT and MVCT contours were not correlated to
planned and delivered EUD, respectively, both kVCT and MVCT results indicated that a
narrower contour resulted in a larger 50 Gy dose-width. Greater rectal motion measured on
MVCT contours resulted in a reduction of the 60 and 65 Gy dose widths. The difference in
equivalent diameter from kVCT to MVCT contours is correlated with the difference between
planned and delivered EUD.
Geometrical contour data was analysed to quantify the bounds of rectal motion, and was
also considered in terms of the impact on delivered dose. Interfraction motion of the rectum
was shown to be significant with respect to baseline planning data, inducing differences
between planned and delivered dose. These results strengthen the motivation for monitoring
interfraction motion to calculate delivered dose, which could ultimately act as a trigger for
adaptive radiotherapy.
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5.3 Sensitivity of dose response to simulated rectal motion
5.3.1 Introduction
The purpose of this study is to use physical-based biomechanical FE modelling to improve
understanding of the effect of rectal deformation on dose, and how this translates to NTCP.
In prostate radiotherapy, daily image guidance is used to confirm that the tumour is being
accurately targeted, but little consideration is given to the rectum other than a visual inspection
for excessive dilation. Due to variations in rectal content from day-to-day, the position, size,
and shape of the rectum can differ from the original rectal contour delineated on the kVCT
planning scan formulating the basis of the radiation treatment plan. This can result in
deviations between the planned dose to the rectum accepted at the time of treatment planning,
and the dose actually delivered (as demonstrated in Chapter 4). Quantifying the effect of
variations in rectal contour on dose has been challenging to date.
In Section 5.2, the range of rectal deformations across the course of 37 daily treatment
fractions was measured for a subset of VoxTox patients. Here, this information is applied
to rectal simulations which deform baseline rectal contours within the measured range
of motion. Simulations include: ‘uniform’ expansion and contraction, where the same
expansion coefficient is applied to each slice of the rectal contour along the full length of the
rectum; and ‘non-uniform’ expansion, where applied coefficients vary per slice depending
on rectal properties measured from patient data. The former provides more information on
motion-dose sensitivity, whereby a known shift is applied to all slices and the dose-effect can
be measured at each increment, and the latter is more representative of the way the rectum
behaves in reality based on measured patient data, i.e. rectal expansion is more limited in the
inferior third than the superior third, for instance.
For each expansion/contraction simulation, two different dose scenarios are investigated.
The first, scenario (i), assumes that the motion of the rectum affects the position of the
prostate and, assuming this is corrected for via the use of image guidance, the dose is
therefore shifted accordingly by the magnitude of simulated radial increase to the rectum.
The second, scenario (ii), assumes that rectal motion does not affect the prostate position, i.e.
the rectum expands into the high dose region causing the prostate to compress or deform,
and so no dose shift is applied to the simulation. Both scenarios are clinically viable and are
illustrated in Figure 5.6. For each simulation and dose scenario, the impact on NTCP was
quantified based on the resulting equivalent uniform dose.
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Fig. 5.6 Rectal (brown) expansion scenarios and impact on prostate (red) positioning, and subsequently dose
(prescription isodose represented by light green line). With respect to baseline, scenario (i) assumes rectal
expansion by δ r pushes the prostate anteriorly by δ r. It is assumed that the dose is correctively shifted following
image guidance (i.e. the patient couch position would be dropped by δ r). Scenario (ii) assumes the same rectal
expansion, but rather than a rigid shift to the prostate, the rectal expansion causes the prostate to deform in
shape, effectively squashing it so the edges become ‘dog-eared’. The dose would then not be shifted with image
guidance, and the rectum would have expanded into the high dose region.
5.3.2 Materials and methods
Biomechanical rectal models were generated for 26 patients from the kVCT planning data,
and the dose was calculated to the FE-DSM. These patients were a separate cohort to the
patients investigated in the motion study in Section 5.2. Different rectal deformation scenarios
were simulated in Abaqus, as detailed below. Deformations were applied to the DICOM
RT STRUCT contours in MATLAB at the pre-processing stage whilst generating the input
file for Abaqus. The model was constructed following the methods described in Section 5.1.
Final simulation positions were exported so that resulting delivered dose could be calculated
in MATLAB. Due to the different starting contours for each patient, dose differences were
reported relative to the baseline dose, and were parameterised using EUD and maximum
point dose.
5.3.2.1 Uniform expansion
Rectal contours from the kVCT planning scan were expanded radially, by 1, 2, 3, 5, 8, 10, 15,
and 20 mm, and contracted by -1, -2, -3, and -5 mm, uniformly across all planes of the rectal
contour. This is illustrated for a sample of contraction and expansions for a single patient
in Figure 5.7. Values were selected to incorporate a representative range of rectal motion.
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The minimum diameter across all rectal contours for all patients was 13 mm, so simulating
contractions of the rectal radius by an absolute value greater than 5 mm was not possible.
For each patient, the coordinates of the rectal contour were extracted from DICOM structure
files, and radially expanded in a polar coordinate system. Expansions were applied uniformly
to each slice along the full length of the rectum. This resulted in 13 simulations per patient,
including a baseline measurement with zero expansion.
(a) FEM simulation of uniform expansion where dose is shifted by expansion coefficient, scenario (i)
(b) FEM simulation of uniform expansion where no dose shift is applied, scenario (ii)
Fig. 5.7
5.3.2.2 Non-uniform expansion
For a separate patient cohort of 76 patients, as defined in Section 5.2, geometric measurements
were taken from rectal contours at the reference slice (the slice containing the most anterior
point of the kVCT prostate contour) and 7 slices in both the superior and inferior directions,
on each of the 37 daily MVCT scans. The number and location of slices within each
fraction’s MVCT scans set varies, with a mean of 12 slices per scan [range: 8-17]. Data were
included where slice measurements were available for 15 or more patients, each containing
5 or more scan sets (i.e. a combined minimum of 75 contours per slice). The purpose of
performing simulations based on extremes of measured patient contours was to determine the
maximum dose deviation from baseline for a single fraction, and to explore the approximate
accumulated effect based on the mean measured contour position.
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Fig. 5.8 Radial rectal expansions as measured from 76 patients, as described in Section 5.2. Radius dimensions
are mirrored about the origin to mimic the physical cross section of the rectum. Mean radii were measured
across all fractions and patients, for each slice of the rectal contour. Maximum and minimum values were
the largest measured absolute expansion or contraction from baseline from any fraction or patient. The 95th
percentiles (95% max and min) were calculated from the max and min across all patients to remove the effect of
outliers. The zero slice is the registration origin, and positive slice number indicates cranial direction, negative
slice indicates caudal direction. Slice thickness was 6 mm.
Using MATLAB’s standard regionprops function, the equivalent diameter for each slice
was calculated as the diameter of a circle with the same area as the segmented contour.
Across all patients and fractions, the mean, global maximum, and global minimum equivalent
diameters were measured per slice. Global maximum and minimum represented the most
extreme measurements across all patients (with final slicewise values not necessarily from the
same fraction or patient). To reduce the effect of outliers, the 95th percentiles of maximum
and minimum values across all patients were also calculated for each slice. For each of the 5
sets of parameters (mean, maximum, 95th percentile maximum, minimum, 95th percentile
minimum), the differences between MVCT and kVCT equivalent diameters were calculated
and halved to find magnitudes of radial expansion to be applied to the rectal simulation.
Radial expansions were non-uniformly applied along the length of the rectum, i.e different
expansions were applied at each slice as shown in Figure 5.8, to the kVCT planning contours
for 26 patients in this sensitivity analysis. An example is shown in Figure 5.9.
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(a) FEM simulation of non-uniform expansion where dose is shifted by expansion coefficient at the zero slice,
scenario (i)
(b) FEM simulation of non-uniform expansion where no dose shift is applied, scenario (ii)
Fig. 5.9
5.3.2.3 Dose shifting
Each set of simulations described above (uniform and non-uniform expansions) was per-
formed twice in order to model different clinical scenarios in terms of dose delivery; scenario
(i) the planned dose is shifted correspondingly, scenario (ii) the planned dose position remains
static, unaffected by the rectal deformation. Because daily image guidance was used, target
coverage was achieved through matching to the planning target volume (PTV) [81] contour
via positional couch shifts or gantry rotations. Both scenarios are illustrated in Figure 5.6.
Scenario (i), assumes that rectal expansion induces prostate motion, i.e. when the rectum
expands (or contracts), the prostate is consequently shifted anteriorly (or posteriorly) by the
same magnitude. The planned dose would then be shifted and matched to the prostate, which
in practice is achieved by altering the height of the treatment couch. This would be the case
in the region where the rectum is connected to the prostate via a thin layer of fibrous tissue,
the Denonvilliers’ fascia [19]. In this investigation, this effect was achieved for uniform
expansion by shifting the dose by the magnitude of the radial expansion, and for non-uniform
expansion by shifting the dose by the magnitude of the radial expansion observed at the
reference slice.
Scenario (ii) assumes that the rectum moves independently of the prostate, i.e. where the
rectum is adjacent to the prostate, and the prostate position remains fixed, the rectum can
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expand into ‘prostate space’, effectively compressing the prostate or causing the prostate
gland to become ‘dog-eared’ in shape (see Figure 5.6). This would cause the rectum to shift
further into the high-dose region, and no adjustment to the planned dose position would
necessarily be made as target coverage is priority. Further from the prostate, this assumption
allows rectal expansion without affecting the position of the prostate (or planned dose). In the
case of contraction in scenario (ii), the assumption is that the rectum contracts away from the
prostate without affecting its position. Both scenarios are clinically plausible and represent
the extremes of a range in which the real clinical situation lies within.
5.3.2.4 Normal tissue complication probability
To understand the clinical implications of the simulated dose variations caused by rectal
expansion and contraction, dose differences were translated into NTCP. A univariate binary
logistic regression model was developed using EUD as the input variable, as a predictor of
CTCAE Grade 2 rectal bleeding or above. The model was constructed following approaches
by Schaake et al. [140], and parameters (Eq. 5.2) were optimised on data from 109 discovery
cohort patients (as discussed in Chapter 4) in order to be distinct from the patients used in
this study. NTCP was calculated using Eq. 5.1. The resulting sigmoidal relationship between





where S is defined as:
S =−19.706+0.302(EUD) (5.2)
Fig. 5.10 NTCP model for rectal bleeding based on EUD, developed using univariate logistic regression on 109
patients from the discovery cohort.
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5.3.3 Results
5.3.3.1 Uniform expansion
Where uniform rectal expansion induced a shift to prostate position, and hence dose po-
sitioning (scenario (i)), ∆ EUD increased with rectal contraction (+1.8 Gy, SD 0.4 Gy, at
-5 mm), and decreased with rectal expansion (-4.0 Gy, SD 0.5 Gy, at +20 mm), as shown in
Figure 5.11a. The magnitude of change in EUD was much greater than the change observed
for maximum point dose, which was less than ±0.15 Gy from baseline across the full range
of expansions from -5 to +20 mm (Figure 5.11b). Contractions less than -5 mm were not
possible to simulate due to the narrow baseline contour diameters of some kVCT contours
(minimum 13 mm). Across the measured range, EUD dose-response was represented using a
second-order quadratic line of best fit (LOBF). Using this fit, the predicted change in EUD
for a reduction in rectal diameter of -1 cm was +1.6 Gy, and an increase in diameter of +1 cm
was -1.4 Gy, across the full course of treatment. This is of the order of magnitude of dose
delivered in a single fraction.
Assuming scenario (ii), where rectal expansion did not induce an anterior dose shift, the
EUD dose-response is in the opposite direction to scenario (i); as shown in Figure 5.11a, an
increase in diameter results in an increase in EUD with respect to baseline, and vice versa.
The maximum increase in EUD was +1.1 Gy (SD 0.9 Gy), occurring after +2 cm increase
in diameter. After this, there was a reduction in EUD which suggests that the low-dose
contribution to the rectal wall begins to dominate as the maximum dose stabilises. Beyond
this, the proportion of voxels receiving a lower dose increases relative to voxels receiving
a high dose. The LOBF applied to the EUD dose-response was a third order polynomial.
Using this fit, a reduction in rectal diameter of -1 cm corresponded to a reduction in EUD
of -2.1 Gy, and +1 cm resulted in +1.0 Gy, when the change is held constant across the full
course of treatment.
Maximum dose-response was of greater magnitude than scenario (i), and in the same
direction as EUD response until around the point of EUD dropoff after an increase of 2 cm
in diameter, where the maximum dose reaches a plateau of around 0.6 Gy (Figure 5.11b).
For each patient, the resulting EUDs from the expansion simulations for each scenario
were input into the NTCP model (Equation 5.1). These were plotted in Figure 5.12, and
both scenarios were modelled using third order polynomials as the LOBF. From simulated
measurements, for scenario (i) based on dose shifted results, an average of 1 cm reduction in
rectal diameter increased NTCP by +11.8 % (SD 3.6 %) due to a higher proportion of the
rectum receiving a higher dose and hence increased NTCP. An average increase of 1 cm in
rectal diameter reduced NTCP by -6.0 % (SD 2.1 %).
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(a)
(b)
Fig. 5.11 Results of uniform rectal expansion simulations for (a) equivalent uniform dose (EUD) and (b)
maximum point dose differences from baseline, over 37 fractions. ‘With dose shift’ shown in blue implies
scenario (i) from Section 5.6, and ‘no dose shift’ shown in orange implies scenario (ii). Polynomial lines of
best fit (LOBF) and corresponding R2 are included in (a). Error bars are standard deviation of mean EUD and
maximum point dose measured across all patients and increase with expansion to reflect the reduction in the
number of successfully executed simulations.
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Fig. 5.12 Change in NTCP due to uniform rectal expansion scenarios based on changes in EUD over 37
fractions. ‘With dose shift’ shown in navy implies scenario (i) from Section 5.6, and ‘no dose shift’ shown in
red implies scenario (ii).
Table 5.1 Predicted changes in EUD and NTCP for representative expansions to rectal diameter based on LOBF
equations for uniform expansion simulations. Figures are representative assuming stated change is maintained
throughout treatment.
With dose shift, scenario (i) No dose shift, scenario (ii)
∆ rectal diameter ∆EUD (Gy) ∆NTCP (%) ∆EUD (Gy) ∆NTCP (%)
-1 cm +1.8 +11.8 -2.1 -10.2
+1 cm -1.3 -6 +0.8 +4.0
+2 cm -2.4 -9.8 +1.1 +4.9
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For scenario (ii) based on no dose shift, an average 1 cm reduction in rectal diameter
reduced NTCP by -10.2 % (SD 4.3 %) where the rectum is contracting away from the prostate
and hence high dose region. An average increase of 1 cm in rectal diameter increased NTCP
by +4.0 % (SD 1.6 %), in contrast to scenario (i). The maximum increase at the point of
inflection in scenario (ii) at 2 cm increase to the rectal diameter was +4.9 % (SD 1.6 %)
NTCP.
5.3.3.2 Non-uniform expansion
Non-uniform expansions demonstrated similar trends in dose response as results from uniform
expansions (Figure 5.13). For scenario (i), where dose was shifted by the magnitude of the
radial expansion at the corresponding reference slice, ∆EUD increased with rectal contraction
to a maximum of +4.0 Gy (SD 0.7), and decreased with rectal expansion to a minimum
of -6.9 Gy (SD 1.7). The change in maximum dose also increased with contraction, and
reduced with expansion, but effects were less than ±0.4 Gy. For scenario (ii) where no dose
shift occurred, EUD reduced with rectal contraction to a minimum of -3.7 Gy (SD 2.0), and
increased with expansion to a peak of +0.6 Gy (SD 0.9) before reducing to -0.3 Gy (SD 1.3),
similar to the behaviour observed in Figure 5.11. Maximum dose changes were greater for
scenario (ii), ranging from -2.2 Gy (SD 2.2) at minimum contraction, to +0.8 Gy (SD 0.7) at
maximum expansion.
Predicted change in EUD based on rectal expansion was calculated using the LOBF
equations derived from uniform expansion results, using the expansion at the reference slice
as the input. Predicted values are represented by the dotted line in Figure 5.13a. These
generally underestimate the deviation from baseline EUD (by 1.8 Gy at minimum contraction
and 2.7 Gy at maximum expansion for scenario (i), and 0.6 Gy at minimum contraction for
scenario (ii)). Expansion results for scenario (ii) were within 0.6 Gy of predicted values.
Changes in EUD were input into the NTCP equation 5.1 and plotted in Figure 5.14.
The mean NTCP at baseline was 22.9 % (SD 10.7). The change in NTCP with dose shift,
scenario (i), ranges from +23.7 % (SD 7.0) at minimum rectal contraction, to -16.1 % (SD
6.2) at maximum expansion. Where no dose shift is applied, scenario (ii), minimum rectal
contraction corresponded to a reduction in NTCP of -11.2 % (SD 5.1), with a peak increase
at the 95th percentile maximum expansion of +3.2 % (SD 4.8), before reducing to +0.7 %
(SD 4.4) at maximum expansion.
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(a)
(b)
Fig. 5.13 Results of non-uniform rectal expansion simulations for (a) equivalent uniform dose (EUD) and (b)
maximum dose differences from baseline. ‘With dose shift’ shown in blue implies scenario (i) from 5.6, and
‘no dose shift’ shown in organge implies scenario (ii). Magnitudes of expansions are shown in Figure 5.8. Error
bars indicate standard deviation of mean EUD and maximum point dose measured across all patients.
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Fig. 5.14 Non-uniform rectal expansion scenarios and impact on NTCP, based on changes in EUD. ‘With dose
shift’ shown in navy implies scenario (i) from Section 5.6, and ‘no dose shift’ shown in red implies scenario
(ii). Error bars indicate standard deviation. Dotted lines indicate predicted change in NTCP using the line of
best fit equations, where the magnitude of rectal expansion used as input into the equation was taken at the
reference plane. Average NTCP at baseline was 22.9 % (SD 10.7).
Using the LOBF equations derived from uniform expansion results, the predicted change
in NTCP was calculated for non-uniform expansions, based upon the change in rectal radius
at the reference slice (dotted lines, Figure 5.13a). For scenario (i) where a dose shift is
applied, the predicted dose underestimated the measured simulated change in NTCP (closer
to baseline by 7.8 % and 5.8 % at minimum and maximum expansions, respectively).
5.3.4 Discussion
Rectal models for 26 patient were simulated in the FEA environment Abaqus based on
manually segmented contours from the kVCT planning scan. Models were expanded (and
contracted) either uniformly, where incremental expansions were applied to all slices of the
rectal simulation, or non-uniformly, where expansions varied in the z-direction according to
the measured deformations from patient data at each slice. Expansions were applied radially,
but in practice the rectal diameter is measured on the IGRT image at the time of treatment,
so to discuss in terms of diameter is more clinically relevant.
For each simulation, two dose scenarios were investigated; (i) where rectal expansion
resulted in a dose-shift, (ii) where no dose shift was applied. These scenarios were designed to
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investigate the extremes of a clinical IGRT scenario and demonstrate different dose-response
behaviours. However, within each scenario the direction of the dose and NTCP responses
agreed for uniform and non-uniform expansions.
Scenario (i) suggests that where rectal expansion causes the prostate to move, and the dose
to be shifted accordingly, that rectal expansion causes EUD to reduce, and rectal contraction
causes EUD to increase. Hence, a narrower rectal diameter with respect to the planning scan
would be associated with an increased likelihood of developing toxicity. This result implies
that achieving as narrow a rectal diameter as possible at the time of the kVCT planning
scan is therefore desirable, as further narrowing throughout the course of treatment would
be less probable. On-treatment clinical imaging protocols often define tolerances for the
maximum acceptable rectal diameter, but do not specify a minimum diameter. Furthermore,
often patients will be instructed to empty their bowels if the rectum is deemed outwith the
maximum tolerance. Results for scenario (i) suggest this practice may need revising, as
larger rectal diameters are associated with decreased dose and NTCP, whereas narrower
rectums should be monitored. Thor et al. [155] reported findings that narrower rectums on
the planning CT scan were associated with higher rates of morbidity. However, VoxTox
results presented in Section 5.2 showed that kVCT diameter was not indictive of MVCT
diameter, and hence delivered dose. Maximum dose appeared to be fairly independent of
rectal wall expansion or contraction, varying by less than ±0.4 Gy.
The results for scenario (ii) are more intuitive, whereby the EUD increases as the rectum
expands into the static high-dose region, and reduces as the rectum contracts away from it.
The EUD reaches a peak and begins to reduce as the maximum dose begins to plateau. This
response suggests that at this point, as the rectal radius increases, the proportion of the rectum
receiving a lower dose is increasing greater than the proportion of the rectum receiving a
higher dose, resulting in a reduction in EUD.
The direction of the dose response for each scenario agreed between uniform and non-
uniform expansions. For scenario (i), rectal expansion resulted in a reduction in dose and
NTCP. This suggests that with an increase in rectal diameter, the proportion of rectal wall
receiving a high dose level is reduced, and the risk of toxicity is lowered. Rectal contraction
resulted in an increase in dose and NTCP, at a greater rate than expansion results. For
uniform expansion with a corresponding dose shift, dose response was modelled using
polynomials and can be interpreted for clinical purposes as approximately: a reduction
of -1 cm in rectal diameter results in an increase of +1.5 Gy (or +10 % NTCP), and an
increase in rectal diameter of 1 cm corresponds to a reduction of -1.5 Gy (or -5 %), where
the rectum remains abutting the prostate maintained over the course of treatment. The results
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for non-uniform expansion suggest that these may be under-estimations of the magnitude of
the dose/NTCP-effects.
When comparing simulated dose measurements for non-uniform rectal expansions with
predicted dose measurements from the equations derived for uniform rectal expansion
simulations for scenario (i), the predicted values underestimate the absolute effect on EUD,
but are within the bounds of the standard deviation error bars (with the exception of minimum
expansion). The differences may be due to expansions only being applied to the central 15
slices, and slices outwith this range, where the dose is equal to the original planning dose,
may be negatively influencing the EUD calculation. Additionally, radial expansions used in
the prediction calculation, were from the reference slice, but the magnitude of the expansion
at each slice varied, which was not accounted for in the prediction model.
For scenario (ii), the trend of the dose response with expansion and contraction from
uniform simulations were generally in agreement with non-uniform simulations. The changes
in EUD were in the opposite direction when compared to scenario (i), with EUD increasing
with rectal expansion, and reducing with rectal contraction. EUD reached a maximum when
the rectal diameter had increased by approximately 2 cm. However, this situation is fairly
clinically unrealistic. The magnitudes of the maximum absolute deviations from baseline
EUD were less than the dose effects in scenario (i).
Maximum dose demonstrated more variability in scenario (ii) than scenario (i), deviating
from baseline by -2.2 to + 0.8 Gy for non-uniform simulations. The upper limit of the
maximum dose is determined by the planned dose prescription, and so such an increase is
greater than expected given the fairly homogeneous doses delivered to the PTV. For minimum
contraction, where the rectum moves away from the static high-dose region, the fall-off in
maximum dose observed is as expected.
Predicted EUD and NTCP response based on uniform expansion underestimated the
simulated changes measured for non-uniform expansions in the case of a dose shift being
applied. In this scenario (i), a wider rectal diameter results in lower EUD and NTCP, and a
narrower diameter results in a higher EUD and NTCP. The expansion parameters used in
the equation were based upon expansions at the reference slice which were greater than the
expansions recorded at most other slices (i.e. rectum narrowed with increasing distance from
reference slice), so should lead to an overestimation in ∆EUD and ∆NTCP. Although the
predicted values generally lie within the standard deviation error boundaries, it is unclear why
these are different than expected. Perhaps the use of a single uniform expansion coefficient
along the length of the rectum may not be adequately physiologically representative, and
could limit the accuracy of the predictive model. As shown in Figure 5.5, the superior rectum
is more susceptible to motion than the inferior rectum so perhaps further investigation into
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typical range and behaviour of motion within superior, middle, and inferior rectal thirds may
improve prediction of the non-uniform range of motion measured throughout the course of
treatment. For scenario (ii), where no dose shift is applied, the predicted change in EUD
for rectal contraction is underestimated with respect to baseline, yet the NTCP effect is
overestimated. However, expansion predictions lie very close to measured for EUD and
NTCP, and all predicted results lie within one standard deviation of the measured result.
The dosimetric implications from this FE study can also be interpreted as a simulation
of contouring sensitivity; for instance, an inter-clinician discrepancy of 2 mm in defining
the radius of the rectal wall might induce a dose difference of ±0.6 Gy for the same patient
anatomy, which corresponds to a change in NTCP of approximately ±3%.
Several limitations to this study should be identified. Firstly, not all simulations could be
completed by the FEM system. For the more extreme scenarios being simulated for uniform
expansion, an increasing number of simulations failed to produce analytical solutions as the
magnitude of simulated radial expansion increased. This is represented within the standard
deviations quoted alongside the results, which increase with absolute expansions. Secondly,
in reality, rectal expansion and contraction are non-uniform along the length of the rectum
in the patient z-axis, so predictions based on uniform expansion may not be representative
(and were shown to underestimate the dose-response of the clinical situation). However,
it is proposed that predictions may be adequate, with acknowledged caveats, for use as a
‘rule-of-thumb’ guide. Validation of the prediction equations on a separate patient cohort
would be beneficial. To independently test model generation would require planned EUD
to the rectal wall combined with late toxicity data, or to assess prediction equations would
require planning structures and planned dose as input into FE simulations. This could
potentially be achievable using data in the literature [3, 35, 52]. An additional limitation
of the study relates to the use of EUD, a single metric describing a 3D dose distribution.
Although selected for its simplicity, results demonstrate a non-linear relationship between
EUD-response and maximum dose response, assumed to be caused by the relative increase
in low dose contribution after a certain expansion threshold (which appears to occur at
approximately +2 cm in diameter). This effect may be influencing the NTCP calculation
which does not consider absolute maximum dose. Finally, the stated changes in EUD and
NTCP are reported in terms of entire treatment prescription and are based on the assumption
that a given expansion is maintained throughout the course of treatment. This is unlikely in
practice, but nevertheless, it is important to appreciate how rectal deformation impacts dose,
and consequently NTCP, based on the full range of measured rectal motion.
To summarise, the effect of rectal motion on dose has been investigated using biomechan-
ical FE modelling. Gradually increasing intervals of uniform expansion and contraction were
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applied to investigate sensitivity, and non-uniform expansions and contractions were applied
throughout the length of the rectum to model the extremes of measured clinical contours. The
behaviour of the dose response depends on whether corrective dose shifts are applied or not.
This was represented by two different clinical scenarios when registering dose. Assuming
scenario (i) where dose is shifted by the magnitude of the rectal expansion, a narrower rectal
diameter at the time of treatment indicates that the delivered dose to the rectum will be
greater. Hence, a constricted rectum at treatment indicates a greater probability of rectal
bleeding. These results emphasise the importance of coherence with rectal filling protocols
at treatment planning, whereby, minimising the rectal diameter at treatment planning would
be representative of a worst-case dosimetric scenario, and therefore delivered dose to rectum
would be less than planned if the rectal diameter at treatment was greater than at planning.
Rectal filling protocols in IGRT generally advise a maximum dimensions that the rectal
diameter should not exceed. However, these results suggest that there should be a tolerance
on the minimum rectal diameter at treatment with respect to baseline. In scenario (ii) where
rectal expansion results in a greater proportion of the rectal wall encroaching into the high
dose region, reactive measures should be taken (e.g. repositioning the patient). Future
work could include contouring of the prostate on MVCT image guidance scans to determine
whether scenario (i) or (ii) is more common.
In terms of recommendations for existing clinical practice, the results suggest that if the
rectal diameter at the time of treatment is consistently smaller than the diameter measured
at treatment planning, in the region where the rectum is abutting the PTV, a dosimetric
evaluation should be undertaken, with a view to adapting the plan to minimise the potential




In this chapter, biomechanical finite element (FE) modelling is introduced to the VoxTox
process with the aim of improving accuracy and robustness of dose calculation. The simulated
rectal model facilitates tracking of dose-histories at the voxel level throughout the course
of treatment. Voxels of the rectal wall deform in 3D according to biomechanical properties
and applied boundary conditions, providing a more anatomically representative basis for
dose accumulation, intra- and inter-patient. The approach described in Chapter 4 for two-
dimensional dose-surface maps (2D-DSMs) was limited to in-plane, isotropic expansion
only, where voxels were uniformly normalised around the circumference. Calculating and
accumulating dose to the rectal wall using FE generated dose-surface maps (FE-DSMs) is a
novel approach that increases the resolution of dose information available for interrogation.
Here, we investigate different methods for parameterising dose from FE-DSMs and explore
dose-toxicity associations.
I designed and conducted the work described in this chapter. My role was to integrate
existing FE code into the VoxTox workflow, edit the code so that it was able to handle
patient DICOM data, and optimise the model for patient conditions rather than experimental
conditions. I wrote the code for generating geometric subregions, and devised the approach
for determining statistical subregions at risk using binary masks. I processed toxicity data and
combined with baseline and dosimetric information, including careful division into training
and validation sets for each endpoint. All dose-toxicity analysis (univariate and receiver
operator characteristic analysis) was performed by me.
I would like to acknowledge the contributions of Dr Simon Thomas who wrote the code
to generate 2D-DSMs and provided guidance for combining 60 Gy and 74 Gy fractionation
regimes, Dr Marina Romanchikova who provided assistance in generating the code for
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dose-widths and EUD calculation, Prof Michael Sutcliffe who wrote the code for performing
FE analysis, and Dr David Noble, Mrs Amy Bates and Mr Karl Harrison who played vital
roles in the extraction and interpretation of toxicity data.
6.1 Introduction
A biomechanical model is a physical-based model that incorporates the mechanical properties
of soft tissue in addition to geometry and boundary conditions [21]. Finite element (FE)
modelling has been adopted for anatomical modelling within the radiotherapy community
for purposes such as deformable image registration for intra- and inter-imaging modality,
improving target localisation, and even dose accumulation [20, 21, 114, 135, 163, 165]. The
novelty and advantage offered by FE analysis is that the material elements, or voxels, are able
to deform in a more anatomically realistic way [21], according to constitutive biomechanical
laws. FE analysis provides a sophisticated tool for tracking organ motion, which facilitates
the ultimate aim of the VoxTox project - to track dose at the voxel level.
A limitation of the 2D-DSM method presented in Chapter 4 was that rectal expansion
was assumed to be restricted to the plane of the transverse imaging slice, as well as being
isotropically normalised around the circumference. The advantage of voxel-tracking using FE
analysis is that anisotropic, extraplanar expansion is possible. FE analysis is even beginning
to be recognised by manufacturers of treatment planning systems as a important feature
in dose accumulation [165]. By implementing FE modelling into the generation of DSMs
within the VoxTox process, we can achieve a more anatomically representative registration
and improve the accuracy in dose calculation and accumulation.
An alternative voxel-based solution for registration of the rectum has been previously
reported in the literature, whereby the planned dose to the rectal wall for 118 patients
were combined to a common anatomical template [59, 61]. By splitting the resulting 3D
voxel-based dose-maps into sub-regions at risk (SRRs) based on geometric and probabilistic
segmentation, features of the planned DVH of each SRR were investigated for associations
with toxicity. This SRR approach was adapted for our work, whereby: geometric subregions
were divided into anterior/posterior hemispheres, anterior/posterior/left/right longitudinal
quarters, and superior/middle/inferior lateral bands around the circumference; and statistical
subregions were determined by performing independent sample t-tests on patients with and
without toxicity.
Here, we test the hypothesis that extracting dosimetric parameters from FE-DSMs im-
proves the strength of dose-toxicity association. As well as comparing FE and 2D-DSM
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analysis methods, we compare different parameterisation techniques of increasing complexity.
The chapter is divided into three sub-studies:
• FE-DSM dose-widths and equivalent uniform dose (EUD), where parameters extracted
from FE-DSMs are compared with previous results for 2D-DSMs
• Spatial division of FE-DSMs into geometric subregions. EUD is calculated for each
subregion and compared with EUD of the full rectal wall.
• Statistically derived subregions at risk are determined by examining dose distributions
of patients with and without toxicity.
Dose-toxicity analysis is performed for each analysis and parameterisation approach. Results
are then compared between sub-studies to interpret the benefit of dose accumulation using
FE-DSMs for toxicity prediction.
6.2 Parameterising FE-DSMs using dose-widths and EUD
6.2.1 Materials and methods
Using the system described in Chapter 3.6, the data from 139 VoxTox prostate cancer patients
from the training set of the consolidation cohort were processed using FE-DSMs to present
planned dose and accumulate delivered dose. Patients were included where a minimum
of 2 years’ follow-up data were available, acquired at 6, 12, and 24 months (±2 months)
post-treatment. Baseline data and details of clinical cofactors were available for all patients
in the consolidation cohort. Patients were prescribed either 74 Gy in 37 fractions (59%),
or 60 Gy in 20 fractions (41%), and were treated with helical image guided radiotherapy
(IGRT) on TomoTherapy. Twelve toxicity endpoints were investigated (including different
staging levels), as detailed in Table 6.1.
For one of the patients, the FEA model could not be successfully completed using the
planning data. This was due to excess distortion at one of the nodes. In practice, this could
be due to a large rectal diameter at the time of CT scanning, and could be solved in the
future by stricter adherence to restrictions imposed within imaging protocols, or alternatively,
may be due to an erroneous contour generated by the autocontouring system. Consequently,
baseline planned dose information was missing so this patient was removed from the analysis.
Toxicity breakdowns are shown for the resulting 139 patients in each dataset in Table 6.1.
Excess nodal distortion also caused the model to terminate prematurely for 1-2 fractions for
4 patients, resulting in missing daily dose data. Due to the relatively low number of fractions
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Table 6.1 Consolidation cohort toxicity incidence for 139 patients in the training set.
Toxicity Scoring System Incidence % (n)
Diarrhoea ≥ G1 CTCAE [158] 25.9 (36)
Faecal incontinence ≥ G1 CTCAE [158] 17.3 (24)
Proctitis ≥ G1 CTCAE [158] 18.7 (26)
Proctitis ≥ G2 CTCAE [158] 14.4 (20)
Rectal bleeding ≥ G1 CTCAE [158] 33.1 (46)
Rectal bleeding ≥ G2 CTCAE [158] 11.5 (16)
GI toxicity ≥ G1 RTOG [127] 52.5 (73)
GI toxicity ≥ G2 RTOG [127] 15.8 (22)
Stool frequency ≥ G1 LENT SOMA [1] 34 (24.5)
Bowel bother ≥ G1 UCLA-PCI [89] 38.8 (54)
Bowel bother ≥ G2 UCLA-PCI [89] 22.3 (31)
Bowel bother ≥ G3 UCLA-PCI [89] 9.4 (13)
affected, missing daily delivered dose data were substituted with planned dose data for the
number of affected fractions.
For each patient, rectal models were generated for planned data, as well as for each of
the 20 or 37 daily treatment fractions. Image sets and contours were processed in Matlab
to determine coordinate systems, positional offsets, contour locations, and centrelines. The
data were consolidated into input files for the Abaqus simulation as described in Sections 3.6
and 5.1.
A central mandrel, based on the planning contour, was used as the common starting
geometry for each daily fraction rectal model so that the material elements, or voxels, can
be tracked. The model expands and deforms to the daily MVCT contour according to
the biomechanical properties and boundary conditions applied. The model used was a
hyperelastic neo-Hookean, appropriate for rubber-like soft tissues. Model properties were
previously described in Chapter 3.6.
A Python script was run to extract surface coordinates of the deformed model from
Abaqus. Delivered dose to each voxel was then calculated via interpolation of the daily
delivered dose matrix in MatLab. Where the patient’s fractionation schedule was 60 Gy in 20
fractions, planned and delivered doses were converted to the equivalent dose in 37 fractions,
using an α/β ratio of 2.149 (as detailed in Section 3.3).
To compare the FE-DSM approach with the 2D-DSM approach discussed in Chapter 4, the
same dose parameters were investigated. DSM ‘dose-widths’ - the lateral extent of an ellipse
fitted to a discrete isodose level - were measured for doses 30 - 70 Gy in 5 Gy increments, and
EUD - a form of weighted mean dose across the full DSM - were calculated for FE-DSMs.
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These parameters were extracted and compared for planned and accumulated FE-DSMs,
and were independent of toxicity endpoint. For each of the 12 endpoints investigated, the
composition of individual patient datasets differed so that toxicity incidence rates could be
retained. However, this difference is not expected to significantly affect results comparing
FE-DSM vs. 2D-DSM or planned vs. accumulated dose. For our VoxTox patient population,
the patients used as the representative sample for this analysis was from the rectal bleeding
dataset (n = 139).
For each of the 12 endpoints, a comparison was made between the mean FE-DSMs
of planned and accumulated dose, patients with and without toxicity for both planned and
accumulated dose, and the difference between planned and accumulated toxicity difference
maps. The greatest dose differences observed in the former indicates the areas most suscepti-
ble to interfraction motion, and in the latter indicates the geometric areas where additional
information on toxicity prediction might be available from accumulated dose.
For a comparison with the 2D-DSM results (Chapter 4), receiver operator characteristic
(ROC) curve analysis was performed on the unfolded FE-DSM for EUD, and dose-widths
of 30 - 70 Gy in 5 Gy intervals. To further investigate spatial aspects of dose, the unfolded
FE-DSMs were divided geometrically into rectal subregions at risk (SRR) following the
methods of Dréan et al. [61]. SRRs were: anterior (ant) and posterior (post) hemis; ant, post,
right, left quarters, split longitudinally; superior (sup), middle (mid), inferior (inf) thirds,
split laterally; and a combination of lateral splits divided by longitudinal splits. Finally, SRRs
were selected based on statistical analysis of the difference maps per endpoint.
Planned and accumulated delivered dose were calculated using FE analysis for a dataset
of 139 patients, distinct for each of the 12 endpoints. FE-DSMs were generated by cutting
the 3D model posteriorly, and virtually unwrapping to a 30 × 80 element 2D map. The
cutting point was defined as the most posterior point of the starting central mandrel, which
was common to each slice.
6.2.2 Results
6.2.2.1 FE-DSM vs. 2D-DSM
FE-DSM parameters were compared with parameters extracted from 2D-DSMs for the
same patients, which were previously presented in Chapter 4. Dose-widths measured
from FE-DSMs were greater than those measured from 2D-DSMs across all dose lev-
els investigated, ranging from an average increase of 2.1 % (SE 0.2 %)/2.3 % (SE 0.2 %)
for planned/accumulated 30 Gy dose-widths, to 7.0% (SE 0.4 %)/8.6 % (SE 0.4 %) for
planned/accumulated 70 Gy dose-widths. Figure 6.1 shows how the average difference
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Fig. 6.1 Mean difference between FE-DSM and 2D-DSM dose-widths for planned (green) and accumulated
(blue) dose. Error bars indicate standard error measured across 139 patients in the rectal bleeding training
cohort. Accumulated dose differences are higher, and increase with dose-width.
between FE-DSM and 2D-DSM calculated dose-widths increases with dose level. EUD was
also greater when calculated using FE-DSMs with respect to 2D-DSMs for both accumulated
dose, with a mean increase of 0.68 Gy (SE 0.05 Gy), and planned dose, with a mean increase
of 0.19 Gy (SE 0.03 Gy). The differences between FE-DSM and 2D-DSM calculated dose
were significant (paired samples t-test, p<0.001) for all measured dose parameters.
6.2.2.2 Planned vs. accumulated dose
The difference between mean planned and mean accumulated FE-DSMs is shown in Fig-
ure 6.2. The difference map shows an inhomogeneous distribution, emphasising the need for
spatial dose quantifiers. Analysing FE-DSMs, the average accumulated EUD was -1.1 Gy (SE
0.1 Gy, range [-6.6, 1.3] Gy) with respect to planned EUD. Differences between planned and
accumulated EUD were significant (p < 0.001). Accumulated EUD was lower than planned
for 112 of 139 patients, with a difference of -1 Gy or lower observed for 69 patients and
-2 Gy or lower for 22 patients. Differences between planned and accumulated dose-widths
were significant at intermediate to higher dose levels from 40 - 70 Gy (p<0.01), but not at 30
and 35 Gy dose-widths. On average, accumulated dose-widths were lower than planned dose
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Fig. 6.2 Spatial dose differences between mean planned and mean accumulated FE-DSMs for 139 patients.
Note inhomogeneous distribution of difference map.
widths for all dose levels above 30 Gy, and the magnitude of the difference increased with
dose level.
6.2.2.3 Dose-toxicity analysis
Results of dose-toxicity analysis for all endpoints are discussed below and the most discrimi-
native dose metrics are listed in Table 6.2. The area under the receiver operator characteristic
curve (AUC) and 95 % confidence intervals (95%CI) for rectal bleeding ≥ G1 and ≥ G2,
RTOG GI toxicity ≥ G2, and stool frequency ≥ G21are shown in Figure 6.3.
Diarrhoea (n = 36, 25.9%)
Planned dose-widths from 30 to 45 Gy were predictive of diarrhoea, with the planned 35 Gy
dose width producing the largest AUC of 0.654 [95% CI 0.550, 0.759]. The mean difference
in planned 35 Gy dose-width between patients with and without diarrhoea was 4.1 % (p =
0.022). Accumulated dose-widths from 35 to 55 Gy and EUD were also predictive. Similar
trends were observed when compared with 2D-DSM results, where planned 35 Gy dose-
width was the strongest predictor (AUC 0.689, [95% CI 0.587, 0.785]), and associations
were observed for planned dose-widths from 30 - 50 Gy, accumulated dose-widths from
30 - 60 Gy, and accumulated EUD.
Faecal incontinence (n = 24, 17.3%)
Planned and accumulated dose-widths from 40 to 55 Gy, and planned 60 Gy dose-widths,
produced AUCs greater than 0.6. However, the lower bounds of the 95%CI dropped below
0.5 so no single dosimetric parameter was considered a significant predictor of faecal
incontinence. The same result was found from 2D-DSM analysis.
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(a)
(b)
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(c)
(d)
Fig. 6.3 Area under the receiver operator characteristic curve (AUC) and 95% confidence intervals (CI) for
planned (plan) and accumulated (acc) dose parameters (dose-widths and equivalent uniform dose, EUD), for four
of 12 toxicity endpoints investigated: (a) Rectal bleeding ≥ G1, (b) Rectal bleeding ≥ G2, (c) RTOG GI toxicity
≥ G2, (d) Stool frequency ≥ G1. Endpoints were selected as examples where FE-DSM analysis improved
upon dose-toxicity associations found from 2D-DSM analysis, and where parameters from accumulated dose
were overall greater predictors than from planned dose.
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Proctitis ≥ G1 (n = 26, 18.7%)
For proctitis ≥ G1, the strongest predictor was the planned 45 Gy dose-width (AUC 0.688,
[95% CI 0.567, 0.809]). The mean difference between patients with and without toxicity was
6.0 % (p = 0.002). Planned EUD and dose-widths from 30 to 65 Gy were also discriminative.
Accumulated dose widths at 60 and 65 Gy were predictive of proctitis ≥ G1, but produced
AUCs lower than corresponding planned dose-widths. From 2D-DSM analysis, the strongest
predictor was the planned 65 Gy dose-width with AUC = 0.650 [95% CI 0.547, 0.753].
Proctitis ≥ G2 (n = 20, 14.4%)
Planned 40 and 45 Gy dose-widths were strongest predictors of proctitis ≥ G2, both with
AUC = 0.674, and 95%CIs [0.540, 0.808], [0.539, 0.808], respectively. Differences between
planned dose-widths for patient with and without G2 proctitis were 6.3 % (p = 0.007) and
5.8 % (p = 0.009) for 40 Gy and 45 Gy, respectively. Planned dose-widths from 30-60 Gy
were also predictive. Accumulated dose-widths at 30, 40-65 Gy were associated with G2
proctitis. AUCs were greater from planned dose-widths up to 55 Gy, and accumulated AUCs
were greater for 60 and 65 Gy. This result is in contrast to the 2D-DSM result which found
the strongest predictor to be the accumulated 60 Gy dose-width with AUC = 0.648 [95% CI
0.524, 0.772].
Rectal bleeding ≥ G1 (n = 46, 33.1%)
The strongest predictor of ≥ G1 rectal bleeding was the accumulated 55 Gy dose-width,
AUC = 0.652 [0.555, 0.749], as shown in Figure 6.3a. The difference in accumulated 55 Gy
dose-width between patients with and without toxicity was 4.6 % (p = 0.003). Accumulated
EUD and dose-widths from 40-70 Gy were also associated with ≥ G1 rectal bleeding, as well
as planned EUD and 40-60 Gy dose-widths. At the 30 Gy dose-width, planned AUC was
greater than accumulated, and for EUD and dose-widths above 45 Gy, accumulated AUCs
were greater than planned AUCs. The 2D-DSM analysis results also found accumulated
dose to be generally more predictive than planned dose, but the strongest predictor was
accumulated EUD with AUC = 0.651 [95% CI 0.556, 0.747].
Rectal bleeding ≥ G2 (n = 16, 11.5%)
Accumulated EUD and 30-70 Gy dose-widths were associated with ≥ G2 rectal bleeding, as
shown in Figure 6.3b, with the strongest predictor being the 60 Gy dose-width (AUC = 0.805
[0.721,0.889]). The difference in accumulated 60 Gy dose-width between patients with and
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Table 6.2 Dosimetric parameters most discriminative of toxicity from planned and accumulated dose surface
maps generated using finite element modelling. Dose-width levels or equivalent uniform dose (EUD) resulting in
the greatest area under the receiver operator characteristic curve (AUC) are listed. Endpoint entries were omitted
where no parameter from planned or accumulated dose produced an AUC with minimum 95% confidence
interval greater than 0.5, so were not considered significant. A dash entry in the table indicates that no significant
parameter was determined. Bold indicates greatest AUC between planned and accumulated results.






Diarrhoea 35 0.654 50 0.623
Proctitis ≥G1 45 0.688 65 0.642
Proctitis ≥G2 40 0.674 60 0.652
Rectal bleeding ≥G1 55 0.635 55 0.652
Rectal bleeding ≥G2 60 0.804 60 0.805
GI toxicity ≥G2 55 0.726 50 0.768
Stool frequency 45 0.637 50 0.661
Bowel bother ≥G1 45 0.616 60 0.611
Bowel bother ≥G2 - - EUD 0.615
without G2 rectal bleeding was 8.4 % (p < 0.001). Planned dose-widths at 40-70 Gy and
EUD were also correlated with ≥ G2 rectal bleeding. AUCs were greater from accumulated
dose than planned dose for EUD, and all dose-widths investigated, except the 65 Gy dose-
width. From 2D-DSM analysis, the planned 65 Gy dose-width was most discriminative, with
AUC = 0.793, [95% CI 0.700, 0.885].
RTOG GI toxicity ≥ G1 (n = 73, 52.5%)
There were no dosimetric parameters from planned or accumulated FE-DSMs that produced
AUCs greater than 0.6.
RTOG GI toxicity ≥ G2 (n = 22, 15.8%)
The strongest predictor of RTOG GI toxicity ≥ G2 was the accumulated 50 Gy dose-width,
with AUC 0.763 [95% CI 0.644, 0.893], as shown in Figure 6.3c. The difference between
patients with and without toxicity was 7.4 % (p < 0.001). At dose-widths from 30-65 Gy,
both accumulated and planned dose were significant predictors. Accumulated dose produced
greater AUCs than planned dose for all measured dose parameters. Results mirror those
from the 2D-DSM analysis, which also found the accumulated 50 Gy dose-width to be most
predictive, with AUC = 0.743 [95% CI 0.621, 0.865].
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Stool frequency (n = 34, 24.5%)
Accumulated dose-widths from 35-60 Gy were associated with increased stool frequency,
where the strongest predictor was the 50 Gy dose-width with AUC 0.661 [95% CI 0.547,
0.776]. Results are shown in Figure 6.3d. The difference in 50 Gy dose-width between
patients with or without increased stool frequency was 4.7 % (p = 0.009). Planned dose-
widths were significant at 35-55 Gy. The planned 30 Gy dose-width produced a greater AUC
than the corresponding accumulated measurement, but for all other significant dose-widths,
accumulated dose produced a greater AUC. Analysis of 2D-DSMs found the accumulated
45 Gy isodose to be most predictive, with AUC = 0.648 [95% CI 0.536, 0.759].
Bowel bother ≥ G1 (n = 55, 39.6%)
The planned 45 Gy dose-width was most strongly associated with G1 bowel bother, with
AUC = 0.625 [95% CI 0.525,0.725]. The difference in planned 45 Gy dose-width between
patients with and without G1 bowel bother was 3.6 % (p = 0.026). Planned dose-widths from
35-55 Gy were all predictive of G1 bowel bother, as were accumulated dose-widths from
40-60 Gy and EUD. The 2D-DSM analysis found accumulated 60-Gy dose-width to be most
predictive, with AUC = 0.638 [95% CI 0.543, 0.733].
Bowel bother ≥ G2 (n = 32, 23.0%)
Accumulated EUD was the only dosimetric parameter predictive of G2 bowel bother, with
AUC = 0.615 [95% CI 0.503, 0.728]. However, the difference in accumulated EUD between
patients with and without G2 bowel bother were not significant (p = 0.069). Planned dose-
widths at 40 and 45 Gy, and accumulated dose-widths at 40 and 60 Gy produced AUCs
greater than 0.6, but the lower bound of the 95%CI dropped below 0.5 so these could not
be considered predictive of G2 bowel bother. The same result was found from 2D-DSM
analysis, where accumulated EUD produced AUC = 0.648 [95% CI 0.536, 0.757].
Bowel bother ≥ G3 (n = 13, 9.4%)
Both planned and accumulated EUD, and the planned 45 Gy dose-width, produced AUCs
greater than 0.6 for G3 bowel bother. The lower extent of the 95%CI fell below 0.5 so could
not be considered significant. Despite not producing a significant result, the highest AUC
was from the accumulated EUD (AUC = 0.650 [95% CI 0.496, 0.804]), which agreed with
the 2D-DSM results.
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6.2.3 Discussion
Dosimetric parameters extracted from both planned and accumulated FE-DSMs of the rectal
wall were found to be associated with 9 of the 12 toxicity endpoints evaluated: diarrhoea,
G1 and G2 proctitis, G1 and G2 rectal bleeding, RTOG G2 toxicity, frequency, G1 and G2
bowel bother. No significant associations were determined for faecal incontinence, RTOG
G1 toxicity, or G3 bowel bother.
When comparing results between FE-DSM analysis and the 2D-DSM analysis conducted
in Chapter 4, there is a combination of both complementary and conflicting data for the
same patient datasets. Dosimetric parameters from FE-DSM were more predictive than those
from 2D-DSM analysis for 6 of the 9 endpoints demonstrating dose-toxicity associations; G1
and G2 proctitis, G1 and G2 rectal bleeding, G2 RTOG toxicity, and frequency. 2D-DSM
analysis produced greater AUCs for diarrhoea and G1 and G2 bowel bother, and also found
associations between accumulated EUD and G1 RTOG toxicity and G3 bowel bother, which
were not evident from FE-DSM analysis. Neither 2D-DSM nor FE-DSM analysis found any
dosimetric parameter investigated to be significantly associated with faecal incontinence. An
improvement in toxicity prediction was expected using the FE-DSM method due to the more
robust approach to anatomical modelling. However, differences were relatively small, with
an average improvement in AUC of 0.022 (range 0.4 - 3.9). In general, the results suggest a
benefit to using FE-DSMs to represent dose to the rectal wall when evaluating dose-toxicity
predictions using dose-widths and EUD.
Dosimetric parameters from accumulated dose was more discriminative of toxicity than
planned dose for 5 of 9 endpoints demonstrating dose-toxicity associations; G1 and G2
rectal bleeding, RTOG G2 toxicity, G2 bowel bother, and frequency. Generally, dose-widths
from 50-60 Gy produced the highest AUCs, ranging from 0.652 for G1 rectal bleeding to
0.805 for G2 rectal bleeding. Dosimetric parameters from planned dose produced stronger
associations than accumulated delivered dose for diarrhoea, G1 and G2 proctitis, and G1
bowel bother. Across these four endpoints, dose-widths between 35-45 Gy consistently
produced the highest AUCs, ranging from 0.615 for incontinence to 0.688 for G1 proctitis.
Stronger associations were observed for dose-widths than EUD across 8 out of 9 endpoints
with significant outcomes, suggesting that spatial dose features are more strongly associated
with toxicity outcomes than a one-dimension dose descriptor, when evaluating both planned
and delivered dose using FE-DSMs.
For diarrhoea, the planned 35 Gy dose-width was the strongest predictor, common to both
2D-DSM and FE-DSM analysis. For proctitis, FE-DSM analysis shows the planned 45 Gy
dose-width to be associated with both G1 and G2 proctitis (equally predictive as the 40 Gy
dose-width for the latter). For G2 proctitis, the strongest 2D-DSM correlation was observed
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for the accumulated 60 Gy dose-width, and the planned 40 and 45 Gy dose-widths were not
found to be significant. In the 2D-DSM analysis, although the planned 45 Gy dose-width
was found to be associated with G1 proctitis, the planned 65 Gy dose-width produced the
greatest AUC.
The 2D-DSM analysis found accumulated EUD to be most strongly associated with G1
rectal bleeding, whereas FE-DSM analysis found accumulated 55 Gy dose-width to be more
predictive than accumulated EUD. However, results were quite similar and differences could
not be considered statistically significant. For G2 rectal bleeding, 2D-DSM analysis found the
planned 65 Gy dose-width to be most predictive, whereas the strongest AUC from FE-DSM
was the accumulated 60 Gy dose-width. From FE-DSM analysis, the accumulated 60 Gy
dose-width produced an AUC of over 0.8 which is considered highly significant, but was not
a significant improvement from the AUC from the equivalent planned dose parameter.
Results from 2D-DSM and FE-DSM analysis were in agreement for G2 RTOG toxicity,
both showing accumulated 50 Gy dose-width as the strongest predictor. Close agreement
was observed for increased stool frequency, where the strongest predictors from 2D-DSM
and FE-DSM analysis were accumulated 45 and 50 Gy dose-widths, respectively.
For bowel bother, 2D-DSM analysis found the accumulated 60 Gy dose-width to be most
strongly associated with G1 symptoms. This was also a significant predictor in FE-DSM
analysis, but the planned 45 Gy dose-width produced a higher AUC. For G2 bowel bother,
accumulated EUD was found to be most discriminative from both 2D-DSMs and FE-DSMs.
Delivered accumulated dose to the rectal wall was different from planned dose for all
patients. In general, accumulated dose was lower than planned dose when comparing using
EUD. Significant predictors were found for 9 of 12 clinical endpoints examined. For 6 of
these 9 endpoints, using FE-DSMs improved the strength of the dose-toxicity association.
Of these, accumulated dose provided a stronger predictor toxicity than planned dose for 4
endpoints, although some differences were not significant. Comparing AUCs with previous
2D-DSM results (Chapter 4), FE-DSM findings supported some conclusions and conflicted
with others. This may be because the difference in measured dose-width between 2D-
DSM and FE-DSM increases with increasing dose level. FE-DSM revealed spatial dose
parameters to be stronger predictors of toxicity than EUD for 8 out of 9 significant dose-
toxicity associations. Improved correlations between spatial dose features and toxicity may
be an indicator that using FE biomechanical modelling is a more accurate method for dose
accumulation than the 2D expansion method described in Chapter 4.
However, the advantage of accumulated dose in discriminating between toxicity outcomes
over planned dose was small. The magnitude of the differences, and widths of the 95% CIs
were not significantly different at the highest AUCs. The dose parameters investigated here
6.3 Voxel-based geometric subregion analysis 113
were based on previous methods described in the literature [27], and may not be optimised for
analysing delivered dose accumulated using FE modelling. Further methods for quantifying
accumulated dose will be explored in the following section.
6.3 Voxel-based geometric subregion analysis
6.3.1 Materials and methods
The investigation in Section 6.2, compares the FE-DSM approach with the 2D-DSM approach
and analyses spatial dose metrics (dose-widths) with a single metric describing a weighted
mean dose across the entire rectal wall (EUD). Figure 6.4 shows the difference in FE-DSM
between patients with and without rectal bleeding. The difference map shows a complex
inhomogeneous dose distribution, where the regions showing the largest differences are
located away from the central region where dose-widths were measured. For this reason, we
explore spatial features of FE-DSMs beyond dose-widths.
Fig. 6.4 Mean difference in accumulated delivered FE-DSM between patients with and without grade 2 rectal
bleeding. S = superior, I = inferior, P = posterior, A = anterior, R = right, L = left.
From the VoxTox consolidation cohort, 139 prostate cancer patients were included in the
analysis. Patient characteristics and toxicity endpoints included were presented previously in
Section 6.2.1. Figure 6.5 shows how the different geometric subregions were defined on the
FE-DSM, divided (a) longitudinally into anterior (ant) and posterior (post) hemispheres, (b)
laterally into superior (sup), middle (mid), and inferior (inf) thirds, as well as (c) longitudinal
quarters, anterior, posterior, right, and left.
Each patient’s planned and accumulated FE-DSMs were divided into a total of 12
subregions. The EUD of each subregion was calculated and used as the input for receiver
operator characteristic (ROC) curve analysis. The area under the ROC curve (AUC) of each
subregion’s EUD was compared with the EUD of the full rectal wall.
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Fig. 6.5 Division of rectal DSMs into geometric subregions, SRRgeom. (a) Longitudinal hemi-rectum (anterior,
ant, and posterior, post), (b) Longitudinal quarter-rectum (ant, post, left, right), (c) Ant and post hemi-rectum
further split into lateral thirds (superior, sup; middle, mid; and inferior, inf).
6.3.2 Results
The strongest dose-toxicity association from a geometric subregion, from planned and
accumulated FE-DSMs, are shown for all endpoints in Figure 6.6 and Table 6.3. Details of
subregions found to be discriminative of toxicity are discussed per endpoint below.
Diarrhoea (n = 36, 25.9%)
The AUC of the accumulated EUD for the full FE-DSM of the rectal wall was 0.617 [95% CI
0.504, 0.731]. Planned EUD was not found to be significant. From the geometric subregions,
the regions producing AUCs greater than 0.617 were: accumulated posterior hemi-rectum
(AUC = 0.620 [95% CI 0.509, 0.731]), accumulated mid-third posterior hemi-rectum (AUC
0.623 [95% CI 0.512, 0.733]), accumulated and planned longitudinal post quarter (AUC
0.622 [0.513, 0.731], 0.645 [0.540, 0.750], respectively). The strongest predictor was found
to be the accumulated longitudinal right quarter (AUC 0.647 [95% CI 0.535, 0.759]).
Faecal incontinence (n = 24, 17.3%)
No significant associations were observed for planned or accumulated EUDs of the full rectal
wall, or from any geometric subregion.
Proctitis ≥ G1 (n = 26, 18.7%)
The AUC of the full rectal wall from the planned FE-DSM was 0.641 [95% CI 0.532, 0.751].
Accumulated EUD was not found to be predictive of G1 proctitis. The subregion with the
greatest AUC was the planned posterior-hemi rectum (AUC 0.682 [95% CI 0.571, 0.794]).
Other subregions with AUC greater than 0.641 were: planned longitudinal right and posterior
quarters (AUC 0.678 [95% CI 0.575, 0.782], 0.660 [95% CI 0.535, 0.785], respectively),
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accumulated longitudinal right quarter (AUC 0.646 [95% CI 0.528, 0.764]), and planned mid
posterior hemi rectum (AUC 0.656 [95% CI 0.537, 0.774]).
Proctitis ≥ G2 (n = 20, 14.4%)
Planned and accumulated EUDs of the full rectal wall did not produce AUC discriminative of
G2 proctitis. By splitting the FE-DSMs into subregions, significant associations were found
for both planned and accumulated posterior hemi-rectum (AUC 0.647 [95% CI 0.525, 0.769],
0.640 [95% CI 0.508, 0.772], respectively), and both planned and accumulated longitudinal
right quarters (AUC 0.648 [95% CI 0.533, 0.763], 0.662 [95% CI 0.535, 0.790], respectively).
Rectal bleeding ≥ G1 (n = 46, 33.1%)
For the full rectal wall FE-DSM, the accumulated EUD was 0.641 [95% CI 0.545, 0.737]
and planned EUD was 0.615 [95% CI 0.520, 0.711]. The rectal subregions greater than
or equal to 0.641 were: accumulated anterior and posterior hemis (AUC 0.641 [95% CI
0.545, 0.737], 0.642 [95% CI 0.545, 0.739], respectively), and planned and accumulated
inferior-third posterior hemi-rectum (AUC 0.645 [95% CI0.544, 0.747], 0.654 [95% CI0.553,
0.755], respectively).
Rectal bleeding ≥ G2 (n = 16, 11.5%)
Accumulated EUD of the full rectal wall produced an AUC of 0.690 [95% CI 0.568, 0.812],
and the AUC for planned EUD was 0.629 [95% CI 0.515, 0.742]. The greatest AUCs from
subregions were for accumulated and planned posterior hemi-rectum (AUC 0.800 [95% CI
0.707, 0.894], 0.772 [95% CI 0.675, 0.869], respectively). Other subregions associated
with AUCs greater than 0.690 were: planned and accumulated longitudinal right quarters
(AUC 0.743 [95% CI 0.651, 0.836], 0.759 [95% CI 0.645, 0.872]), planned and accumulated
longitudinal posterior quarters (AUC 0.746 [95% CI 0.625, 0.868], 0.768 [95% CI 0.649,
0.886], respectively), and accumulated mid and inferior posterior hemi-rectum (AUC 0.697
[95% CI 0.563, 0.831], 0.693 [95% CI 0.543, 0.844], respectively).
RTOG GI toxicity ≥ G1 (n = 73, 52.5%)
EUDs of the full rectal FE-DSM were not predictive of G1 RTOG toxicity. Splitting the
rectal wall into geometric subregions revealed an association with accumulated longitudinal
right quarter (AUC 0.601 [95% CI 0.507, 0.695]), but no other planned or accumulated dose
metric was significant.
116 Biomechanical modelling for dose-toxicity prediction
Fig. 6.6 Area under the receiver operator characteristic curve (AUC) and 95% confidence intervals (CI) for
planned (plan) and accumulated (acc) equivalent uniform dose calculated from geometrically defined subregions
for 12 toxicity endpoints. For each endpoint, the subregion demonstrating the strongest association has been
plotted. Results were considered significant where mean AUC ≥ 0.6 and lower 95% CI ≥ 0.5.
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RTOG GI toxicity ≥ G2 (n = 22, 15.8%)
For G2 RTOG toxicity, planned and accumulated EUDs of the full rectal FE-DSMs were
not considered significant. When dividing into geometric SRRs, accumulated and planned
longitudinal posterior quarter were most strongly associated with G2 RTOG GI toxicity, with
AUCs of 0.738 [95% CI 0.609, 0.867], 0.697 [95% CI 0.568, 0.827], respectively. Significant
associations were also observed for accumulated and planned posterior hemi-rectum (AUC
0.731 [95% CI 0.601, 0.861], 0.689 [95% CI 0.566, 0.813], respectively), accumulated and
planned longitudinal right quarter (AUC 0.701 [95% CI 0.566, 0.836], 0.667 [95% CI 0.544,
0.791], respectively), and accumulated and planned mid posterior hemi-rectum (AUC 0.696
[0.562, 0.831], 0.639 [0.511, 0.768], respectively).
Stool frequency (n = 34, 24.5%)
The subregions found to be associated with increased stool frequency were: planned and
accumulated posterior quarter (AUC 0.651 [95% CI 0.544, 0.758], 0.632 [95% CI 0.520,
0.744], respectively), accumulated and planned posterior hemi-rectum (0.650 [95% CI 0.537,
0.762], 0.619 [95% CI 0.505, 0.733], respectively), accumulated longitudinal right quarter
(AUC 0.646 [95% CI 0.531, 0.760]), and accumulated mid posterior hemi-rectum (AUC
0.631 [95% CI 0.515, 0.747]). Neither planned nor accumulated EUD of the full rectal wall
were associated with stool frequency.
Bowel bother ≥ G1 (n = 55, 39.6%)
Accumulated EUD for the full rectal FE-DSM was predictive of G1 bowel bother, with AUC
0.614 [95% CI 0.517, 0.710]. This AUC was found to be matched by the accumulated EUD
of the longitudinal right quarter subregion (AUC 0.614 [95% CI 0.518, 0.711]). Planned
posterior quarter was also also associated with G1 bowel bother, with AUC of 0.609 [95% CI
0.509, 0.709].
Bowel bother ≥ G2 (n = 32, 23.0%)
The accumulated EUD of the full rectal wall was found to be associated with G2 bowel bother
(AUC 0.615 [95% CI 0.503, 0.728]). Accumulated anterior hemi-rectum and longitudinal
right quarter (AUC 0.615 [95% CI 0.501, 0.728], 0.615 [95% CI 0.502, 0.729], respectively)
were found to be equally predictive. No planned FE-DSM parameter was significantly
associated with G2 bowel bother.
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Bowel bother ≥ G3 (n = 13, 9.4%)
The only FE-DSM rectal subregion associated with G3 bowel bother was the planned
longitudinal right quarter, with AUC 0.657 [95% CI 0.504, 0.810]. No planned FE-DSM
parameter was significantly associated with G3 bowel bother.
Table 6.3 Geometric rectal subregions at risk (SRRgeom) most discriminative of toxicity from planned and
accumulated dose surface maps generated using finite element modelling. SRRgeom producing the greatest
area under the receiver operator characteristic curve (AUC) are listed. Endpoint entries were omitted where
no parameter from planned or accumulated dose produced an AUC with minimum 95% confidence interval
greater than 0.5, so was not considered significant. A dashed entry indicates that no significant parameter was
determined. Bold indicates greatest AUC between planned and accumulated results.
Planned dose Accumulated dose
Toxicity endpoint SRRgeom AUC SRRgeom AUC
Diarrhoea post-quarter 0.645 right-quarter 0.647
Proctitis ≥ G1 post-hemi 0.682 right-quarter 0.646
Proctitis ≥ G2 right-quarter 0.648 right-quarter 0.662
Rectal bleeding ≥ G1 inf-post-hemi 0.645 inf-post-hemi 0.654
Rectal bleeding ≥ G2 post-hemi 0.772 post-hemi 0.800
GI toxicity ≥ G1 - - right-quarter 0.601
GI toxicity ≥ G2 post-quarter 0.697 post-quarter 0.738
Stool frequency post-quarter 0.651 post-hemi 0.650
Bowel bother ≥ G1 post-quarter 0.609 EUD/right-quarter 0.614
Bowel bother ≥ G2 - - EUD/ant-hemi/right-quarter 0.615
Bowel bother ≥ G3 - - right-quarter 0.657
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6.3.3 Discussion
For all endpoints where significant dose-toxicity associations were determined, the AUCs
from geometric subregions were greater than those for the full rectal wall - with the exception
of bowel bother greater than grade 1 and grade 2 where the effects were equal. No association
was detected for faecal incontinence. For all other endpoints, the strongest AUCs were found
from a range of different geometric subregions. There were 5 cases for accumulated dose,
and 4 from planned dose, where the EUD of the full rectal wall was not found to be associated
with the toxicity endpoint, but upon further division into geometrical subregions, significant
associations were uncovered.
For 11 of 12 toxicity endpoints with significant dose-toxicity associations, the strongest
association was found from accumulated dose. Subregions located posteriorly (n=6) and to
the patient’s right (n=4) revealed the strongest associations, with the exception of G2 bowel
bother which found the longitudinal right-quarter and anterior-hemi to be equally predictive.
For 9 of the 11 toxicity endpoints with significant dose-toxicity associations, significant
AUCs were found for a geometric subregion on the right side of the rectal wall. It is expected
that dose to the right and left sides of the rectum should be approximately equal, so this effect
may be due to an unknown clinical or anatomical phenomenon. This result may suggest that
the rectum is able to expand more to the right, where differences were observed between
planned and accumulated dose, which may be due to the continuation at the rectosigmoid
junction where the rectum moves anteriorly and to the left.
EUD calculated to geometric subregions of the rectal wall demonstrated stronger asso-
ciations with toxicity than EUD calculated to the full rectal FE-DSM. This result supports
the hypothesis that the rectum has non-homogeneous radio sensitivity. Dose to the posterior
and right side of the rectal wall were most discriminative of toxicity, suggesting that low
and intermediate doses are more associated with toxicity than the high dose region. This
effect has previously been reported by other groups using planned dose data [76, 87, 97, 115].
Furthermore, results indicate that different regions of the rectal wall may be associated with
different toxicity endpoints, suggesting that the pathophysiology of toxicity side-effects
differs per endpoint [70].
Overall, accumulated dose was more predictive of toxicity than planned dose, and dose
to geometric subregions revealed stronger associations than dose to the full rectal wall.
Knowledge of specific subregions associated with toxicity could be considered as regions
to avoid during the treatment planning process, and as areas to monitor when concerns
arise with regards to adaptive radiotherapy, to prospectively minimise the risk of developing
toxicity.
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6.4 Voxel-based statistical subregion analysis
6.4.1 Materials and methods
For each of the 12 toxicity endpoints considered (Table 6.1), patients in the training set
were split according to those with toxicity, and those without. The FE-DSMs of prostate
radiotherapy patients prescribed 60 Gy in 20 fractions were radiobiologically converted to
the equivalent dose in 37 fractions using an α/β ratio of 2.149 (as described in Section 3.3).
Planned and accumulated FE-DSMs were compared. It was postulated that specific regions
of the rectal wall were more radiosensitive and hence more strongly associated with toxicity.
The purpose of this investigation was to determine the areas of increased radiosensitivity
associated with different toxicity endpoints to interrogate the dose differences specific to
these regions.
For each voxel of the 30×80 FE-DSM, a two-sample t-test for equality of means was
performed in MATLAB® (Mathworks®, Natick, MA). The two groups were defined by
patients with and without toxicity and the null hypothesis assumed no difference in voxel
dose between groups. Voxels were identified in areas where the dose was significantly higher
for patients with toxicity than those without. Test were set to reject the null hypothesis at the
5 % significance level (p < 0.05).
Where the p-value at each voxel was less than the significance level, the dose difference
between patients with and without toxicity was considered significant, and the null hypothesis
was rejected. From the map of voxel-wise p-values (example shown for grade 2 rectal
bleeding in Figure 6.7), a binary mask was generated where a value of 1 was assigned
when the null hypothesis was rejected, and a value of 0 was assigned otherwise (Figure 6.8).
Post-processing performed on the resulting binary masks included removing clusters of fewer
than 10 pixels (unless the cluster would have been connected to a larger cluster had it not been
for the posterior splitting of the FE-DSM for visualisation in 2D), applying a least-squares
smoothing filter (Savitzky-Golay filter in the MATLAB image processing toolbox), and
filling in any remaining holes. The function of the post-processing stage was to smooth
sharp edges and remove noise. This identified the rectal subregion at risk corresponding to a
p-value < 0.05, SRRpmap.
The issue of correcting for multiple comparison testing in voxelwise dose-toxicity studies
has been debated in the scientific literature. Here, the parameter of interest for differentiating
between patients with and without toxicity is the spatial pattern of the resulting distribution,
rather than the significance level of individual pixels, so conventional approaches to multiple
testing may be unnecessarily restrictive and overly conservative. In their analysis of bladder
dose-surface maps, Palorini et al. [121] discussed the issue at depth, and argued against
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adjusting p-values in this context, emphasising that their main goal was ‘to identify the
shape of dose regions that show the highest discrimination between the two groups of
patients (toxicity versus no toxicity) without looking at significance at the single-pixel
level’. They applied a similar post-processing smoothing approach and removed small
regions with p < 0.05. Based on these recommendations, Onjukka et al.[115] reported results
for unadjusted p-values in a recent pattern analysis of rectal dose surface maps. Data for
adjusted p-values were also included for completeness. Their results support the concept
that adjusting the p-values has the effect of being increasing sensitivity to the point of over-
fitting to the data when applied to voxel-level DSM analysis. Because of this paradigm
shift towards using unadjusted p-values for evaluating the spatial patterns of DSMs between
patients with and without toxicity, the unadjusted p-values have been applied in this analysis.
However, to complement the methodology applied by Dréan et al. [61] in their work on
subregion analysis, their selected approach to multiple testing using the Benjamini-Hochberg
procedure [17, 69, 146] was also investigated.
The Benjamini-Hochberg procedure involves determining a p-value threshold by ordering
and ranking voxels based on their p-value test statistic. The Benjamini-Hochberg critical
value was calculated using the formula ( j/m)q∗, where j is the rank number assigned to
the voxel’s p-value, m is the total number of tests (= 2400), and q∗ is the false discovery
rate (taken to be 0.2 [121]). The test with the highest rank, for which the p-value is less
than the Benjamini-Hochberg critical value, determines the final modified p-value threshold
(replacing the previous 0.05 value).
Voxel-level analysis was used to determine larger spatial patterns of interest. The final
processed binary masks derived using unadjusted and adjusted p-values represent the proba-
bilistic rectal subregions at risk. The binary masks shown in Figures 6.8 and 6.9 were applied
Fig. 6.7 Voxel-wise probability map for 139 patients with (n = 16) and without (n = 123) grade 2 rectal bleeding,
for planned and accumulated dose. Test statistics with p < 0.05 are displayed.
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to each patient’s planned and accumulated FE-DSMs such that only the dose to voxels from
the non-zero (white) regions were considered. The EUD was then calculated based on the
voxel dose within these subregions. ROC analysis was performed for the endpoints that
produced a binary mask, and AUCs were reported if greater than 0.6 with a minimum 95%CI
greater than 0.5 [71].
6.4.2 Results
The binary masks generated using the unadjusted p-value of 0.05 are shown in Figure 6.8 for
8 toxicity endpoints where areas of significant dose patterns were identified between patients
with and without toxicity. These correspond to the SRRpmap that resulted in significant
associations with the toxicity endpoint of interest, and are discussed below. The only endpoint
not to produce a binary mask indicating spatial regions of significant dose difference was the
planned FE-DSM for RTOG G2 GI toxicity. Binary masks using the Benjamini-Hochberg
adjusted p-value were generated for 6 endpoints and have been included for comparison in
Figure 6.9. Where binary masks could not be generated indicates that no areas of significant
dose difference could be identified. For the endpoints where probabilistic subregions were
identified, the binary mask was applied to each patient’s FE-DSM individually. The EUD
was calculated based on the voxels in the probabilistic subregion, and ROC analysis was
performed. Results for unadjusted p-value binary masks are presented in Table 6.4 discussed
below where SRRpmap revealed an association with toxicity, with AUC ≥ 0.6 and lower 95%
CI ≥ 0.5.
Diarrhoea (n = 36, 25.7%)
The binary mask for p < 0.05 showed significant differences for patients with and without
diarrhoea in a band across the inferior quarter, with a mid-posterior cluster for both planned
and accumulated FE-DSMs. The mid-posterior cluster appeared more prominently towards
the right for accumulated dose. Accumulated SRRpmap, AUC 0.665 [95% CI 0.560, 0.770],
was more strongly associated with diarrhoea than planned SRRpmap, AUC 0.656 [95% CI
0.0.555, 0.757].
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(a) Binary masks showing probabilistic subregions of FE-DSMs where voxel dose difference were significant
(p<0.05) between patients with and without toxicity for Diarrhoea, faecal incontinence, proctitis ≥ G1,
proctitis ≥ G2 (top to bottom).
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(b) Binary masks showing probabilistic subregions of FE-DSMs where voxel dose difference were significant
(p<0.05), as indicated in white, between patients with and without toxicity for rectal bleeding ≥ G1 and ≥ G2,
RTOG gastrointestinal (GI) toxicity ≥ G2, and bowel bother ≥ G1 (top to bottom). Grey indicates no
significant regions were identified.
Fig. 6.8
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Fig. 6.9 Binary masks showing probabilistic subregions of FE-DSMs where voxel dose difference were
significant between patients with and without toxicity, generated using Benjamini-Hochberg adjusted p-values.
Binary masks were determined for 6 of 12 toxicity endpoints investigated: grade 1 diarrhoea (diar. G1), grade
2 proctitis (proc. G2), G1 & G2 rectal bleeding (RB), G1 gastrointestinal toxicity (GI tox), grade 1 bowel
bother (BB G1).
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Faecal incontinence (n = 24, 17.3%)
A cluster at the inferior right-lateral was common to both planned and accumulated FE-DSMs.
A mid-posterior to mid-right cluster was also apparent on the accumulated p < 0.05 binary
mask. Accumulated dose to SRRpmap, AUC 0.633 [95% CI 0.506, 0.760] was associated
with faecal incontinence, and planned dose was not considered significant.
Proctitis ≥ G1 (n = 26, 18.7%)
Significant clusters were observed at the 5 % significance level extending from the mid to
inferior post-hemi rectal wall, common to planned and accumulated FE-DSMs. Planned
dose to SRRpmap produced the strongest association, with AUC 0.677 [95% CI 0.557, 0.797],
compared to accumulated SRRpmap, AUC 0.647 [95% CI 0.525, 0.770].
Proctitis ≥ G2 (n = 20, 14.4%)
Similar p < 0.05 cluster patterns were observed for G2 proctitis as described for G1 proctitis,
although compared to the previous cluster pattern, clusters were connected by a band at the
inferior end of the rectal wall, spanning the full circumference. The accumulated SRRpmap
was associated with G2 proctitis, with AUC 0.647 [95% CI 0.505, 0.788], and no significant
association was found for planned SRRpmap.
Rectal bleeding ≥ G1 (n = 46, 33.1%)
A wide band spanning right to left posteriorly at the inferior third of the rectal wall was
common to both planned and accumulated SRRpmap for G1 rectal bleeding, as was a smaller
cluster in the mid-right lateral region which was larger for accumulated dose than planned
dose. Accumulated dose (AUC 0.691 [95% CI 0.598, 0.785]) was more strongly associated
with G1 rectal bleeding than planned dose (AUC 0.684 [95% CI 0.592, 0.776]).
Rectal bleeding ≥ G2 (n = 16, 11.5%)
Larger regions of significant dose differences were observed for G2 rectal bleeding than
for G1. Clusters spanned the circumference of the inferior third, and most of the superior
third circumference for planned and accumulated dose, with additional expansion into the
mid-posterior-right lateral region on the accumulated binary mask. Accumulated dose to
SRRpmap was most strongly discriminative of G2 rectal bleeding, AUC 0.756 [95% CI 0.641,
0.870], than planned SRRpmap, which was not considered significant due to the relatively
large width of the 95% CI.
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(a) FE-DSM SRRpmap AUCs from unadjusted p-values (p ≤ 0.05)
(b) FE-DSM SRRpmap AUCs from adjusted p-values
Fig. 6.10 Area under the receiver operator characteristic curve (AUC) and 95% confidence intervals (CI) for
planned (plan) and accumulated (acc) equivalent uniform dose (EUD) calculated from rectal subregions at risk
(SRR) defined on FE-DSMs using unadjusted and adjusted p-values. Twelve toxicity endpoints were analysed;
results are shown only where a binary mask of regions of significant dose difference between patients with and
without toxicity could be generated.
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Table 6.4 Area under the receiver operator characteristic curve (AUC) indicating discriminative ability of
probabilistic rectal subregions at risk EUD, for different toxicity endpoints, calculated using both planned and
accumulated finite element generated dose surface maps. Dash entries indicate no binary mask was generated,
or result was not significant.
Toxicity endpoint AUC - Planned dose AUC - Accumulated dose
Diarrhoea 0.656 0.665
Incontinence - 0.633
Proctitis ≥ G1 0.677 0.647
Proctitis ≥ G2 0.600 0.647
Rectal bleeding ≥ G1 0.684 0.691
Rectal bleeding ≥ G2 0.607 0.756
GI toxicity ≥ G2 - 0.713
Bowel bother ≥ G1 0.601 -
RTOG GI toxicity ≥ G2 (n = 22, 15.8%)
Accumulated SRRpmap revealed a single cluster at the mid-right-posterior area of the rectal
wall. No binary mask could be generated using planned FE-DSMs. Accumulated SRRpmap
resulted in an AUC of 0.713 [95% CI 0.591, 0.836].
Bowel bother ≥ G1 (n = 54, 38.8%)
For both planned and accumulated binary masks, clusters spanned the circumference of the
inferior rectal wall, dipping inferiorly at the most anterior point. Planned SRRpmap was
associated with G1 bowel bother, with AUC = 0.601 [95% CI 0.504, 0.699], and accumulated
SRRpmap was not found to be significant.
6.4.3 Discussion
Subregions of the rectal wall were statistically identified by interrogating dose differences
at the voxel level, comparing FE-DSMs of patients with and without toxicity. Several
binary masks found clusters in the inferior part of the rectum to be significant for different
toxicities, and a few indicated regions of significant dose difference on the right side of the
rectal wall. This depth of voxel-based toxicity analysis has not previously been reported for
accumulated dose to the rectum. Clusters of pixels were identified that facilitated higher
resolution interrogation of associations between rectal subregions and toxicity, beyond
the previous geometric-based approach described in Section 6.3. Results complement the
results of the geometric subregion analysis by supporting the hypothesis that the rectum has
non-homogeneous radiosensitivity [3, 87, 141], and that particular areas are more strongly
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associated with different toxicity endpoints. This effect has also been reported in the literature
for planned dose to the rectal wall [34, 115].
EUD of SRRpmap revealed significant dose-toxicity correlations for 8 of 12 endpoints.
Accumulated dose produced stronger associations than planned dose for 6 of the 8 toxicity
endpoints; diarrhoea, faecal incontinence, G2 proctitis, G1 rectal bleeding, and RTOG G2 GI
toxicity. However, for endpoints other than G2 rectal bleeding and RTOG G2 GI toxicity,
differences between accumulated dose and planned dose were small. Planned dose difference
was found not to be significant at p < 0.05 between patients with and without RTOG G2 GI
toxicity so no binary mask could be created.
Results were calculated using an unadjusted p-value of 0.05. To address the issue of
multiple comparisons, results were also calculated based on adjusted p-values, as shown
in Figure 6.10b. Binary masks could only be generated for 6 toxicity endpoints based on
adjusted p-values (shown in Figure 6.9). Where comparative measurements were available,
similar trends were observed between adjusted and unadjusted results, and notably the
accumulated AUC became significantly greater than planned AUC for G2 rectal bleeding
when using the adjusted p-value. However, this study focused on the use of the unadjusted p-
value because, as argued by Palorini et al. [121], it is the shape of the identified subregion that
is of interest, not the test statistic of each individual pixel. This way, maximum information is
being extracted in order to identify regions of the rectum most associated with rectal toxicity.
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6.5 Concluding discussion
6.5.1 Comparing analysis and parameterisation approaches
In this chapter, FE-DSM analysis is compared with 2D-DSM analysis using the same dose
parameterisation approach (dose-widths and EUD). Increasingly complex methods of dose
parameterisation were then investigated, from spatially determined geometric subregions
(SRRgeom), to subregions identified using statistically derived probability maps (SRRpmap)
based on unadjusted and adjusted p-values. Here, we compare the results presented for each
analysis and parameterisation approach presented.
For planned and accumulated dose, the average AUC of the parameter found to be
most discriminative of each toxicity endpoint, per analysis/parameterisation approach: 2D-
DSM dose-width/EUD, FE-DSM dose-width/EUD, FE-DSM SRRgeom region, and FE-DSM
SRRpmap (unadjusted), are presented in Figures 6.11 and 6.12.
For planned dose, 9 of 12 endpoints resulted in significant associations between dose and
toxicity. Of these, FE-DSM analysis (dose-width/EUD, SRRgeom, or SRRpmap) produced
greater AUCs than 2D-DSM analysis for 8 of 9 endpoints. Parameterising FE-DSMs using
dose-widths resulted in larger AUCs than EUD for 5 of these 8 endpoints. SRRgeom produced
the greatest AUCs for 2 endpoints, and SRRpmap for 1 endpoint.
For accumulated dose, all 12 endpoints resulted in significant associations between dose
and toxicity. Of these, the largest AUC was found using FE-DSM analysis (dose-width/EUD,
SRRgeom, or SRRpmap) for 8 endpoints. The 4 endpoints where 2D-DSM analysis resulted in
the largest AUC were for the 3 different grades of bowel bother and G1 RTOG GI toxicity.
For FE-DSM analysis, SRRpmap resulted in the greatest AUC for 4 endpoints, SRRgeom
for 1, and dose-widths for 2 endpoints. The general trend across individual endpoints with
significant dose-toxicity associations was that AUC improved with increasing complexity of
parameterisation technique.
Overall, results support the hypothesis that using FE-DSMs to analyse dose to the rectal
wall improves the discriminative power of dose-toxicity predictions when compared to the
2D-DSM approach. However, this was not consistent across all endpoints examined, and
the differences were generally not statistically significant. A direct comparison between
2D-DSM and FE-DSM using dose-widths and EUD found results to be significantly different.
Where stronger dose-toxicity associations were observed with increasing complexity of
dose parameterisation, this was generally more pronounced for accumulated dose than
planned dose. Results are encouraging and further research into advanced parameterisation
approaches tailored to FE-DSMs is recommended.
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Fig. 6.11 Area under the receiver operator characteristic curve (AUC) for the highest performing dose metric
from planned 2D-DSM, FE-DSM, geometric subregion (SRRgeom), and probabilistic subregion (SRRpmap)
for 12 toxicity endpoints. Errors have been discussed in corresponding sections.
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Fig. 6.12 Area under the receiver operator characteristic curve (AUC) for the highest performing dose met-
ric from accumulated 2D-DSM, FE-DSM, geometric subregion (SRRgeom), and probabilistic subregion
(SRRpmap) for 12 toxicity endpoints. Errors have been discussed in corresponding sections.
Chapter 7
Predictive models for rectal toxicity
Predictive models are used in radiotherapy to maximise tumour control probability (TCP)
and minimise normal tissue complication probability (NTCP). In this chapter, we develop
NTCP models specific to our data to address three questions:
1. Is accumulated dose a better predictor of toxicity than planned dose?
2. Does finite element dose accumulation improve the predictive power of NTCP?
3. Can finite element derived subregions improve toxicity prediction?
In previous chapters we explored different methods for parameterisation of planned and
delivered dose to the rectal wall in prostate radiotherapy. In Chapter 4, two dimensional
dose surface maps (2D-DSM) were generated by uniformly normalising the circumference
of the rectal wall, assuming in-plane expansion only. 2D-DSMs were parameterised using
equivalent uniform dose (EUD) and DSM dose-widths, the lateral extent of an ellipse fitted to
a given isodose level. Chapter 5 describes generating dose surface maps using finite element
analysis (FE-DSM), where voxels deform in 3D according to applied boundary conditions
and biomechanical properties. For comparative measurement with 2D-DSM results, FE-
DSMs were also parameterised using EUD and DSM dose-widths (Chapter 6). Spatial dose
information contained within FE-DSMs was further parameterised by identifying rectal
subregions at risk using geometric division (SRRgeom) and statistical mapping (SRRpmap).
Here, we combine dosimetric parameters from planned and delivered dose with pre-
treatment clinical factors to construct multivariate NTCP models for 12 toxicity endpoints.
Final model performance indicates whether delivered dose is a better predictor of toxicity
than planned dose, whether dosimetric information extracted from FE-DSMs improves model
performance with respect to features from 2D-DSMs, and whether subregions reveal areas of
heightened radiosensitivity.
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The knowledge base of the underpinning statistical methods for constructing NTCP mod-
els within this PhD was largely formed by attending the European Society for Radiotherapy &
Oncology (ESTRO) school ‘Quantitative Methods in Radiation Oncology: Models, Trials and
Clinical Outcomes’, as well as following approaches described in the literature. The format
adopted for documenting model development and validation follows the recommendations of
the Transparent Reporting of a multivariate prediction model for Individual Prognosis Or
Diagnosis (TRIPOD) Statement [45] where possible.
7.1 Introduction
The aim of radiotherapy treatment planning is to maximise radiation dose to the tumour
whilst minimising dose to nearby healthy organs. In prostate radiotherapy, the planning target
volume (PTV) is the prostate, and the organs at risk (OARs) include the rectum, bladder,
femoral heads. With advances in radiotherapy imaging and hardware, greater conformity and
targeting accuracy has enabled dose escalation to the PTV, which has led to improvements in
biochemical control of the tumour [84, 85, 130]. However, as a consequence, this can lead to
higher dose being received by the healthy OARs. During the iterative radiotherapy treatment
planning process, the plan is optimised such that the PTV receives the prescribed radiation
dose and the OARs do not exceed certain normal tissue dose thresholds, or constraints. These
OAR constraints are generally based on consensus guidelines (e.g. Quantitative Analyses
of Normal Tissue Effects in the Clinic, QUANTEC [94]), or the outcomes of randomised
clinical trials [10, 54, 148]. The overarching goal is to maximise tumour control probability
(TCP) and minimise normal tissue complication probability (NTCP).
NTCP is based on dose-response modelling. OARs generally receive non-homogeneous
doses, so the complex 3D dose distribution, often presented as a dose-volume histogram
(DVH,) is reduced to a simplified dose metric for NTCP modelling. For example, the
proportion of volume receiving a percentage of the prescribed dose or more, the mean dose,
and the equivalent uniform dose (EUD), are commonly used. A limitation of these metrics is
the loss of spatial dose information due to dimension reduction.
Many studies have investigated the relationship between dose and rectal toxicity using
NTCP models[87, 131]. Often, dose has been considered to the entire rectum, but more recent
studies have parameterised dose to specific regions of the rectum [34, 35, 61, 115]. This
allows potential inhomogeneous intra-organ radiosensitivities to be investigated. Furthermore,
various rectal toxicity endpoints have been reported in the literature, and the difference in
underlying pathophysiology [70, 126] may be associated with different dose levels. A study
by Schaake et al. [140] presented the first multivariate NTCP model considering dose to
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specified regions of the rectum, for different toxicity endpoints, as well as clinical prognostic
factors. They conclude that different rectal subregions and dose levels are associated with
different toxicity effects, which may be useful for plan optimisation to reduce side-effects in
future studies.
A common limitation of the published literature is that, to date, rectal NTCP models
have been based on planned dose data. This is calculated from the pre-treatment CT scan
that represents the anatomy at a static point in time. These data are readily available in
radiotherapy as they form the basis of each patient’s radiation treatment. However, planned
dose does not incorporate the effects of interfraction motion, which introduces deviations to
dose parameters [139, 142] and spatial dose patterns [34], and may be more pronounced in
hollow structures such as the rectum [140].
Here we present, for the first time, multivariate NTCP models developed for both planned
and motion-inclusive accumulated delivered dose to the rectum. The effect of incorporating
different spatial dose features of dose surface maps (DSMs) and patient prognostic vari-
ables, are investigated for 12 different toxicity endpoints. The approach follows published
methodologies [16, 140] for building robust NTCP models in order to demonstrate the merits
of different dose parameterisation approaches, and the differences between planned and
accumulated dose models.
The risk of toxicity approximately follows a sigmoidal curve when plotted against dose
due to radiation dose response relationships. This supports the use of logistic regression
to predict the probability of a binary outcome, or the proportion of patients with a given
toxicity endpoint. Schakke et al [140] developed multivariable model for rectal bleeding,
faecal incontinence and stool frequency based on planned dose volume histograms and found
different dose levels and patient characteristics to be associated with each of the discrete
endpoints. Following a similar approach, binary logistic regression was selected to develop
NTCP models based on VoxTox data. Patient baseline cofactors were included in model
development, as well as the spatial dose parameters derived throughout this thesis for planned
and accumulated dose.
.
7.2 Material and methods
7.2.1 Patient selection
One hundred and eighty-six prostate cancer patients treated with TomoTherapy between June
2013 and January 2018 were identified from the VoxTox consolidation cohort (as presented
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in Section 3.1) based on the availability of a minimum of two year follow-up data available
at timepoints 6, 12, and 24 months (± 2 months). Twelve toxicity endpoints were considered,
as detailed in Table 7.1.
Within each toxicity category, patients were stratified by radiation dose prescription, then
according to cumulative toxicity status at 2 years post-radiotherapy, and randomised. Patients
were split into training (75%, n = 139), and validation (25%, n = 47) sets such that the ratio of
toxicity incidence and prescription proportions were preserved as closely as possible. Using
non-random split-sample training and validation sets implies that the final model will be
more powerful than internal validation using resampling techniques only [45], and acts to
help avoid overfitting of data. External validation was not possible because, as far as we are
aware, this is the only dataset to exist with prospectively collected toxicity data, daily image
guidance with rectal contours, and daily dose calculation accounting for interfraction motion.
Table 7.1 Voxtox consolidation cohort toxicity incidence rates split into training and validation sets for each of
the 12 endpoints under investigation.
Consolidation





Toxicity endpoint n % n % n %
Diarrhoea ≥ G1 48 25.8 36 25.9 12 25.5
Faecal incontinence ≥ G1 32 17.2 24 17.3 8 17.0
Proctitis ≥ G1 35 18.8 26 18.7 9 19.1
Proctitis ≥ G2 27 14.5 20 14.4 7 14.9
Rectal bleeding ≥ G1 62 33.3 46 33.1 16 34.0
Rectal bleeding ≥ G2 21 11.3 16 11.5 5 10.6
GI toxicity ≥ G1 98 52.7 73 52.5 25 53.2
GI toxicity ≥ G2 30 16.1 22 15.8 8 17.0
Stool frequency ≥ G1 45 24.2 34 24.5 11 23.4
Bowel bother ≥ G1 73 39.2 55 39.6 18 38.3
Bowel bother ≥ G2 43 23.1 32 23.0 11 23.4
Bowel bother ≥ G3 17 9.1 13 9.4 4 8.5
Patients were prescribed either 74 Gy in 37 fractions (n = 110) or 60 Gy in 20 fractions
(n = 76). The decision to combine fractionation regimes was based on the findings of the
CHHiP trial [52] where the 74 and 60 Gy trial arms were found to be isoeffective, with
no significant difference in rectal toxicity rates. Our data were fit to the CHHiP protocol
dose constraints and, assuming equal biologically effective dose, we calculated an α/β
ratio of 2.149 for the rectum. Using this α/β , the individual voxels of DSMs for patients
prescribed 60 Gy in 20 fractions were corrected to the equivalent dose in 37 fractions (see
Section 3.3). By calculating the α /β ratio specific to our study, we can better account for the
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Table 7.2 Occurrence of predictor variables in the consolidation cohort, split into training and validation sets.
Patient characteristics and clinical history were quoted using the diarrhoea dataset as the representative sample.
Baseline incidence rates were quoted from the relevant endpoint where applicable.
Predictor variables Training (n=139) Validation (n=47)
Patient characteristics
Mean age (range), years 69 (51-84) 70 (51-82)
Mean Body Mass Index (range), kg/m2 29 (20-47) 29 (21-39)
Clinical history
Diabetes 22 (16%) 5 (11%)
Cardiovascular disease 32 (23%) 8 (17%)
Hypertension 65 (47%) 17 (36%)
Inflammatory bowel disease 2 (1%) 2 (4%)
Diverticular disease 15 (11%) 4 (9%)
Haemorrhoids 22 (16%) 6 (13%)
Previous abdominal or pelvic surgery 26 (19%) 13 (28%)
Smoking (range), eq. pack years 14 (0-104) 7 (0-52)
Alcohol (range), av. units/week 12 (0-80) 9 (0-52)
Baseline symptoms
Diarrhoea 10 (7%) 2 (4%)
Faecal incontinence 1 (1%) 0 (0%)
Proctitis 5 (4%) 1 (2%)
Rectal bleeding 7 (5%) 2 (5%)
GI toxicity 19 (14%) 4 (9%)
Stool frequency 8 (6%) 2 (5%)
inhomogeneous doses received by the rectum, where previous assumptions have been based
on a homogeneous dose distributions, as received by the prostate.
One patient’s FE model failed from the planning CT data. The reason for this was
excessive distortion of a material element, meaning that the deformation of the rectal contour
was outwith the capabilities of the model and no solution could be determined. As a
consequence, no baseline data would be available to compare planned and accumulated dose,
so this patient was removed prior to any analysis. Final numbers are shown in Table 7.2. Four
further patients had up to 3 daily FEMs that failed, but rather than excluding these patients,
the missing daily delivered dose was substituted with planned dose for the corresponding
number of fractions and used to calculate the accumulated delivered dose.
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7.2.2 Univariate analysis
7.2.2.1 Pre-treatment factors
Pre-selection of predictor variables was performed prior to developing the model for each
toxicity endpoint. Inclusion was based upon previous investigations of rectal toxicity in
the literature [87]. Univariate logistic regression analysis was used to test for a relationship
between the following patient characteristics and every toxicity endpoint: age, body mass in-
dex, alcohol intake (units/week), smoking history (equivalent pack years), and pre-treatment
status (1/0) of diabetes, cardiovascular disease, hypertension, inflammatory bowel disease,
diverticular disease, haemorrhoids, previous abdominal or pelvic surgery, and presence of
baseline toxicity for the endpoint of interest, as shown in Table 7.2. Odds ratios were calcu-
lated, and crudely observed effects with p ≤ 0.157 (Wald test) were selected for inclusion in
multivariate modelling [140].
7.2.2.2 Dosimetric parameterisation approaches
Previously in this thesis, planned and accumulated dose to the rectal wall have been parame-
terised using four discrete approaches:
1. 2D-DSM: EUD and dose-widths (Chapter 4)
2. FE-DSM: EUD and dose-widths (Chapter 6)
3. FE-DSM: EUD of geometrically defined subregions, SRRgeom (Chapter 6)
4. FE-DSM: EUD of statistically determined subregions, SRRpmap (Chapter 6)
The results of the receiver operator characteristic (ROC) analysis have been presented in the
relevant previous chapters. Dosimetric parameters that demonstrated significant association
with toxicity (area under the ROC curve (AUC) ≥ 0.6 and the lower 95% confidence interval
≥ 0.5) were selected for inclusion in multivariate modelling in this chapter. Dose parameters
were tested for collinearity using the Pearson coefficient of determination, r2 and tolerance
(tol = 1− r2), and removed if the variance inflation factor (V IF = 1/tol) was > 5, indicating
a high degree of collinearity [140]. This affected immediately adjacent dose levels for DSM
dose-width measurements. If in the final model, two collinear dose parameters were included
in the model, the lesser weighted parameter was removed from the model.
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7.2.3 Multivariate analysis
Multivariate logistic regression modelling was performed in SPSS®(IBM®23.0.0.2) for each
toxicity endpoint. Separate models were developed for each of the four methods of dose
parameterisation described above, for both planned and delivered dose. Covariates were
included in the model using stepwise forward variable selection. At each step, the most
significant predictor variable was added to the model, and the difference between the model
with and without the added predictor variable was assessed using a likelihood ratio test [16].
Covariates were included in the final model where the difference was statistically significant
(p ≤ 0.05). Any covariates resulting in a negative coefficient were retrospectively removed
from the analysis, and the model re-generated [140].
Each model was internally validated and corrected using 1000-sample bootstrapping. This
is a form of internal validation whereby the model simulation is iteratively run on a randomly
resampled proportion of the data. The performance is evaluated at each iteration, effectively
reducing the statistical uncertainty in the final model parameters. Model performance was
assessed using a Hosmer-Lemeshow test for goodness-of-fit (where a non-significant χ2
statistic indicates good agreement between expected and observed toxicity rates) and the
Nagelkerke R2 which approximates explained variance.
The output of the binary logistic regression model (Table 7.3) determined the coefficients





Receiver Operator Characteristic (ROC) analysis was performed to determine the discrimina-
tory ability of each NTCP model with the corresponding toxicity endpoint. The area under
the ROC curve (AUC) is equal to 1 for an ideal correlation, and is considered significant
when the AUC is ≥ 0.6 with a lower 95% confidence interval (CI) ≥ 0.5 [71].
7.2.4 Validation
The validation set approximately maintains the incidence rates of the different toxicity end-
points as well as the ratios of the different prescription groups of the training set (Table 7.1).
However, proportions may be less consistent for patient characteristics, clinical history, and
baseline symptoms (Table 7.2). NTCP was calculated for the validation set using the linear
regression coefficients obtained from the training set, for each relevant toxicity outcome.
Model performance was evaluated using AUCs.
140 Predictive models for rectal toxicity
Table 7.3 Output of the binary logistic regression analysis forming the equation for S used in the NTCP
equation 7.1. Entries for endpoints or method of dose parameterisation have been excluded where binary
logistic regression did not produce a model, or did not produce a model which included a dosimetric variable.
Abbreviations: Incont.: faecal incontinence, alc.: average weekly alcohol intake, BLtox: baseline status of tox,
dw: dose-width, post.: posterior, quart.: quarter, inf.: inferior, hemi.: hemisphere.
Toxicity Method Splanned Saccumulated
Diarrhoea
≥ G1
2D-DSM 0.030(alc.)+1.871(BLdiarr)+0.065(35 Gy dw)-7.285 0.031(alc.)+2.109(BLdiarr)+0.053(35 Gy dw)-6.250
FE-DSM 0.030(alc.)+1.992(BLdiarr)+0.063(35 Gy dw)-7.335 0.028(alc.)+2.128(BLdiarr)+0.068(50 Gy dw)-6.196
FE-SRRgeom 0.027(alc.)+2.068(BLdiarr)+0.106(post-quart)-5.403 0.028(alc.)+2.213(BLdiarr)+0.120(post-quart)-5.846
FE-SRRpmap 0.028(alc.)+1.849(BLdiarr)+0.051(SRRpmap)-4.048 0.028(alc.)+1.933(BLdiarr)+0.079(SRRpmap)-5.564











2D-DSM 0.141(60 Gy dw)-9.456 0.124(60 Gy dw)-8.079





2D-DSM 1.368(diab.)+0.113(60 Gy dw)-7.759 1.187(HTN)+0.108(45 Gy dw)-9.915






2D-DSM 2.460(BL f req)+0.050(50 Gy dw)-4.541 2.575(BL f req)+0.065(60 Gy dw)-4.436
FE-DSM 2.667(BL f req)+0.073(60 Gy dw)-5.291




2D-DSM 0.040(40 Gy dw)-3.577 0.069(60 Gy dw)-3.658
FE-DSM 0.045(40 Gy dw)-4.155 0.049(55 Gy dw)-3.428
FE-SRRgeom 0.119(right-quart)-7.229
7.3 Results
7.3.1 Logistic regression output
The output of the multivariate binary logistic regression modelling is presented in Table 7.3.
Models that did not produce an output based on the forward selection criteria were omitted, as
were models that did not include a significant dose metric contribution. This may occur when
patient characteristics or clinical cofactors were most strongly associated with the toxicity
outcome, and the addition of a dose contribution into the model was of no additional benefit.
In total, 7 toxicity endpoints resulted in statistically significant models, based on different
dose parameterisation approaches. Final models were internally validated using 1000-sample
bootstrapping. Performance indicators of models with the greatest discriminating ability for
planned and accumulated dose metrics are shown in Table 7.4. NTCPs were calculated using
Equation 7.1 by inserting patient data into equations for S. An example NTCP curve for
rectal bleeding is shown in Figure 7.1. AUCs were calculated for all models, and the top
performing models for each endpoint are shown in Figure 7.2a, tested on training set data,
and Figure 7.2b, tested on validation set data.
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Fig. 7.1 Example normal tissue complication probability (NTCP) model calculated for CTCAE rectal bleeding
≥ G2, based upon planned (green) and accumulated (blue) EUD of the probabilistic rectal subregions at risk
(SRR0.05) from the finite element based dose surface map (FE-DSM). The resulting NTCP curve is steeper
when using accumulated dose, meaning that a small change in dose has a greater effect on NTCP.
7.3.2 Planned versus accumulated dose
Binary logistic regression produced 23 models using accumulated dose data, compared to
18 from planned dose data, across 7 toxicity endpoints using up to four different methods
of dose parameterisation (Table 7.3). Of the 23 models developed using training set data,
the AUCs of NTCP models generated from accumulated dose metrics were greater than
those from planned dose metrics for 15/23 models (65 %). The dosimetric parameters
included in the planned dose model were generally the same as or close to those selected
for the equivalent accumulated dose model. Of particular note is the repeated occurrence
of subregions of the posterior rectal wall (lower dose regions) selected for models based
upon geometric subregions, across different endpoints. Testing the NTCP models using
the validation set produced greater AUCs when using accumulated dose metrics for 16/23
models (70 %). The model resulting in the greatest AUC for each endpoint is shown in
Table 7.4, alongside measures of performance of logistic regression output. Per endpoint,
the Nagelkerke R2 was greater by an average of 2.5% (range -1.4, 6.9) when comparing the
best performing accumulated dose based model with planned, indicating an overall increase
in explained variance when using accumulated dose models. The logistic regression results
for all endpoints shown in Table 7.4 found the Hosmer-Lemeshow test to be non-significant,
indicating good agreement between expected and observed toxicity rates for planned and
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Table 7.4 Performance of multivariate binary logistic regression models for 7 toxicity endpoints. Models
were internally validated using a 1000 sample bootstrapping procedure. Plan./acc. indicates whether model
was developed using planned or accumulated dose-surface maps (DSMs). Method and metric indicate DSM
calculation and parameterisation approach. Performance indicators Nagelkerke R2 and Hosmer-Lemeshow
(H-L) χ2 and p-value describe explained variance and goodness-of-fit, respectively, where a non-significant χ2
statistic indicates good agreement between expected and observed toxicity rates.
Toxicity endpoint plan./acc. Method Metric Nagelkerke R2 H-L χ2 H-L p-value
Diarrhoea plan. 2D-DSM 35 Gy dw 0.220 4.094 0.849
≥ G1 acc. 2D-DSM 35 Gy dw 0.206 7.261 0.509
Incont.≥ G1 acc. FE-SRRpmap EUD(SRR0.05) 0.130 11.576 0.171
Rectal bleeding plan. FE-SRRpmap EUD(SRR0.05) 0.172 9.496 0.302
≥ G1 acc. FE-SRRpmap EUD(SRR0.05) 0.190 5.054 0.752
Rectal bleeding plan. FE-DSM 60 Gy dw 0.258 1.765 0.987
≥ G2 acc. FE-SRRgeom EUD(post-hemi) 0.290 7.378 0.496
GI toxicity plan. FE-DSM 55 Gy dw 0.228 14.012 0.081
≥ G2 acc. FE-DSM 50 Gy dw 0.297 14.613 0.067
stool frequency plan. FE-SRRgeom EUD(post-quart) 0.159 6.157 0.63
≥ G1 acc. FE-DSM 60 Gy dw 0.172 5.242 0.731
Bowel bother plan. FE-DSM 40 Gy dw 0.054 10.117 0.257
≥ G1 acc. 2D-DSM 60 Gy dw 0.091 4.833 0.775
accumulated dose based models. A student t-test found differences in NTCP distributions to
be significant (p≤ 0.01) between patient groups with and without toxicity.
7.3.3 2D-DSM versus FE-DSM
When considering different methods of calculating dose to the rectal wall, NTCP models
based on FE-DSM dose metrics were found to have higher discriminative ability than those
based on 2D-DSM dose metrics for 5/7 toxicity endpoints (71 %) in the training set, and 6/7
NTCP models (86 %) in the validation set.
7.3.4 Dose metric comparison
Considering the 5/7 toxicity endpoints where FE-DSM-based NTCP models produced greater
AUCs than 2D-DSM-based NTCP models in the training set, of these, the greatest AUCs were
found for faecal incontinence ≥ G1 and rectal bleeding ≥ G1 using FE-SRRpmap (2/5), for
rectal bleeding ≥ G2 using FE-SRRgeom (1/5), and for GI toxicity ≥ G2 and stool frequency
≥ G1 using FE-DSM dose-widths (2/5). In the validation set, rectal bleeding ≥ G1 still
produced the greatest AUC using FE-SRRpmap (1/5), but all others produced the greatest
AUC from FE-DSM dose-widths (4/5).
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(a) Training set data (n = 139), used in model generation.
(b) Validation set data (n = 47), not used in generating models.
Fig. 7.2 Discriminative ability of NTCP model and respective toxicity outcome presented using area under
the receiver operator characteristic curve (AUC) and 95% confidence intervals (CI). Planned and accumulated
models plotted correspond to those with the highest discriminative ability per endpoint, as listed in Table 7.4,
and detailed in Table 7.3. Note no NTCP model was generated for incontinence from planned dose.
144 Predictive models for rectal toxicity
7.4 Discussion
For the first time, NTCP models have been developed for different rectal toxicity endpoints
based on pre-treatment variables and dosimetric parameters from accumulated delivered
dose. Robust methodologies have been followed to compare the predictive power of NTCP
models optimised for accumulated dose, with those optimised for planned dose. Overall,
results suggest that models based on accumulated dose have greater predictive power than
those based on planned dose metrics.
Different approaches to dose parameterisation have been investigated throughout this
thesis and compared using NTCP modelling in this chapter. Generally, accumulating dose
using FE-DSMs was found to be more predictive of toxicity. FE modelling allows dose
to be tracked per voxel according to biomechanical properties which is more anatomically
representative [21] than the more simple in-plane uniform normalisation approach used for
2D-DSMs. However, in terms of parameterising dose from the FE-DSMs, there was no
consensus agreement as to the best method selected by the logistic regression model across all
endpoints. This may be due to inherent differences in underlying toxicity pathophysiologies.
With increasing sophistication in identifying SRRs, there was no clear generalised gain in
terms of discriminative ability, but some benefit was observed on an endpoint-by-endpoint
basis. Further investigation into methods of extracting meaningful dose information from
FE-DSMs may be beneficial. However, this result supports the findings in the literature that
the underlying pathophysiology is endpoint-specific [12, 126], and as such, dose to specific
regions of the rectum may be more strongly associated with different toxicities, hence the
variations in dose parameters being found most significant in NTCP modelling.
Strong associations were observed for rectal bleeding ≥G2 with NTCP models developed
using both accumulated (AUC 0.826, 95% CI [0.735, 0.917]) and planned (AUC 0.819,
95% CI [0.727, 0.911]) dose metrics. The accumulated NTCP model found the dose to the
posterior-hemi subregion of the rectal wall to be most significant, which put more weighting
on lower doses (SRR EUD median 46 Gy, range 27-55 Gy, compared with EUD median
61 Gy, range 45-65 Gy, of entire rectal wall). The planned dose metric found to be the
most significant was the FE-DSM 60 Gy dose-width. Although there are no results in the
literature using FE-DSMs for planned dose data, findings based upon 2D-DSMs of planned
dose to the rectal wall have found dose-widths close to 60 Gy to be predictive of rectal
bleeding [27, 70, 142, 115, 34, 49]. This was supported by the outcome of the logistic
regression for the planned 2D-DSM (and accumulated 2D-DSM, but the final NTCP model
was found to be more discriminative of rectal bleeding when using FE-DSM 60 Gy dose-
width). Both planned and accumulated NTCP models were found to be highly associated
with rectal bleeding during model validation ≥ G2 (AUC 0.838 [95% CI: 0.708, 0.968]
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and AUC 0.810, [95% CI: 0.675, 0.944], respectively). Rectal bleeding is one of the more
commonly reported endpoints in the literature as symptoms are less subjective that other
endpoints. In particular, grade 2 rectal bleeding by definition requires medical intervention,
so this result could be useful in clinical decision making in radiotherapy treatment planning
as well as adaptive radiotherapy.
Rectal bleeding ≥ G1 was most strongly associated with rectal subregions identified
through statistical analysis (Chapter 6). The SRRpmap regions were defined where differences
in pixel dose were most significant between patients with and without toxicity. For rectal
bleeding ≥ G1 this roughly incorporated a lateral band around the circumference of the lower
third of the rectal wall, and a smaller cluster around the mid-right of the rectum. Validation
results were significant for accumulated SRRpmap based NTCP model, but 95% CI extended
below 0.5 for the equivalent planned NTCP model. Findings suggest that different regions of
the rectal wall associated with ≥ G1 and ≥ G2.
The NTCP model developed for GI toxicity ≥ G2 based on the accumulated FE-DSM
50 Gy dose-width produced the greatest AUC across all endpoints (AUC 0.833 [95% CI:
0.732, 0.935]). From the planned dose based NTCP model, the FE-DSM 55 Gy dose-width
was found to be the most significant dose metric (AUC 0.803 [95% CI: 0.697, 0.909]).
However, the 95% CIs calculate for AUCs during model validation were wide and extended
below the 0.5 threshold (accumulated AUC 0.702, [95% CI: 0.481, 0.923], planned AUC
0.683 [95% CI: 0.457, 0.908]).
All remaining NTCP models were found to have associations with the relevant toxicity
endpoint. Considering the significant dose metric included in NTCP modelling following
logistic regression, results from both accumulated and planned dose suggest that there are
features of low, intermediate, and high doses associated with different toxicity endpoints.
This has been an effect reported in the literature based on planned dose, but it is supported
here by accumulated dose results.
The multivariate model was generated using forward variable selection based on likeli-
hood ratios, which carries an associated risk of overfitting [16]. However, to address this,
the number of variables was kept low (between 1 and 3), with only one dosimetric variable
appearing in each equation for S shown in Table 7.3. Furthermore, because the data were
considered as TRIPOD Type 2b non-random split-sample development and validation, not
only was the model internally validated using bootstrapping, but the predictive power of the
final model was further interrogated using data not considered during model development.
This approach gives strength to the model design when compared with internal validation
only.
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Testing the NTCP models using the validation set resulted in wider confidence intervals
across all models. This is expected due to the reduced number of samples in the validation set,
and may also be due to differences in rates of baseline variables. The models found to have
significant discriminative ability following validation were: rectal bleeding ≥ G2 and bowel
bother ≥ G1, for both planned and accumulated dose metrics, and rectal bleeding ≥ G1 for
accumulated dose only. Notably, GI toxicity and stool frequency produced AUCs greater
than 0.6, but the widths of the 95 % CIs extended below 0.5. However, the same cutoff
thresholds are not applicable because the performance of the validation set will generally not
be as good as the training set. Accumulated dose produced AUCs greater than planned for 5
out of 7 endpoints.
Although the intuitive conclusion is that accumulated dose is a stronger predictor of
toxicity than planned dose because it incorporates the effects of interfraction motion, and
that FE-DSMs are a better tool for dose accumulation than 2D-DSMs, the differences in
AUC when translated into NTCP models are small. Across a population, this suggests a
small but measurable effect. This can be considered a positive outcome when put in the
context of the low event rates being investigated, and the inherent noise in toxicity reporting.
Meaningfully quantifying accumulated delivered dose is not yet fully understood, and further
research is recommended because the DVH approaches used for describing planned dose
are not appropriate for dose accumulation. However, the results presented here suggest that
for most endpoints, there is a small but non significant improvement in calculating NTCP
using accumulated dose rather than planned. Although we have detected large deviations in
daily rectal contours from the planning CT baseline (Chapter 5), the most extreme effects
are blurred when considering the entire course. Work is ongoing to improve the accuracy of
dose accumulation techniques, including autosegmentation and FE refinement. Results for
NTCP modelling suggest that planned dose is an adequate surrogate for delivered dose over
the course of a radiotherapy treatment.
Where the small but measurable differences reported here may begin to influence a
patient’s treatment are for ultra-hypofractionated treatments on standard linacs or cyberknife,
where more dose is being delivered per fraction and α/β ratios come into account in terms
of biological dose-effects. Hypofractionated treatments are anticipated to be delivered on the
MR-linac (magnetic-resonance linear accelerator). Another consideration is proton beam
radiotherapy whereby small effects of intra/interfraction motion can have a large impact
on the patient’s dosimetry due to the inherent high dose gradients and range of narrow
beams. If patients were treated with hypofractionated proton treatment this would also be a
consideration.
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NTCP models have been generated to compare predictive power between planned and
accumulated dose metrics, with several clinical endpoints. Models developed on a training set
and internally validated were found to be strongly associated with each endpoint investigated.
Each model was tested using a validation set of patients who had not been considered
during model development. Five of thirteen models were successfully validated, but other
validation results may have suffered from insufficient numbers in the validation set. Generally,
NTCP models based on accumulated dose were more strongly associated with toxicity
than those based on planned dose, but the benefits were marginal. Planned dose may be
adequately representative of accumulated dose for the course of radiotherapy, and the models
developed here may contribute new information on subregions associated with different
toxicity endpoints. In particular, some endpoints were found to be associated with low to
intermediate dose levels, not only doses approaching the prescription value, and spatial
distribution of dose were found to be significant across all NTCP models. By furthering
our knowledge of geometrical dose distributions and the corresponding associations with
toxicity outcomes, we can improve our understanding of the pathogenesis of toxicity, and
therefore inform development of treatments. We envisage that the NTCP models developed
in this work will be incorporated into decision-making tools in adaptive radiotherapy, with




Conclusions and future work
8.1 Conclusions
The hypothesis of the VoxTox research programme is that delivered dose is a better predictor
of toxicity than planned dose. The multidisciplinary project has brought together technical
contributions from bioengineering, medical physics, oncology, applied mathematics, and
high energy physics, to enable the calculation of delivered dose from daily image guid-
ance radiotherapy scans. The research conducted within this thesis focuses specifically on
the calculation of motion-inclusive delivered dose to the rectum in prostate radiotherapy.
Through collaborative working, images being routinely acquired for the purposes of patient
positioning, can now be exploited to explore delivered dose-toxicity correlations. Within
this PhD research: different approaches to interrogating delivered dose were investigated; a
biomechanical finite element (FE) rectal simulation was introduced; voxel-level dose analysis
was performed; and multivariate normal tissue complication probability (NTCP) models
were developed, optimised, and compared between planned and accumulated dose.
8.1.1 Quantifying spatial aspects of delivered dose to the rectum
Two-dimensional dose-surface maps (DSMs) were used to represent dose to the rectal wall
so that spatial features of the dose distribution could be preserved during accumulation of
daily delivered dose. Equivalent uniform dose (EUD) and spatial dose-width metrics were
used to parameterise both planned and accumulated dose.
Dose-toxicity analysis was performed on two separate patient cohorts. Results from both
cohorts found accumulated dose to have stronger associations with several toxicity endpoints:
grade 2 proctitis, grade 1 rectal bleeding, grades 1 & 2 GI toxicity, stool frequency, and all
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3 investigated levels of bowel bother. This was the first reporting of delivered dose being
linked with toxicity using image guidance scans from a large patient cohort.
8.1.2 Biomechanical finite element modelling
Biomechanical finite element modelling (FEM) was introduced into the VoxTox workflow
for accumulating dose to the rectum. This addressed several limitations associated with
the original DSM approach in terms of degrees of freedom for rectal motion. The model
was optimised for patient data, and provided a more anatomically-representative solution,
allowing accurate accumulation of dose at the voxel level.
8.1.3 FEM motion-dose sensitivity study
FEM was used to simulate different magnitudes and scenarios of rectal motion based on
measured patient data. The outcome was to quantify the sensitivity of dose with rectal motion,
and interpret this in terms of NTCP implications. Improving the understanding of how dose
varies with motion may influence clinical considerations and imaging protocols in the future.
8.1.4 FEM for voxelwise analysis of dose
FE-calculated DSMs were generated for further dose-toxicity investigations in a large patient
cohort. Overall, the introduction of FE-based dose calculation led to improved toxicity
correlations for both planned and accumulated dose, with accumulated dose tending to
perform better. Beyond EUD and dose-width metrics, geometric and probabilistic approaches
to defining rectal subregions were investigated. However, increasing resolution of dose
parameterisation did not always correspond to improvements in toxicity prediction, despite
seeming to reveal intra-organ areas of radiosensitivity. Optimal spatial dose metrics varied
across different toxicity endpoints, suggesting differences in underlying pathophysiologies.
8.1.5 NTCP modelling
Multivariate NTCP models were developed based on spatial dose parameters from planned
and accumulated DSMs, combined with clinical risk factors. Seven models were considered
significantly discriminative of toxicity; grade 1 & 2 rectal bleeding, grade 2 GI toxicity,
faecal incontinence, diarrhoea, stool frequency, and grade 1 bowel bother. Models were
validated on a separate test cohort. For 6 of 7 endpoints, models based on accumulated dose
performed better. However, differences with planned dose-based models were small, and
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further research is recommended into extracting clinically useful dosimetric information
from delivered dose.
The small detected differences between accumulated and planned dose may be due to
limitations within VoxTox calculation systems, or perhaps, in the current era of image guided
radiotherapy, planned dose is an adequate surrogate for delivered dose and is in fact a good
predictor of radiobiological response.
8.1.6 Research outcomes
The outcomes and models developed within this thesis will help to advance and improve the
understanding of the links between dose to the rectum and toxicity in prostate radiotherapy.
For the first time, it has been demonstrated that delivered dose can be a better predictor of
rectal toxicity than planned dose. Different approaches to dose accumulation and parame-
terisation metrics have been presented and translated to NTCP models for different toxicity
endpoints. Rectal motion has been quantified and modelled within a sensitivity study to
demonstrate the relationship between motion, dose, and NTCP. A summary of the research
outcomes from this thesis are included in Appendix B. Ultimately, it is anticipated that this
research will contribute towards advancing systems for adaptive radiotherapy with the aim of
reducing the incidence of rectal toxicity for prostate cancer patients.
8.2 Future work and applications
8.2.1 Machine learning
The approaches applied for parameterising DSMs in this thesis have been adapted from
methods presented in the literature for planned dose data [27, 64]. Whilst these metrics have
indicated an advantage to using accumulated dose for dose-toxicity investigation over planned
dose, the differences are not as distinct as expected, and further research into parameterisation
approaches specific to accumulated dose is recommended. Machine learning has already
been shown to have some application in this area [177] and may prove to be a useful tool for
improving autosegmentation or voxel-level dose-toxicity analysis.
8.2.2 Voxel-level dose analysis
Voxelwise analysis of the anatomy is becoming an area of increased interest [61, 59, 105].
At the recent congress of the European Society for Radiotherapy & Oncology (ESTRO),
a working group was assembled of representatives from research groups sharing common
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interests. I was fortunate to be invited to sit on the working group and look forward to
working collectively to put together guidelines and recommendations for voxelwise analysis
to be published in the future.
8.2.3 Rectal spacers
With increasing evidence demonstrating associations between spatial dose patterns and rectal
toxicity, research outcomes could complement the emerging use of rectal spacers in prostate
radiotherapy [62, 147, 160]. Physical spacers are surgically implanted to insert a gel-based
or solidifying barrier between the prostate and rectum, subsequently shifting the rectum away
from the high dose region. Evidence has shown a reduction in rectal toxicity of 8-12% [160]
and the procedure is being trialled by the NHS. However, additional considerations include
any contraindications to general anaesthetic, surgical facilities and availability, and the
additional cost, reported as over 2000 USD per patient [80]. The research outcomes from
this PhD thesis could be used to help identify patients who would benefit most from rectal
spacers, and those patients unlikely to benefit from the procedure due to having low risk of
developing toxicity.
8.2.4 Latest technologies
Accumulated delivered dose is becoming an increasingly important consideration for proton
beam therapy [2]. Accuracy and precision are of utmost importance because higher doses of
radiation are deposited to a focal spot due to the nature of the Bragg peak. Small changes in
anatomy can lead to greater differences between planned and delivered dose, and subsequently
NTCP, than previously observed for photon based radiotherapy. Accumulated delivered dose
has also become of interest to the adaptive workflow of the MR-linac [144]. Treatment has
commenced on the first two units installed in the UK [157], and the market is increasing and
advancing. The MR-linac was designed for the purpose of image-based adaptive workflow,
so implementation of online systems for toxicity monitoring would be a logical addition.
The research outcomes of this PhD thesis have potential implications for directly im-
proving the adaptive workflow for TomoTherapy patients. The systems may also have
useful applications for conventional linear accelerators, Cyberknife, MR-linac and proton
beam therapy, as well as in delivery techniques such as ultra-hypofractionated radiotherapy.
The ultimate aim is that these tools will be used in the development of clinical decision-
making tools for adaptive radiotherapy that will benefit the patient by minimising the risk of
radiation-induced rectal toxicity.
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The research conducted within this thesis was only possible due to the multidisciplinary
nature of the VoxTox research programme. Much of the analysis was dependent upon systems
that were previously developed within VoxTox. The work presented in this thesis is my
own, unless stated otherwise. Every attempt has been made to appropriately accredit the
scientific contributions of others throughout the thesis; a concise summary is included below
for clarity.
Image archiving and patient tokenisation
Retrieval and processing of patient data from the TomoTherapy planning system was im-
plemented by Dr Marina Romanchikova (Medical Physics), and Karl Harrison (Cavendish
Laboratory), [132]. Referred to in chapters: 3-6
CheckTomo dose calculation software
The dose calculation algorithm for independent calculation of dose based on MVCT image
guidance scans was developed by Dr Simon Thomas, Head of Medical Physics & Clinical
Engineering at Addenbrooke’s Hospital, who is co-supervisor of this PhD research. Referred
to in chapters: 3-6
Determining an alpha-beta ratio for the rectum
In order to combine patient datasets from the 60 Gy in 20, and 74 Gy in 37 fractionation
schedules, the 60 Gy group were converted to the equivalent dose in 37 fractions. Our data
were fit to the CHHiP constraints, and the α/β ratio was iteratively optimised until the
equivalent uniform dose and biologically effective dose were equal between the two groups.
172 Statement of originality
The original calculation spreadsheet was generated by Dr Simon Thomas. My involvement
was the independent checking and verifying of the calculation. Referred to in chapters: 3-4,
6-7
Autosegmentation
The autosegmentation software was developed by Prof Michael Sutcliffe, Cambridge Univer-
sity Department of Engineering, and co-supervisor of this PhD thesis. As a consequence of
work conducted in this PhD project, several areas of improvement were identified from the
original version of the autosegmentation software. Example cases were identified where con-
tours suffered due to restrictions of the region of interest used as the search area for the rectal
contour, as well cases where air cavities were not being correctly identified. As a result of
these investigations, improvements were implemented to the algorithm by Prof Sutcliffe. The
version used for discovery cohort analysis was v1.4, and for consolidation cohort analysis,
v1.6. Details of version 1.6 were presented in the article ‘Autosegmentation of the rectum on
megavoltage image guidance scans’ published in Biomedical Physics & Engineering Express
in January 2019, co-authored by Prof Sutcliffe and myself [143]. Referred to in chapters: 3-6
Toxicity recording and processing
Electronic case reporting forms were used to interrogate and record patient toxicity. These
were designed by Amy Bates, Lead Research Radiographer at Addenbrooke’s Hospital, and
Dr Jessica Scaife, former research fellow in the VoxTox research programme. Mapping rules
to translate raw data to standard toxicity reporting systems were developed by Dr Scaife
and Dr David Noble, VoxTox research fellow. Mapping rules were externally verified by
Dr Agnieszka Lemanska, University of Surrey. Toxicity spreadsheets were populated and
maintained by Amy Bates and Karl Harrison. Referred to in chapters: 3-4, 6-7
Dose surface maps and analysis
The MATLAB code to generate dose surface maps (DSMs) was developed by Dr Simon
Thomas, following approaches in the literature. Code for calculation of EUD and dose-widths
were also written by Dr Thomas. The code was embedded within the code developed within




The 109 patients analysed from the discovery cohort were selected according to the avail-
ability of baseline data. This was acquired manually as discovery patients were recruited
prior to the formalised recording of baseline data. Dr Jessica Scaife retrospectively assessed
patient notes in order to determine the status of baseline symptoms. Dr Scaife performed a
dose-toxicity analysis using DVH data for these 109 patients [137]. Referred to in chapters:
3,4
Toxicity data for the consolidation cohort
The patient toxicity spreadsheet was frozen in February 2018 for analysis of patients in the
consolidation cohort. Freezing of the database was performed by Amy Bates. Processing of
raw data into final clinical toxicity scores was overseen by Karl Harrison. Data processing to
finalise the list of patients with a minimum of 2 year follow up was performed by Dr David
Noble. I performed further processing of patient toxicity data following these stages in order
to split by staging, interpret baselines and patient characteristics, record dose prescription,
then combine all toxicity, baseline, and dose information. The final list of patients was then
split into training and validation sets by toxicity rate and prescription. Referred to in chapters:
3-4, 6-7
Finite element model
The biomechanical finite element model was initially developed by Prof Michael Sutcliffe
for ‘proof of concept’ experimental measurements. Prof Sutcliffe developed the MATLAB
code for writing the input files to be run in Abaqus, and Python code for extracting final
model coordinates. My involvement was: modifying the code so that it could read from
patient DICOM files; optimise the element type and hyperelastic properties to represent the
anatomy; and introduce an additional function in MATLAB to calculate the dose based on
the Abaqus output. In addition to parameterising the resulting FE-DSMs using EUD and
dose-widths, I developed the code for division of the rectal wall into geometric subregions,
and probabilistic subregions at risk. Referred to in chapters: 3, 5-7
The motion-dose sensitivity study conducted in Chapter 4, and the NTCP modelling
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